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Abstract 
Cardiac troponin is the reference standard biomarker for the diagnosis of acute 
myocardial infarction (AMI). In the appropriate clinical context, the detection of 
a rise and/or fall of cardiac troponin is highly sensitive and specific for this 
diagnosis. However, troponin testing has two key limitations. First, as levels in 
serum or plasma can take several hours to rise, the diagnostic sensitivity of 
troponin testing is insufficient to allow acute coronary syndromes to be safely 
‘ruled out’ and serial testing remains necessary. Second, because of the need 
to detect a rise and/or fall of troponin, serial testing is essential to differentiate 
chronic troponin elevations from those related to AMI. As a result, international 
guidance currently recommends serial testing over 6-12 hours. Recent 
evidence suggests that, with contemporary sensitive troponin assays, AMI can 
often be ‘ruled out’ and/or ‘ruled in’ with serial testing over as little as 1 to 3 
hours However, as the turnaround time of laboratory-based testing is typically 
1-2 hours, these results may still be unavailable at the time key decisions 
about initial treatment and patient disposition are made in the Emergency 
Department (ED). Point of care troponin (POCT) testing at the patient’s 
bedside has a shorter turnaround time than laboratory-based assays and 
eliminates the need to transport the sample to a central laboratory. When 
patient pathways are appropriately designed to accommodate point of care 
testing, key management decisions may be expedited, potentially reducing ED 
length of stay. If the accuracy and safety of rapid diagnostic strategies using 
point of care troponin testing over 3 hours can be demonstrated, there are 
tremendous potential benefits for ED throughput, healthcare resource use and 
for patients (both in terms of receiving appropriate reassurance with avoidance 
of hospital admission and receiving appropriate early treatment for acute 
coronary syndromes). In this study, we will evaluate several promising 
strategies that may enable clinicians to make accurate diagnoses based on 
information available in the ED and a single blood test for cardiac markers at 
the POC. During the study period of February 2015 to March 2017 there were 
1,613 patients enrolled. Of this cohort, some patients were excluded for 
missing i-Stat on arrival, and the patients who did not have an ECG recorded 
were excluded. This left 733 patients in the final group for analysis consisting 
xiv 
of 457 men (62.3%) and 276 women (37.7%). The mean age was 58 years 
(standard deviation 16). In a pragmatic study we determined the  interobserver 
reliability of Heart-type fatty acid–binding protein (h-FABP) the absolute 
agreement between investigators was 93.0% with a kappa of 0.81 (95% CI 
0.6–1.0), indicating near perfect agreement. In total there were three (7.0%) 
disagreements. The diagnostic accuracy of POC h-FABP lateral flow 
immunoassay (True Rapid, FABPulous BV) device for diagnosing or excluding 
AMI using a single test at the time of patient presentation to the ED and three 
hours later has been evaluated, the sensitivity and NPV to rule out AMI were 
48.24% (95%CI: 37.26% to 59.34%) and 92.48 % (95%CI: 90.91% to 93.80%) 
respectively. While Specificity and PPV were 89.27 % (95%CI: 86.53%to 
91.62%) and 38.68% (95%CI: 31.45% to 46.44%) respectively. However, this 
strategy would allow 85 % of patients to be discharged (rule out percentage). 
The diagnostic accuracy of a contemporary POC cTn assay used on arrival 
and 3 hours later in patients with suspected ACS, at the conventional 99th 
percentile and novel LoD cut-offs was also evaluated. Finally, we were 
validated the T-MACS with a contemporary POC cTn assay (i-Stat, Abbott 
Point of Care, New Jersey) in order to investigate the clinical diagnostic 
accuracy of i-Stat device to rule out AMI in EDs.  By setting the cut off levels 
of POC at 10ng/ml and functional sensitivity at 10% CV, the T-MACS rule has 
successfully ‘ruled out’ > 41.8% of patients with suspected cardiac chest pain 
following a single blood test, with a sensitivity of 97.4% (90.8 - 99.7%) and 
NPV of 99.3%  (97.1 – 99.8%), in a very short turnaround time of 5-10 minutes. 
On the other hand T-MACS has risk stratified the patients who were at high 
risk to have AMI with a specificity of 93.56% (91.27% to 95.40%) and a PPV 
of 50.00% (42.08% to 57.92%). To our knowledge, this is the first successful 
validation of a single test ‘rule out strategy’ using a POC cTn assay. With a 5-
10 minute turnaround time, this assay could help to unburden crowded EDs 
by enabling almost immediate reassurance and discharge for >40% of patients 
with suspected cardiac chest pain. 
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1.1. Background 
Chest pain is the most frequent symptom presented in Emergency 
Departments (ED). Cardiovascular disease (CVD) remains the leading cause 
of mortality globally, and accounts for about one-third of all deaths.  About 
114,000 patients with acute coronary syndromes (ACS) are admitted to 
hospital each year in United kingdom  (Souter, 2014). Several underlying 
pathophysiological processes might be a reason for chest pain, but the most 
common, serious cause is ACS. ACS refers to a set of signs and symptoms 
that occur when the blood supplied to the heart muscle is suddenly blocked. 
This symptom combines the clinical conditions of acute myocardial infarction 
(AMI) and unstable angina (UA) (Timmis, 2015). A recent report released by 
the British Heart Foundation (BHF) on Cardiovascular Disease Statistics, 
reported that cardiovascular disease was the cause of death in 27.4% of men 
and 25.2% of women (BHF, 2017). Patients with symptoms suggestive of AMI 
account for about 10% of all (ED) consultations in the United Kingdom (UK). 
By 2030, it is expected that 23.3 million will die annually from cardiovascular 
disease (Peters et al., 2007; World Health, 2014). From updated trends using 
data from the national statistics agencies of the United Kingdom, coronary 
heart disease by itself is still the single most significant cause of death with 
increases in treatment and hospital admissions for all CVD patients 
(Bhatnagar et al., 2016). Between 2010/2011 and 2013/2014, hospital 
admissions for all CVD patients increased by over 46,000 with more than 
36,500 of these increased admissions for men (Bhatnagar et al., 2016).  
Patients presenting with chest pain account for 5% to 10% of all visits to 
emergency departments (ED). Approximately one-third of attendances and 
half of the admissions had a clinical diagnosis of ACS without clear ECG 
changes (Goodacre et al., 2005). In the UK, a Clinical Practice Research 
Datalink (CPRD) database reports that more than 915,000 people suffer from 
AMI and more than 1.3 million are living with angina (Bhatnagar et al., 2015). 
A recent report by the BHF, suggests that CVD’s cost to the UK economy is 
estimated to be over £15 billion each year, and the healthcare costs relating 
to CVD are estimated to be about £11 billion each year. Conversely, in the US 
in 2011, the cost of admitting patients with chest pain totalled $11.5 billion, 
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which represents 3% of that nation’s healthcare expenses and $11,504 of the 
aggregate hospital (Torio and Andrews, 2006). On the other hand, the 
pressure to find hospital beds in the National Health Service (NHS) in England 
and Wales is well known. It has been reported that the number of patients 
ready to be discharged medically, but still occupying a medical bed, has 
increased significantly. According to a report from Delayed Transfers of Care 
Data, up to July 2017, there were 118,100 patients delayed in acute care.  
These so-called “delayed transfers” are a crucial driver for high bed-occupancy 
rates within hospitals. On the other hand, emergency departments are under 
enormous pressure to meet the 4-hour target (<4 hours from patient 
presentation to discharge or transfer), which is a key metric by which NHS 
Trusts are evaluated and accordingly compensated or disciplined. As a result 
of this challenge, there has been considerable interest in research on rapid 
decision-making as well as extensive interest in developing a single test, 
available acutely, to discharge patients in EDs safely. The prompt and 
accurate evaluation of acute chest pain has immense implications for patient 
morbidity and mortality, and healthcare economics overall. In contrast, 
identifying patients with chest pain who are at risk of adverse events is crucial, 
as the mortality rate of patients with missed AMI is at least double that of 
similar patients who are accurately diagnosed (Pope et al., 2000). However, 
this is important not only to ED physicians, but also to all physicians who 
evaluate chest pain patients.   
Only 10% to 20% of patients, who are admitted to hospital with the symptoms 
of chest pain, are diagnosed with MI; most patients are diagnosed with non-
cardiac conditions and 10% of women experience no chest pain at all during 
a heart attack (Dey et al., 2009). Most patients examined for ACS do not have 
this condition, and previous studies report up to 90% of all patients 
investigated have normal findings (Hollander, 1999; Pope et al., 2000). Based 
on latest statistics report in 2015, cardiac heart disease (CHD) is responsible 
for nearly 70,000 deaths in the UK each year, an average of 190 people each 
day, or one death around every eight minutes (BHF, 2015). The diagnosis (rule 
in) of ACS is based on clinical assessment, which includes electrocardiograph 
(ECG) and cardiac troponin (cTn) measurements. The challenges for ED 
4 
physicians in evaluating chest pain in patients is not only to rapidly rule in ACS, 
but also to rule out this serious condition that may cause morbidity and 
mortality. However, to meet this challenge, numerous diagnostic procedures 
have been investigated during the past two decades, including new cardiac 
biomarkers, early stress testing, clinical risk scores and non-invasive imaging 
of the myocardium and coronary arteries (Kontos et al., 2010). These have 
been incorporated into various accelerated diagnostic protocols (ADPs) or 
chest pain unit (CPU) pathways to provide a rapid, cost-effective mechanism 
for evaluation. It has been reported that only a quarter of all patients (25%) 
who are admitted on suspicion of ACS have AMI (R. Body et al., 2014c). Most 
of these protocols are based on laboratory testing, and this poses a question. 
Can a Point-of-Care Troponin I Assay be as good as a central laboratory 
assay, and become an alternative diagnostic method to diagnose AMI in EDs? 
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1.2. The pathophysiology of coronary heart disease 
Coronary artery disease (CAD) is most commonly caused by atherosclerosis 
(Hobbs and Arroll, 2009), which is developed when plaque builds up in the 
artery walls from low-density lipoproteins (LDL). The (ACS) refers to any group 
of clinical symptoms resulting from acute reduction in blood flow to the heart. 
ACS includes both chest pain at rest (unstable angina) and  Acute Myocardial 
Infarction  (AMI) (Kumar and Cannon, 2009). Figure 1.1 shows how the infarct-
related coronary artery can experience complete or partial thrombosis as a 
result of atherosclerotic plaque rupture, which is associated with ACS 
(Weissberg, 1999). Before patients experience this acute event, it can take 
several decades for processes of atherosclerosis to progress and develop 
from syndromes that display pathophysiologic mechanisms that often remain 
hidden.  
Plaque is formed on arterial walls due to fibroblasts, smooth muscle cells and 
cholesterol accumulation, which cause these arterial walls to narrow and 
thicken. Subsequently, the circulation of blood becomes blocked or slowed, as 
plaque accumulation increases, but the blood vessels also experience 
constriction caused by endothelial dysfunction before the formation of the 
plaque (Ambrose and Singh, 2015). Risk factors include genetic causes, diets 
that are high in cholesterol and saturated fat, obesity, diabetes, hypertension, 
smoking, and LDL and other lipoprotein abnormalities known as dyslipidaemia 
that are widely reported, which contribute to medium sized arteries inner lining 
or intima that become increased by its low-grade inflammatory state (Siri-
Tarino et al., 2010). Figure 1.2 shows how coronary atherosclerosis 
contributes to the lumen of the artery narrowing over time to various degrees, 
so that the coronary arteries’ inner layers are subjected to thickening in a 
progression that is slow (Lilly and Harvard Medical, 2016).  The flow of blood 
in the artery is often changed at arterial bifurcation points, so that sudden 
cardiac death (SCD) and AMI caused by atherosclerosis is shown to prefer 
proximal segments of major coronary arteries (J. C. Wang et al., 2004). There 
are two processes where cycles of rapid progression could interrupt the slow 
progress of atherosclerosis: involving plaque haemorrhage, or when a non-
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occlusive intraluminal thrombus is formed with asymptomatic plaque 
disruption. Stages of plaque development are illustrated in Figure 1.3 
 
Figure 1-1. Atherosclerosis plaque formation 
A. Normal artery with normal blood flow. The additional image shows a cross-section of a 
normal artery. B. An artery with plaque build-up. The additional image shows a cross-section 
of an artery with plaque build-up (taken from (NIH, April 25, 2013). 
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Figure 1-2. Disruption of atherosclerotic lesion results in atherothrombosis 
This leads to an abrupt reduction in coronary blood flow. STE-ACS (STEMI) 
occurs if the occlusion is complete. On the other hand, STE-ACS (NSTEMI 
and unstable angina) occurs if the occlusion is partial. 
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Figure 1-3. Stages of plaque development 
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1.3. Myocardial infarction 
Myocardial injury frequently occurs in patients without ACS. The development 
of a myocardial infarction begins with the initial onset of myocardial ischemia, 
which comes from an imbalance of oxygen supply and demand, which leads 
to myocardial cell damage or death (Ambrose and Singh, 2015).  The four-
decade-old World Health Organisation (WHO) definition of AMI has been 
replaced by clinical criteria. This definition, established by the European 
Society of Cardiology (ESC) and American College of Cardiology focuses 
mainly on defining infarction as evidence of myocardial necrosis. This 
definition refers to the Third Universal Definition of myocardial infarction (MI) 
published in October 2012 by the Global Myocardial Infarction Task Force 
(Thygesen et al., 2012a). In the diagnosis, this definition requires cardiac 
myocyte necrosis with an increase and/or decrease in plasma of cardiac 
troponin (cTn). This requires at least one value to be above the 99th percentile 
normal reference limit in addition to evidence of myocardial ischemia from 
symptoms, significant electrocardiogram (ECG) changes, or cardiac imaging, 
or other evidence showing a new wall motion abnormality in a segment of the 
myocardium. International guidelines recommend patients with myocardial 
infarction to be classified by etiology (Roffi et al., 2015).  AMI is categorised 
according to the underlying mechanism. The acute myocardial injury is 
classified where troponin concentrations are elevated with evidence of 
dynamic change in the absence of apparent myocardial ischemia, whereas in 
chronic myocardial injury troponin concentrations remain unchanged on serial 
testing (Chapman et al., 2016). 
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Table 1-1. Classification of Myocardial infarction  
 
Abbreviations: myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary 
artery bypass grafting (CABG) 
  
Type Mechanism 
1 Spontaneous MI caused by atherosclerotic 
plaque rupture. A thrombus will block one or 
more of the coronary arteries leading to 
decreased myocardial blood flow and ischemia 
2 MI secondary to myocardial oxygen supply and 
demand imbalance, caused by a condition other 
than atherosclerotic disease, such as coronary 
artery spasm, sepsis, arrhythmias, respiratory 
failure, hypotension or hypertension 
3 MI caused by presumed myocardial ischemia 
leading to cardiac death before biomarkers are 
obtained or before the biomarker appears in the 
blood.  
4a MI related to coronary angiography or PCI 
4b MI associated with stent thrombus as diagnosed 
by angiography or autopsy 
5 MI associated with CABG 
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1.3.1. ECG: AMI classification 
ECG tests are immediately given to ED patients that present with chest pain 
in hospital and clinical settings, and Figure 1.4 shows an abnormal record and 
a normal record. STEMI is one form of myocardial infarction associated with 
pathologic Q waves, but this cannot provide differentiation between MI that 
presented years or weeks earlier and an acute event. However, when the T 
wave shows a peaked appearance and when the ST segment is elevated, a 
distinction can be observed when T-wave abnormalities and ST abnormalities 
in a temporal sequence are produced by an acute STEMI.  Q-waves have not 
developed and myocardial cells remain viable at this early stage, so that ST 
segments can return to baseline when treatment is given to patients to restore 
blood flow with acute coronary reperfusion. In contrast, when acute coronary 
reperfusion is not successful for patients, the ECG shows the R wave has a 
loss of amplitude and a pathologic Q wave is inscribed and positioned above 
the infarction territory. The Q wave deepens, the T wave inverts and ST 
segments remain elevated around 2 days after infarction, and after more days, 
the T wave is still inverted but the ST segment elevation changes to baseline. 
When a period of months or weeks has elapsed after the infarct, the T wave 
and ST segment are shown to be normal, but MI produces a permanent 
marker of persistent pathological Q waves, and at the site of infarction, a 
bulging fibrotic scar often develops, when after several weeks the ST segment 
is still elevated. The leads that overlie the infarction zone record the T wave, 
ST and QRS evolutionary changes (Lilly and Harvard Medical, 2016) (see 
Figure 1.4). 
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Figure 1-4. Myocardial infarction during acute ST-elevation 
ECG evaluation during acute ST elevation myocardial infarction (also termed acute Q wave 
myocardial infarction) if successful early reperfusion of coronary occlusion is achieved the 
elevated ST segments return to baseline without subsequent T wave inversion or Q wave 
development. (Adapted from (Lilly and Harvard Medical, 2016) 
 
The first concern for emergency physicians is whether the patient presents an 
ST-segment elevation myocardial infarction (STEMI), where the ST-segment 
signifies the interval between ventricular depolarisation and the start of 
repolarisation (Lux, 2017). Patients with suspected STEMI should receive an 
ECG within 10 minutes of arrival at a hospital, remain on continuous 
electrocardiogram monitoring, and have blood drawn for cardiac biomarkers 
(Steg et al., 2012) When an atherosclerotic plaque in the artery wall ruptures, 
it could be the main reason for total artery occlusion, causing ischemia in the 
myocardium supplied by that artery (Hanna and Glancy, 2015). The National 
Institute for Health and Clinical Excellence (NICE) has recently issued 
guidelines for physicians (Cooper et al., 2010) 
Patients with STEMI have a well-established treatment path, including drugs 
or percutaneous coronary intervention (PCI) (Damman et al., 2017), and these 
patients should rapidly undergo either coronary angiography or thrombolysis. 
Conversely, in UA and NSTEMI, a disrupted atherosclerotic plaque 
progresses into a non-occlusive thrombus, which causes a 15% narrowing of 
the coronary artery, decreased myocardial perfusion, and can present as a 
transient or persistent ST segment depression or T wave inversion, flattened 
T waves, pseudo normalisation of T waves, or no changes on the 
electrocardiogram (Amsterdam et al., 2014; Hamm et al., 2011). The ECG may 
show ST segment depression or T wave changes. In the case of partial 
coronary artery occlusion, an earlier onset of sub endocardial repolarisation 
occurs leading to a depression of the ST segment, and a reverse 
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electrophysiological wave results in an inverted T wave. However, in this case 
the main goal is to stabilise patients’ pain using medication for blood-thinning 
agents, such as aspirin and heparin, because these have been proven to 
improve outcomes for patients with NSTEMI (Kumar and Cannon, 2009). 
During NSTEMI, the primary goal is to stabilise the patient using nitrates and 
morphine for the chest pain, beta-blockers, platelet inhibitors and 
anticoagulants. Thereafter, the physician decides on conservative therapy or 
invasive methods, such as coronary angiography with the possibility of 
revascularisation (Jokhadar and Wenger, 2009).  
 Biomarker evaluation, risk stratification and responses to prescribed therapy 
for the basis for clinical decisions, and NSTEMI and unstable angina are 
mostly similar, except that biomarkers for unstable angina are not increased, 
but the same treatment is given for both conditions. Comparisons of patients 
with type 1 AMI and type 2 AMI have been investigated in many studies to 
reveal differences in patient outcomes and differences in diagnosis. One 
recent study reports that type 2 AMI was present in 14% of cases and type 1 
AMI was shown in 86% of cases (Lopez-Cuenca et al., 2016). When 
investigating all MIs in patients admitted to hospital, the most recent study 
reports that 88.5% of patients presented type 1 AMI, while (7.1%) were 
classified as type 2 AMI (Radovanovic et al., 2017). Type 3 MI is uncommon, 
and found in approximately 3% to 4% among all types of AMI (Jangaard et al., 
2017). 
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1.4. Acute coronary syndrome assessment and management 
1.4.1. Risk factors for acute coronary syndrome 
The likelihood of developing coronary heart disease is generally determined 
by various risk factors, and Table 1.2 shows that these can be non-modifiable 
or modifiable, but changes in lifestyle are proven to reduce many of these 
modifiable risk factors (Huma et al., 2012). MI long-term risks are increased 
by these factors, but for patients in EDs presenting with chest pain symptoms, 
the ongoing probability of MI is not necessarily increased. In one study, the 
influence of risk factors for CHD was investigated, and it reported 21.3% of 
patients with 4 or 5 risk factors had AMI, but 12.2% of patients who presented 
no cardiac risk factors had AMI (Body et al., 2008). Sudden cardiac death, 
premature atherosclerosis and myocardial infarction are mostly caused by 
patients smoking, which is a strong risk factor, and compared with patients 
with healthier lifestyles; early STEMI is caused in patients who smoke. 
Therefore, smoking doubles the chances of CHD compared with non-smoking 
individuals, and patients who smoke are likely to develop heart disease around 
seven years earlier than individuals with healthier lifestyles (Zhang et al., 
2010). 
Table 1-2. Modifiable and non-modifiable risk factors for coronary heart 
disease 
Modifiable risk factors Non-modifiable risk factors 
• Diabetes 
• Diet (lack of fruit and vegetables) 
• Hypercholesterolaemia 
• Hypertension 
• Lack of exercise 
• Obesity 
• Smoking and alcohol use 
• Stress 
• Age 
• Ethnicity 
• Gender 
• Genetic factors, for example family 
history in a first-degree relative at 
premature age 
Adapted from (BHF, 2011)  
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1.4.2. The use of risk scores for stratification of acute coronary 
syndrome patients 
Clinicians need to decide which patients can be discharged and sent home, 
and which patients need further tests and treatment, so it is important to 
accurately measure the levels of risks that chest pain patients present with 
techniques and tools that are objective. Therefore, clinicians need to avoid 
discharging patients with adverse cardiac events that are short-term by using 
specific and sensitive risk-level techniques and tools that are quick and cost-
effective, so that patients with chest pain that have a low risk of heart disease 
can be safely discharged from EDs. Early risk stratification plays a crucial role 
in the optimal management of non-ST-elevation ACS. However, the challenge 
is not only to identify high-risk patients, but also to identify patients with low to 
very low risk with the absence of disease, so that these patients are 
discharged immediately with minimal testing or interventions (Backus et al., 
2011).   
International cardiac guidelines state that chest pain patients presenting to the 
ED should be assessed with a risk stratification tool or risk score (Roffi et al., 
2016; Thygesen et al., 2013).  Over the past two decades, several clinical 
prediction rules and scoring systems have been established. These 
multivariable prognostic models were derived from clinical trial databases or 
specific subgroups of chest pain (CP) in EDs.  Ideally, a clinical scoring system 
is developed as an effective risk stratification tool that guides clinicians during 
their evaluation and improves the standardisation of clinical management. 
However, few of these are used in practice. Risk scores combine and evaluate 
various predictors to calculate the risk of ACS for individual patients. They are 
based on clinical information collected during the initial diagnosis of chest pain 
patients. 
Recently, numerous studies have shown increased identification of low-risk 
patients when combining a risk score with troponin measurements ((Body et 
al., 2015a; E. W. Carlton et al., 2015b; Halpern et al., 2013; Six et al., 2013). 
A large amount of literature has been published on the evaluation of risk 
scores in addition to comparing the discriminatory performance of each score 
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in clinical practice (Van Den Berg and Body, 2017; Burkett et al., 2014; Khalill 
et al., 2009). However, the implementation of scoring systems in clinical 
practice and their current use has some limitations that are addressed in 
several studies  (Engel et al., 2014; Poldervaart et al., 2017; Long, 2016 ). 
1.4.3. Decision aids derived in patients with ACS 
1.4.3.1. The Thrombolysis in Myocardial Infarction (TIMI) Score  
The Thrombolysis in Myocardial Infarction (TIMI) risk score is a 7-item tool 
derived from trials of patients with confirmed ACS. The score is used to define 
the likelihood of ischemic events or mortality in patients with UA or non–ST 
segment elevation myocardial infarction (NSTEMI). The scoring model helps 
to divide the patients into low (score 0-2), intermediate (score 3-4) and high 
(score 5-7) risk categories. The score predicts the risk of all causes of 
mortality, MI and critical repetitive ischemia needing urgent revascularisation 
within 14 days after admission.  The initial study showed that 4.7% of patients 
with a score of 0 or 1 had adverse outcomes within 14 days (Antman et al., 
2000). Validation studies showed 1.7 to 2.1% of patients with a score of 0 still 
had adverse outcomes within 30 days (Chase et al., 2006; Scirica et al., 2002).  
Recently, several trials have addressed the utility of the TIMI risk score in ED 
patients with undifferentiated chest pain in a risk stratification and patient 
decision aid for early discharge from the ED.  
ASPECT is the name given to the Asia-Pacific Evaluation of Chest Pain Trial 
to identify ED patients presenting chest pain who are undifferentiated, and is 
an early example of risk stratification techniques (Than et al., 2011b). The 
intention was to identify patients that could be discharged early who were 
identified as a low-risk group by using a biomarker panel point-of-care  test 
with myoglobin, creatine kinase MB (CK-MB) and troponin, ECG and TIMI 
score at first presentation and then two hours later, in a study of 14 EDs in 
Pacific and Asian countries. This study applied the following end points for 
investigation, which were AMI, high-degree atrioventricular block requiring 
intervention, ventricular arrhythmia requiring intervention, cardiogenic shock, 
emergency revascularisation, cardiac arrest and death. This investigated a 
sample population of 3,582 patients, and those that met one of the end-points 
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mentioned were reported to be 11.8%. This study reports that biomarker 
panels with no myocardial injury evidence were supported by a rate-rise on 
repeat testing and predefined cut-offs for single measures, non-ischemic ECG 
and a TIMI score of 0 were low risk, which represented 9.8% of patients, or 
352. Only 0.9%, or 3, had adverse events within these patients at low risk. The 
study reported a NPV of 99.1% (CI: 97.3%–99.8%), specificity of 11% (CI: 
10.0%–12.2%) and confidence interval [CI]: 97.9%–99.8%), which is reported 
to achieve a sensitivity of 99.3%. 
Early discharge for patients is feasible when low-risk groups are identified and 
risk stratification decision tools are used, which is demonstrated in this 
research. According to Than (Than et al., 2011b) patients could be discharged 
early by using the biomarker that uses troponin and a decision tool that is 
similar to ASPECT, based on findings that more sensitive troponin assays 
have become more widely available. Another study, known as ADAPT, 
adopted observation as a methodology to investigate chest pain symptoms 
presented by patients at EDs, as well as other patients defined at high risk of 
ACS by perceptions of physicians in the  study (Than et al., 2012). It confirmed 
that these meet ASPECT primary outcomes as a composite, where the risk 
stratification tool was adopted for patients at three intervals. At presentation, 
this tool included troponin testing, non-ischemic ECG and a TIMI score of 0, 
which was repeated after 2 hours, and then again after 30 days for a cohort, 
and reported an overall rate of adverse outcomes of 15.3% after 30 days.  
When this study compared its results with those of ASPECT, it reported that 
the number of patients identified for discharge from the ED after 2 hours, 
because they presented as low risk from the results, was significantly 
increased to 20%, compared with the results reported when adopting ASPECT 
that were 9.8%. This study also reported that one patient defined as low risk 
experienced myocardial infarction who then was given revascularisation, as 
an adverse event. 
These researchers report 99.7% NPV (C I: 98.6%–100.0%) and 99.7% 
sensitivity (CI: 98.1%–99.9%) for this tool, and based on the ADP or 
accelerated diagnostic protocol, the rates for low-risk patients and high-risk 
patients were reviewed in terms of interventions, treatment and follow-up 
testing. 
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Around 75% of low-risk patients are subjected to stress tests and significant 
other investigations in current routine medical care. Sensitivity of ADP for 
MACE could explain the greater sensitivity reported in this study, as 18.3% 
received additional treatment. Another study in the Asia-Pacific region reports 
that an acceptable miss rate is possible for short ED time periods when 
patients can be safely discharged, which attempted to validate earlier studies 
(Than et al., 2014a). Another study by Cullen (Cullen et al., 2013)  in Europe 
and the Asia-Pacific region reported similar results when using a TIMI score 
of 0 or 1 and high-sensitivity troponin I measures within a modified ADAPT 
ADP. However, a lower rate of early discharge of 8.3% compared with routine 
care was reported in a randomised trial study of ADAPT, which classified 
patients as not low risk when presenting two chest pain episodes within a 24 
hour period or those that used aspirin, and when adopting the TIMI score, this 
could produce limitations for trial results (Than et al., 2014a). 
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1.4.3.2. The Modified TIMI Score 
The modified TIMI score (Jaffery et al., 2007) is abbreviated for ease of use in 
ED settings. Unlike the TIMI risk score, the modified TIMI score utilises only 
four variables: elevated cardiac marker, ischemic ECG changes, age >65 
years, and history of coronary artery disease. In a retrospective study of 947 
ED patients with concern for ACS, the modified TIMI had a similar predictive 
performance compared to the original TIMI risk score. Based on these 
findings, the authors indicated that their simpler modified score might be more 
useful in the ED setting than the original TIMI risk score. However, the modified 
TIMI risk score also suffers from the same disadvantages as the original TIMI 
risk score, with a 2.4% MACE rate even in the lowest risk category and thus 
is not sensitive enough to be used in isolation as a decision aid to determine 
which patients are appropriate for early discharge. See Table 1.3 for score 
variables. 
Table 1-3. TIMI Risk Score variables for unstable angina and NSTEMI 
Criteria Value 
Age ≥65 +1 
≥3 CAD risk factors* +1 
Known CAD (stenosis ≥50%) +1 
Use of aspirin in past 7 days +1 
Severe angina (≥2 episodes in 24 hrs) or persisting discomfort  +1 
ST segment deviation of ≥0.05 mV on initial ECG  +1 
Positive cardiac marker +1 
Total score  
Low risk 
Intermediate risk 
High risk 
 
1-88 
89-118 
≥119 
(CAD): Coronary artery disease. *Risk factors for CAD: Family history of CAD, hypertension, 
hypercholesterolaemia, diabetes, or current smoker. Adapted with modification from (Antman 
et al., 2000). 
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1.4.3.3. The Global Registry of Acute Cardiac Events (GRACE) 
Score 
This GRACE score is reported to be similar to the TIMI score from a study of 
a large sample population of patients who were confirmed to have ACS 
(GRACE, 2001). Two distinct risk stratification scores were developed from 
this large data set in this derivation study, as these represented 14 different 
countries and used observational data to record outcomes and characteristics 
of patients with ACS. Eight variables were developed to give predictions for in-
hospital mortality by Granger et al. (Granger et al., 2003)  and score variables 
are shown in Table 1.4, where the predictive value of each item was used to 
give a weighted score. This study also used derivation cohorts to validate 
these scores (Granger et al., 2003) and mortality was predicted at excellent 
levels by the GRACE scores, so that patients with scores ≥250 had >50% risk 
of mortality, and those with scores of ≤100 had ≤0.8% risk of in-hospital 
mortality (see Table 1.4). 
Table 1-4. The GRACE risk score 
GRACE score  
Age Points  HR Points  SBP Points  Cr Points  Killip class Points 
<39 0 <70 0 <80 40 0.0–0.39 1 I 0 
40-49 18 70-89 5 80-99 37 0.4–0.79 4 II 15 
50-59 36 90-109 10 100-119 30 0.8–1.19 7 III 29 
60-69 55 110-149 17 120-139 23 1.2–159 10 IV 44 
70-79 73 150-199 26 140-159 17 1.6–1.99 13 Cardiac arrest 30 
80-89 91 ≥ 200 34 160-199 7 2.0–3.99 21 Elevated cardiac 
markers  
13 
>90 100 - - ≥ 200 0 ≥4  28 ST segment 
deviation  
17 
Low risk  1-88 
89-118 
≥119 
Intermediate risk  
High risk  
GRACE: Global Registry of Acute Coronary Events HR: heart rate, SBP: systolic blood 
pressure, Cr: creatinine, Killip classification: I: no clinical sign of CHF II: Presence of rales 
(crackles) in the lungs, raised jugular venous pressure, or third heart sound (S3 gallop). III: 
Acute pulmonary oedema, IV: Cardiogenic shock. Adapted with modification from (Alley and 
Mahler, 2015). 
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1.4.3.4. HEART Score 
The HEART (history, ECG, age, risk factors and troponin) Score was recently 
developed for chest pain patients presenting to the ED (Six et al., 2008; 
Backus et al., 2013). The algorithm was not established on multivariate 
regression analysis, but was developed based on clinical decision experience 
in patients with known CAD with high a probability of having ACS. These 
studies reported a short-term MACE rate (AMI or death) between 0.6% and 
1.4%. The HEART score is different from TIMI Risk score or GRACE, because 
the HEART score was designed to predict the likelihood of ACS in patients 
presenting to the ED with acute chest pain. Instead, TIMI and GRACE are 
used to risk-stratify patients who have been diagnosed with ACS. By giving 
each of the five previous variables a score of zero, 1 or 2, each patient will 
have a score of zero to ten. However, the score divides patients into a low-risk 
group from zero to three, intermediate risk group from four to six or high-risk 
groups from seven to ten.  The HEART score divides patients into a low-risk 
group (0-3) and this score supports early discharge of patients. Intermediate 
discharge (4-6) are the patients who have a risk of 20.3% for an adverse 
outcome and should be admitted for further clinical observation, and finally, 
high-risk groups (7-10) are patients with a 72.7% risk, and these patients 
would require immediate, early treatment including invasive strategies without 
preceding non-invasive testing. The HEART score was designed to predict the 
likelihood of ACS in patients presenting to the ED with acute chest pain, when 
TIMI and GRACE were used to risk stratify patients who had been diagnosed 
with ACS. Recently, Mahler et al. evaluated 282 patients randomised to the 
HEART Pathway. Researchers confirmed a proven impact on reducing time 
for patient discharge from the ED. In the study, patients spent significantly less 
time in the hospital when compared with standard procedures of care. The 
time of early discharge in the HEART algorithm was 21% higher than the usual 
care group, 9.9 hours versus 21.9 hours respectively, with no adverse events 
occurring at 30 days in both groups (Mahler et al., 2015). The pathway has 
also been tested on secondary analysis using a contemporary sensitive assay 
and high sensitivity troponin assay. The researchers found no difference in the 
score of the HEART Pathway between the two assays with both achieving 
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100% sensitivity and NPV (Mahler et al., 2017). Another study has reported 
proof that using the HEART Pathway as a decision aid for patients is cost-
effective (Riley et al., 2017). 
1.4.3.5. MACS and T-MACS 
The Manchester Acute Coronary Syndromes (MACS) decision rule and the 
Troponin-only Manchester Acute Coronary Syndrome decision rule (TMACS) 
were applied in a computer model, and were derived by multivariate analysis 
to identify patients with acute coronary syndromes in the ED in 2014 by Body 
et al. These decision rules take account of eight variables, which are recorded 
or measured at the time of arrival in the ED (Body et al., 2014c).   See Table 
1.5 for MACS and T-MACS algorithm variables and for the rule formula.  The 
estimated probability of ACS, based on clinical judgment, is described in 
Table1.6. A patient arrives at the ED complaining of chest pain suspected to 
have a cardiac aetiology. A single serum blood test is taken from the patient 
and the risk of ACS is calculated using the (TMACS) or (MACS) formula.  This 
calculates the probability that the patient will experience a major adverse 
cardiac event (MACE) within the next 30 days. Based on that estimated 
probability, the rule assigns the patient to one of four risk groups: very low risk 
(ACS ‘ruled out’; suitable for immediate discharge); low risk (suitable for serial 
troponin testing in a low dependency environment such as an ED observation 
unit); moderate risk (requires admission to an Acute Medical Unit); and high 
risk (‘ruled in’ and therefore requires admission to a cardiologist). However, by 
applying the rule in the ED, the sensitivity of MACS for a MACE within 30 days 
ranged from 100-97.9%. The study reporting the lowest sensitivity stated that 
the two coronary stenoses (accounting for all the missed MACE) in the very 
low risk group did not require intervention. Applying the MACS rule could avoid 
unnecessary hospital admission for over one quarter of patients based on the 
results of a single blood test, while also immediately identifying 10% of patients 
as being at high risk (with over 95% positive predictive value). Earlier in 2014, 
in the original work of the research group, the h-FABP test in the MACS rule 
was a laboratory-based h-FABP assay using a commercially available ELISA  
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(enzyme-linked immunosorbent assay) kit. ELISA tests take several hours to 
be completed and this disadvantage makes the test inconvenient to run in 
emergency settings with a sufficiently short turnaround time. However, 
researchers then recalibrated the MACS rule to include a new, automated, 
commercially available immune turbidimetric assay suitable for quantitative 
measurement of h-FABP in serum and plasma in blood, which makes the 
assay appropriate to be used in emergency settings within faster turned 
around time, and makes it possible to influence clinical decisions within the 
required timescale for patients attending the ED (Body et al., 2015a).  In this 
study, the researchers included 456 patients, where 78 (17.1%) had AMI and 
97 (21.3%) developed a MACE. However, in comparison with the original 
MACS rule (including the ELISA assay for h-FABP), the recalibrated MACS 
rule applies the automated h-FABP test assay and identifies fewer patients as 
being at very low risk and suitable for immediate discharge. In the modified 
MACS rule study, 18.9% of the patients were classified as very low risk 
compared to the original MACS 27% of patients classified as very low risk. 
This makes the modified MACS with automated h-FABP assay much more 
useful (Body et al., 2015a). In 2016, the researchers then refined the MACS 
module with a version that required only a measurement by a high sensitivity 
troponin test (T-MACS). Therefore, the research suggests that MACS has 
greater sensitivity for ruling out ACS, however the assay required (h-FABP) is 
not widely used, minimising the utility of such a tool. TMACS requires only the 
hs-cTnT used in most hospitals. It has a sensitivity of up to 98.7%, and it can 
rule out ACS in more patients than LoD and MACS-based strategies. The goal 
was to diagnose ACS with a single blood test at patient arrival at EDs in order 
to avoid the limitations of adding a new test (h-FABP) as mentioned earlier, 
which increases the barrier of implementing MACS in clinical practice. TMACS 
demonstrated a sensitivity for a 30-day MACE of 98.7% from the original study 
and 96.3% from the external validation in Australia and New Zealand 
(Greenslade et al., 2017). The rule could have enabled the 35.5% of patients, 
as the ‘very low risk’ group, to be rapidly discharged with zero (0.0%) missed 
AMI and one (0.4%) missed MACE . The MACS and T-MACS rules have been 
validated in two different studies with two different troponin assays (Body et 
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al., 2014c; Va Den Berg et al., 2017). See Table 1.7 for a comparison of MACS 
and TMACS. 
 
Table 1-5. Troponin-only Manchester Acute Coronary Syndrome decision rule 
(TMACS) and the Manchester Acute Coronary Syndrome decision rule 
(MACS) Variables 
The T-MACS rule estimates the probability (p) of acute coronary syndromes 
as follows:  1 / (1 + exp –(-4.77 + 1.71E + 0.85A + 0.61R + 1.42V + 2.06S+ 
1.21B + 0.089T) where E is evidence of acute ECG ischaemia, A is worsening 
angina, R is pain radiation to the right arm or shoulder, V is pain associated 
with vomiting, S is sweating observed, B is systolic blood pressure <100mm 
Hg and T is cardiac troponin concentration (ng/L) on arrival in the ED. For 
dichotomous variables, a value of ‘1’ is entered for ‘yes’ and ‘0’ for ‘no’.  
Table 1-6. MACS and T-MACS risk groups 
Risk group defined by T-MACS  Probability threshold in the T-MACS Rule 
Very low risk <2% 
Low risk Between 2% and 4.9% 
Moderate risk Between 5% and 94.9% 
High risk >95% 
 
  
Present in Diagnostic algorithm MACS TMACS 
Heart-type fatty acid binding protein (h-FABP) Yes No 
High sensitivity cardiac troponin T (hs-cTnT) Yes Yes 
ECG ischaemia Yes Yes 
Sweating observed by treating clinician Yes Yes 
Vomiting associated with presenting symptoms Yes Yes 
Systolic BP <100 mmHg on arrival Yes Yes 
Symptoms of Crescendo Angina Yes Yes 
Pain radiating to the right arm/shoulder Yes Yes 
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Table 1-7. Comparison between MACS and T-MACS rule 
 MACS  T-MACS  
Number of patients included in the study  456 patients 703 patients  
Cut-off used in the rule  Rise and/or fall of >9.2 ng/L 
(≥10 ng/L as levels was 
considered to be significant) 
Lower Limit of detection of the 
high sensitivity Troponin assay  
Percentage of very low risk group (rule out)  18.9% 40.5%  
Percentage of high risk group (rule in)  11.1%  5%  
The sensitivity of rule for 30 day MACE Ranged from 100% -97.9% 98.7% from the original study 
and 96.3% from the external 
validation  
NPV  97.7% 99.3% 
30 day risk of ACS <2% <2% 
 
1.5. Risk Stratification and Clinical Decision-making 
When patients present ischemic symptoms, ACS diagnosis should be 
considered, but decisions regarding whether patients should be discharged or 
admitted with suspected MI should be based on biomarkers and ECGs 
combined with separating MI from other possible causes based on 
assessments by physicians (Smith et al., 2015). Judgments of clinicians are 
critically important, as these also provide information for health care 
managers, scientists and other clinicians (Kienle and Kiene, 2011). Treatment 
plans and conclusions developed by clinicians are based on objective and 
subjective data, as well as radiologic results, laboratory data, physical 
symptoms and signs, and patient history. The diagnostic value of ED 
physicians’ overall clinical assessments (gestalt) of ACS, in combination with 
ECGs and initial troponin results, has been evaluated in several studies 
(Chandra et al., 2009; Kline and Stubblefield, 2014; Dezman et al., 2017). One 
previous study has shown improved accuracy when combining clinical 
judgment with the ECG and biomarker findings in the assessment of 458 
patients with chest pain in the ED. The researcher's strategy would have 
avoided admission for 23.1% (95% CI 19% to 28%) and 41.7% patients could 
have been discharged immediately (Body et al., 2014a).  Recently, a study 
evaluated the HEART score and clinical gestalt in chest pain patients 
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presenting in the ED and found a similar diagnostic accuracy for diagnosing 
ACS for both risk stratification tools (Visser et al., 2014). Another study 
conducted in Sweden reported that patients with a non-ischemic ECG and 
normal initial troponin values shows that a history of UA chest pain can 
moderately predict UA, but a history of MI chest pain does not significantly 
predict MI. In addition, ACS is strongly predicted by an ischemic ECG and 
positive initial troponin values, and for ruling in ACS this appears to be more 
important than the pain history of patients. Finally, all ACS can be ruled out for 
patients younger than 40 years of age, when gestalt does not indicate ACS 
overall and is confirmed with patients’ chest pain history. Therefore, in terms 
of ruling out ACS and ruling in ACS, this study argues that gestalt is better 
than its components (Mokhtari et al., 2015).   
Another study by Carlton et al.(Carlton et al., 2015a) suggests that when no 
diagnostic ECG is used for assessing patients, gestalt could provide the most 
useful help for clinicians, and investigated 912 patients that had presented at 
ED with chest pain and were not given a diagnostic ECG. An ACS diagnosis 
was based on the rating given by physicians for the type of chest pain 
presented by patients, and to confirm their personal experience level where 
over two years of practice was shown to be experienced, and less than one 
year of experience was shown to be novice. 
For both experienced and no-experience clinicians, the Receiver Operating 
Characteristic (AUROC) was 0.54 to 0.55 (p<0.05), so there was a low 
correlation for the type of chest pain presented by patients with the final 
diagnosis of ACS, and when significant CAD on catheterisation was shown by 
examination of the patients and evaluated by clinicians, this did not change. 
For all comparisons, there was a low AUROC of 0.43–0.56, (p>0.05) for 
experienced and novice physicians. These findings conclude that when 
compared with troponin and ECG testing, there is little diagnostic value shown 
by the judgment of physicians, so that there should be greater focus on rapid 
rule-out protocols and high-sensitivity assays in future research studies to 
enable patients to be discharged quickly from EDs when they are accurately 
identified as no-risk or low-risk patients.    
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1.6. Cardiac Biomarkers: Historical Perspective 
The concept of the biomarker was defined in 1998 by the National Institute of 
Health Biomarkers Definitions Working Group as a contracted version of 
biological marker, which is an indicator that accurately measures and 
evaluates therapeutic intervention pharmacologic responses, as well as 
identifying pathogenic and normal processes (Strimbu and Tavel, 2010).  
However, patient outcomes and management provide the evaluation of 
whether a biomarker has a positive clinical value by its impact potential, so 
that before recommendations can be given for clinical use of new biomarkers, 
the American Heart Association in 2009 published detailed criteria that need 
to be met for newly developed biomarkers within a framework that is 
standardised (Hlatky and Hong, 2009).  
There are significant medical challenges when approaches adopt biochemical 
diagnostic methods, as these are considered to be contentious and difficult 
(Rosalki et al., 2004), because to achieve accurate diagnosis, specific criteria 
are needed for biomarkers used to diagnose myocardial ischemia. These 
criteria should include cost- effective, rapid and simple testing procedures, 
biomarkers must diagnose the extent of the injury by remaining within the 
blood for sufficient time, and at the time of ischemia, should be released rapidly 
into the blood, as well as being specific to cardiac muscles and demonstrating 
significant concentrations in the myocardium (Lippi et al., 2006).  Various 
cardiac biomarkers are shown as a timeline in Figure 1.5.  During the 1960s, 
AMI was first diagnosed with a biomarker known as aspartate transaminase 
(AST), and during this decade the WHO incorporated this into its definition of 
AMI, but the characteristics of AST are not sufficiently specific for cardiac 
damage to be effective for detection, as it cannot specify cardiac muscle 
(Ladue et al., 1954). AST returns to values that are normal five days after AMI, 
achieves maximum value in the blood from 15 hours and up to 28 hours, and 
after AMI, AST increases in the blood from 3 to 4 hours (Penttila et al., 2000).  
Creatine kinase (CK) and lactate dehydrogenase (LDH) are additional cardiac 
biomarkers that began to be used during the 1970s and, although within the 
context of AMI, LDH is less specific for cardiac muscle than CK, both of these 
newly introduced biomarkers have no specific criteria for cardiac muscle. LDH 
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and the LDH-1 isoenzyme return to values that are normal after 12 days, 
achieve maximum value in the blood after 60 hours and until 144 hours, and 
after AMI these increase in the blood after 5 hours and until 10 hours 
(Christenson and Azzazy, 2006). CK returns to normal values after 72 hours, 
achieves a maximum value in the blood after 10 hours and until 20 hours, and 
after AMI increases in blood after 3 hours until 9 hours (Al-Hadi and Fox, 
2009). In 1998, a RIA or radioimmunoassay was developed to detect 
myoglobin in serum, which is found in cardiac and skeletal muscle, and is 
defined as an oxygen-binding small cytoplasmic protein (Varki et al., 1978). 
This became more useful than previous cardiac biomarkers, as it could be 
used for differential diagnosis of potential AMI, returned to normal values 
immediately, peaked between 4 and 12 hours, and after myocardial injury this 
is released into the serum after 1 hour, which is extremely early (Mair et al., 
1992; Keffer, 1997).  
This innovative development replaced enzymatic assays that had been used 
previously, so this introduced protein concentration as an immunologic 
determination of CKMB mass, and in 1985, the first mass immunoassay for 
CKMB was reported (Chan et al., 1985). The isoforms of the brain and the 
muscle are combined as letter symbols of B and M for forming the basis for 
MB, MM and BB isoenzymes, because the CK enzyme is present in humans. 
The highest concentration of the CKMB isoenzyme is shown in cardiac 
muscle, but for skeletal and heart diseases this can be very low or 
undetectable in the blood, whereas in the skeletal muscle it is  ~1–3% total CK 
content, but in the myocardium it is 22% (Maisel and Jaffe, 2016). Within the 
first few hours of cardiac symptom diagnosis, CKMB sub-forms provide high 
accuracy, and diagnoses that are specific and reliable, which is reported in 
various studies (Puleo et al., 1990; Puleo  et al., 1994).  Rapid enzyme 
immunoassays was developed in 1990 to enable direct mass measurements 
of CKMB by using rapid enzyme immunoassays (Wu, 1999; Brandt et al., 
1990).  For the purposes of this current study, the research focuses on heart 
fatty acid binding protein and troponin as cardiac biomarkers, which are 
discussed in detail in the following sections. 
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Figure 1-5. The kinetics of release of creatine kinase MB (CKMB) and 
cardiac troponin 
Patients who do not undergo reperfusion are shown in the solid green and red curves as 
multiples of the upper reference limit (URL). Note that when patients with ST segment 
elevation myocardial infarction (STEMI) undergo reperfusion, as depicted in the dashed green 
and red curves, the cardiac biomarkers are detected sooner, rise to a higher peak value, but 
decline more rapidly, resulting in a smaller area under the curve and limitation of infarct size. 
AMI = acute myocardial infarction. Adapted from (Lilly and Braunwald, 2015). 
1.7. AMI Definitions: Historical Perspective 
The WHO published a definition of AMI in 1971 that applied the criteria of 
extensive laboratory testing, ECG or electrocardiogram abnormalities, and 
myocardial ischemia suggested by chest pain presented by patients, which 
changed its previous definition of AMI (Fox et al., 2004). This definition was 
extended by the WHO in 1979 by including criteria of typical rise and fall 
patterns of LDH, CKMB and CK or AST activities (WHO, 1979). Between the 
late 1980s and early 1990s, myonecrosis cardiac troponin biomarkers were 
first developed, and were shown to be highly sensitive and specific, which 
contributed to MI being given its first universal definition and further updates 
(Alpert et al., 2000). In 2000 and in 2007, further definitions of MI were 
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published that became universal, because new classifications of MI were 
included, as well as definitions that were more reproducible and standardised. 
The first of these definitions enabled the characterisation of the timing, trigger 
and size of AMI, and within the setting of AMI or myocardial ischemia, the 
classification of all degrees of myocardial necrosis (Alpert et al., 2000). The 
second of these new definitions included a new classification with five 
categories, as well as updating the first definition of MI (Thygesen et al., 2007).  
Subsequently, myocardial infarction’s definition was developed further with a 
third universal definition because, within the settings of post revascularisation 
and critical illnesses, myocardial necrosis definitions were revised, and use of 
high-sensitivity assays to diagnose cardiac necrosis was developed 
significantly (Thygesen et al., 2012a). 
1.8. Cardiac Markers: Characteristics 
Table 1.8 shows characteristics of cardiac markers that are optimal, as certain 
criteria are needed in secondary care or primary care when ACSs are 
indicated in chest pain reported by patients, so that myocardial injury can be 
evaluated by using an optimal plasma marker. Cardiac markers need to 
demonstrate low concentrations in non-cardiac tissue, but demonstrate high 
concentrations in the myocardium, and must provide cardiac specificity. As 
well as normal physiological conditions, it is also important to consider 
pathological states when evaluating the tissue distribution of potential 
markers. Therefore, CKMB or creatine kinase MB isoenzyme is not a perfect 
cardiac marker, because it is found in significant, but small, concentrations in 
skeletal muscle, and the absolute activity of the CKMB fraction in blood could 
be increased due to skeletal muscle injury (Babuin and Jaffe, 2005).  
When evaluating injured myocardial tissue with a marker, the speed of its 
release in the blood is influenced by various factors, such as large molecules 
being released slower than small molecules, so that, when selecting a marker, 
its molecular size is important (Zaninotto et al., 2004). The rate of release can 
also be limited by the intracellular location of the marker, so that structural 
proteins will appear later in the bloodstream than molecules located in the 
cytoplasm. See Table 1.9 for Acute Myocardial Infarction: Plasma Biomarkers 
Characteristics depends on the sensitivity of the assay have been used.  
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Table 1-8. Optimal Cardiac Marker: Characteristics 
High sensitivity Cardiac tissue shows abundance 
High specificity Non-myocardial tissue shows absence 
Non-diseased subjects cannot be detected in blood  
Release  Early diagnosis due to rapid release 
Late diagnosis due to long half-life in blood 
Analytical Accurate  
Precise 
Short turnaround time 
Cost effective 
Clinical Patient outcomes improved as therapy is influenced   
Clinical studies provide validation 
Table 1-9. Acute Myocardial Infarction: Plasma Biomarkers Characteristics 
Marker protein Molecular 
mass 
(kDa) 
*First elevation in 
plasma after AMI (h) 
Peak plasma 
concentrations 
*Normalisation of 
plasma level (days) 
h-FABP 14.5 1–2 6–12 1–1.5 
Cardiac troponin I 22.5 3-8 12-24 7-10 
Cardiac troponin T 37.0 3-8 12-24 7-10 
Myoglobin 17.8 2-3 6-12 1-2 
Creatine kinase MB 86 2-6 12-24 2-3 
Abbreviations: AMI, acute myocardial infarction; h, hours; h-FABP, heart-type fatty acid-
binding protein; kDa, kilo Dalton. *First elevation in plasma after AMI above the upper 
reference level of the marker protein. *Normalisation of plasma level (days) this level depends 
on time of reperfusion after arterial occlusion. Adapted with changes from (Willemsen et al., 
2016). 
 
1.9. Heart-type fatty acid-binding protein  
In 1988 in a study of myocardial injury, h-FABP was first reported to have 
potential as a plasma marker (Glatz et al., 1998). This plasma marker can 
supply substrates that are essential for energy production in the monocytes -
,in parenchymal cells, it functions as an intracellular fatty acid carrier - but also 
h-FABP is relatively small in size at 14.5 kDa (Glatz et al., 2003). H-FABP is 
one of the most abundant cytosolic proteins, as it presents 1–2 % of total 
cardiac cytosolic proteins, and found in small quantities in parts of the brain, 
in distal tubule cells of the kidney and in slow twitch oxidative skeletal muscle 
(O'Donoghue et al., 2006). In addition, when patients present with myocardial 
cellular damage, it is released in significant quantities to the interstitial space 
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and also rapidly, and then escapes into the vascular space through endothelial 
clefts due to the factors of small size, cardiac tissue abundance and cytosolic 
occurrence (VanNieuwenhoven et al., 1996) 
Troponin I is one and a half times larger than h-FABP at 22 kDa, and troponin 
T is three times larger than h-FABP at 37 kDa but, despite their smaller size, 
these and other troponins can present in plasma much later than h-FABP, 
because these need to be cleaved proteolytically from the contractile matrix 
after cellular damage. Therefore, to investigate possible cardiac injury, the first 
available plasma marker is h-FABP (Reddy et al., 2016), and the cumulative 
release of h-FABP into the plasma enables estimations of infarct size, because 
the injured myocardium releases h-FABP when complete (Groot et al., 1999). 
However, these estimations could be limited by renal clearance, as the kidneys 
are subsequently responsible for clearing h-FABP from the plasma (Al-Hadi 
and Fox, 2009).  It is also affected by any coronary intervention that might be 
initiated immediately in a symptomatic patient (Wodzig et al., 1998). H-FABP 
and other small proteins are cleared rapidly by the kidneys, which maintains a 
generally low plasma reference. Reports on plasma H-FABP reference values 
are limited (Niizeki et al., 2007). The reported upper reference limit, i.e., the 
99th percentile of the plasma H-FABP reference concentration, ranges from 5 
ng/mL (Bathia et al., 2009) to 9 ng/mL (Carless et al., 2013) these levels are 
higher for men at 1.9 ng/ml than for women at 1.5 ng/ml (Glatz and Mohren 
2013). Adults over the age of 50 years often present with decreased renal 
function and although circulating levels of h-FABP increase slightly with age. 
However, these effects should be taken into account in determining 
appropriate reference values for H-FABP. 
 
1.10. Ruling out ACS: Combining Troponin and h-FABP 
Numerous studies have investigated the utility of h-FABP for supporting the 
diagnosis of AMI and for prognostic stratification. A study by Liebetrau et al. 
(2014) has been reported that the h-FABP level is increased within only 15 
min following trans coronary ablation of septal hypertrophy, a procedure 
mimicking AMI in patients with hypertrophic obstructive cardiomyopathy 
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(Liebetrau et al., 2014). A recent meta-analysis published in 2017 by Xu et al. 
noted that routine use of h-FABP could not be necessary to diagnose AMI in 
early after-symptom onset even within 3 h (Xu et al., 2017). Recent studies 
showed that h-FABP has high negative prognostic value for AMI in patients 
with suspected ACS, and it could be a supportive test when used in addition 
to high-sensitive troponin T. Recent clinical research has compared the 
diagnostic accuracy of h-FABP and high-sensitive troponin. A study by Kellens 
et al.  (2016) evaluated the diagnostic accuracy of hs-TnT troponin and h-
FABP tested by POC assays in 152 patients on admission, 6 h after admission 
and 15 hours after admission. The diagnostic sensitivity for ACS diagnosis 
when combining both tests was 82%, 88% and 89% respectively and the NPV 
for combining test was 70%, 82 % and 83% respectively, while the hs-TnT 
diagnostic sensitivity by its own was 72%, 93% and 94% respectively. These 
results showed that combining both hs-TnT and h-FABP tested by POC 
assays did not substantially improve diagnostic accuracy (Kellens et al., 2016). 
Another more recent study analysed the data from 2,735 patients taken from 
eight earlier studies with qualitative h-FABP tests, and reported combining cTn 
with h-FABP increased pooled sensitivity 73 % to 91 %, but decreased pooled 
specificity from 94 % to 82% (Lippi et al., 2013).  Moreover, Keller et al. (2011), 
reported on combining quantitative hs-cTnI with h-FABP in a rule out strategy 
for ACS diagnosis and the NPV increased from 95.9 % to 97.6 %, PPV 
decreased from 66 % to 60 %, specificity decreased from 95% to 91%, and 
sensitivity increased from 73% to 85%. However, this finding indicated that the 
NPV of the combined test fulfils the diagnostic requirements for a rule-out 
strategy. In this study, the time between chest pain onset and admission to the 
ED was between 2 hours to 13 hours. However, it was not evaluated whether 
the performance of the combined test is dependent on the time of presentation 
of the patient (Keller et al., 2011a).  Similar findings were reported in another 
study, so that for MI diagnosis, when a conventional sTnI assay was combined 
with h-FABP this increased NPV from 92 % to 97 % and sensitivity from 77 % 
to 92 %, which shows significant enhancement. This study also reported that 
in patients who present to clinical settings within a few hours, combining hs-
cTnI and h-FABP resulted in NPV and sensitivity achieving 100%, but overall 
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diagnostic accuracy did not improve when h-FABP was combined with hs-cTnI 
compared to hs-cTnI alone (Ruff et al., 2013).  
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1.11. Cardiac Troponin  
Cardiac troponin is the reference standard biomarker for the diagnosis of AMI. 
In the appropriate clinical context, the detection of a rise and/or fall of cardiac 
troponin is highly sensitive and specific for this diagnosis. However, troponin 
testing has two key limitations. First, as levels in serum or plasma can take 
several hours to rise, the diagnostic sensitivity of troponin testing is insufficient 
to allow ACS  to be safely ‘ruled out’ and serial testing remains necessary. 
Second, because of the need to detect a rise and/or fall of troponin, serial 
testing is essential to differentiate chronic troponin elevations from those 
related to AMI. As a result, international guidance currently recommends serial 
testing over 6-12 hours. Troponin is not present in smooth muscle, but is a 
protein filament segment of skeletal muscles and the myocyte or contractile 
cardiac muscle cell (Zoltani, 2014). Figure 1.6 shows the troponin complex, 
tropomyosin, actin and myosin that form the contractile unit of the cardiac 
muscle cell. Actin produces the thin filament, and G actin units or globular 
proteins form a double coil, so that a tropomyosin protein covers each thin 
actin myofilament, and is linked to the troponin complex (Pinnell et al., 2007). 
This is illustrated in Figure 1.7 TnT or Tropomyosin binding subunit, a TnI or 
inhibitory subunit, and a TnC or Ca²+ binding subunit form the heterotrimer 
protein known as the cardiac troponin complex. Calcium signalling regulates 
excitation-contraction coupling in cardiac muscle and skeletal muscle. Muscle 
contraction results from structural changes in the thin filament proteins initiated 
by calcium binding to TnC (Takeda et al., 2003; Farah and Reinach, 1995).  
The TnI protein binds the heterotrimer to the thin filament closely when calcium 
is not bound by TnC. A hydrophobic section is exposed and the TnI prefers to 
bind to this, when conformational change is caused by the binding of calcium 
by TnC. This action results in the thin filament moving away from the complex, 
so that tropomyosin binds to TnT, and actin binding sites are then exposed 
that had been covered by TnI. All these actions contribute to muscle 
contraction. (Geeves and Lehrer, 2014; Tortora and Grabowski, 1996). cTnI 
or troponin I and cTnT or cardiac troponin T control calcium-mediated 
interactions between the myosin and actin, and are found in small quantities 
(5%) in the cytoplasm, but mostly in myofibrils (95%), as these are cardiac 
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regulatory proteins ('Troponins, Cardiac A2 - Wilson, David A', 2012). There is 
a unique structure for each of the three isoforms of cardiac muscle, fast-twitch 
skeletal muscle and slow-twitch skeletal muscle (Berridge et al., 2013). 
However, after cardiac injury, specific genes code the regulatory proteins of 
the cardiac forms, so that these unique proteins are released into serum from 
the myocardium. Within skeletal muscle, some cardiac troponin T is present, 
but beyond the myocardium, cTnI is not present (Wu, 2017). 
 
 
Figure 1-6. The troponin complex, tropomyosin, actin and myosin that form the 
contractile unit of the cardiac muscle cell 
TnT or Troponin T, TnC or Troponin C and TnI or Troponin I. Adapted from  (Hasić et al., 
2003). 
 
37 
 
Figure 1-7. Troponin Complex Cross-Section 
Actin produces the thin filament, and G actin units or globular proteins form a double coil, so 
that a tropomyosin protein covers each thin actin myofilament, and is linked to the troponin 
complex. Picture adapted from (Tortora and Grabowski, 1996). 
Based on the literature review, cTnI and cTnT are known to be very sensitive 
and specific for myocardial damage despite the underlying cause of these two 
markers’ elevation. Lately, it has been found that cTns can be elevated and 
indicate worse prognoses in many other conditions where ACS is not present. 
However, this finding affects the troponin validation as a cardiac marker for 
ACS without classic symptoms. Also, this finding makes the area of the 
troponin cut-off value challenging (Tanindi and Cemri, 2011; Al-Otaiby et al., 
2011). Table 1.10 illustrates the potential causes of troponin level elevation in 
blood, excluding AMI. 
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Table 1-10. Potential Causes of Troponin Level Elevation in Blood, Excluding 
AMI 
-Sepsis 
-Pulmonary embolism 
-Hypothyroidism 
-Hypotension with arrhythmias 
-Hypertension and gestational 
-Haemoglobinopathy with transfusion haemosiderosis 
-Heart transplant 
-End of life stage renal failure 
-Over 30% of body affected by burns       
-Drug toxicity  
-Diabetic ketoacidosis  
-Patients who are critically ill 
-Congestive heart failure 
-Cardiotoxicity caused by cancer therapy 
-Carbon monoxide poisoning 
-Increased wall stress 
-Anaemia 
-Amyloidosis 
-Acute rheumatic fever 
Table 1-11. Troponin characteristics 
Characteristics Troponin I Troponin T Troponin C 
Weight 26.5 kDa 39 kDa 18kDa 
Function 
Actomyosin–
ATP-
inhibition 
subunit 
Anchors troponin 
complex to the 
tropomyosin strand 
Calcium binding subunit   
Cardiac Specificity Yes Yes No 
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1.12. Myocardial Injury: Time of Protein Release 
Early diagnosis could be facilitated quickly following an injury, as some 
markers released into the blood make an early appearance. Following 
infarction events, there is a rise in cardiac troponins between four and six 
hours, which is similar to CKMB, and could take weeks for normal levels to 
return, but these peak between 12 and 24 hours. Previous research findings 
indicate that developing myocardial injury could be detected by using serial 
troponin measurements, because after an ischemic event, troponin elevation 
timing is important as, after myocardial injury, cTnI and cTnT are normally 
shown to be elevated between 4 and 9 hours, but also peak between 12 and 
24 hours. Then, over the next 7 to 14 days, these enzymes remain in a state 
of elevation in the blood (Mythili and Malathi, 2015)  
Therefore, emergency department clinicians need to know the time when 
chest pain was first presented in patients, because if the injury occurred within 
two hours of presentation at a hospital, commonly used assays might not be 
able to detect troponin elevations. However, this limitation could be overcome 
by observing patients that lack changes in ECG test results, because this could 
suggest a negative initial troponin, as well as suggesting ST segment 
myocardial infarctions. This period of patient observation could take several 
hours and involves cTn measurements, telemetry monitoring and physical 
examinations that are repeated.  To enhance efficiency in EDs and ensure 
patient safety, studies have attempted to identify the shortest time needed for 
these observation periods, and findings report that after presentation, cTn 
evaluations should be repeated at 6 to 8 hour periods. However, there is 
pressure on clinicians working in EDs due to high numbers of patients 
presenting, so time points are not realistic options, and the only choices 
available are for clinicians to admit patients believed to be at health risk to 
observation units or inpatient wards in hospitals. One previous study suggests 
that for specific patients, repeat measurements could be taken at between two 
and three hours as a time point, based on findings related to troponin release 
and measurements (Collinson, 2015). 
Findings also indicate that for patients with chest pain that developed from 6 
to 24 hours before presentation at the ED, serial troponin measurements are 
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shown to improve sensitivities for ACS diagnosis (Nagurney et al., 2005). In 
regard to risk stratification scores, researchers noted that in properly risk-
stratified patients, chest pain evaluation with standard troponin I at patient 
presentation and two hours later lead to decreased disposition times without 
any significant increase in MACEs when compared to a conventional serial 
troponin measurement at time zero. After the observation period, the patient 
will follow the second troponin test in six to twelve hours. Those patients were 
classified as low risk on the “accelerated diagnostic protocol” in the study 
(Than et al., 2014a). AMI diagnosis is often reached by choosing this marker 
within clinical settings, as it represents a significant rise and fall, and is 
recommended by the American College of Cardiology and European Society 
of Cardiology. The diagnostic criteria for MI enables clinical decision-making 
when healthy individuals are represented by a cut-off at the 99th percentile and 
normal, but above this indicates health concerns. Myocardial infarction was 
given its third universal definition in 2000 by a consensus group that was 
internationally based, and reported cardiac troponin or other cardiac biomarker 
values that are detected to rise or fall with a value higher than the 99th 
percentile and one of the following factors provides confirmation  
• Autopsy or angiography that identifies intracoronary thrombus, 
• Regional wall motion abnormality that is new, or imaging evidence of 
loss of viable myocardium that is new, 
• ECG or electrocardiogram detecting pathological Q waves, 
• Possible new left bundle branch block or possible new significant ST 
segment-T wave or ST-T, and 
• Ischaemia symptoms. 
1.13. Cardiac Troponin Assays  
Serum cardiac markers of TnI were first classified in the 1970s, and of TnT 
were first classified in the 1980s, to indicate myocardial injury (Dean, 1998). 
The quantity of bound troponin is determined by a detection antibody, and cTn 
assays with either polyclonal antibodies or monoclonal antibodies to bind the 
molecule uses a two-sided sandwich immunoassay (Suetomi and Takahama, 
1995). Cummins and colleagues reported the development of a cardiac-
specific troponin I assay in 1987 for the first time (Cummins et al., 1987), and 
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in 1989, Katus and colleagues reported the first cTnT assay (Katus et al., 
1989). To achieve a timescale that is clinically useful, results need to achieved 
within a short period, so the assay should be quick, specific and sensitive, and 
the development of the assay has needed to address these factors (Hawkins, 
2007).  Proteolytic degradation complexing with other molecules and 
phosphorylation are some of the factors that could affect cTn measurements, 
because there are various complexes and forms of cTn as it circulates in the 
blood, such as oxidised, reduced and phosphorylated cTn, T-I-C ternary 
complex, I-C binary and free cTn. However, manufacturers normally identify 
specificity for all antibodies, and the circulating form should be detected by 
antibodies (Sato et al., 2012; Melanson et al., 2007). Acute MI is diagnosed 
with a cut-off value above the 99th percentile with precision and a variance 
coefficient of around 10% within recommended professional guidelines, as 
discussed earlier, but the normal reference population of the 99th percentile 
has been insufficiently precise when using cTnI assays and cTnT assays, until 
recently (Thygesen et al., 2012a). Conventional assays are known as initial 
first-generation troponin assays and are used to assess troponin for patients 
presenting at EDs with chest pain. Therefore, after the onset of chest pain 
between 6 hours and 12 hours, troponin can be detected in the blood with 
100% sensitivity, and troponin is detected at microgram levels in these assays.  
Therefore, in guidelines to rule out MI, patients needed a second 
measurement assessment after between 6 and 12 hours (Thygesen et al., 
2012a). In healthy individuals, troponin concentrations are not accurately 
detected with conventional assays, and there are problems identifying upper 
reference limits, so that patients have needed to be categorised as 
undetectable or troponin-negative or detectable or troponin-positive following 
qualitative assessments (Ammann et al., 2003). Conventional assays present 
a significant limitation, because after patients first present at emergency 
department, they often display a delayed rise in circulating concentrations of 
cTn. Therefore, new assays have been developed to overcome these 
weaknesses in analysis, and the high sensitivity troponin assay is capable of 
measuring troponin at picogram levels and nanogram levels, so that troponin 
can be detected in blood much quicker and with greater sensitivity (Apple et 
al., 2012a).  
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An hs-cTn assay that would be ideal should measure below the 99th percentile 
for a healthy population at around 95% of normal values and achieve high 
sensitivity (Apple et al., 2012a). A URL or upper reference limit applies 
accurate assessments of the 99th percentile with a coefficient of variation (CV) 
or confidence interval of 99%, and around 10% total CV for the 99th percentile 
for a population defined as healthy, and with variations of ethnicity, race and 
sex (Apple et al., 2012a). Developing more sensitive assays should help to 
limit those patients in EDs whose myocardial injuries have not been previously 
detected, and many studies report that EDs that apply hs-cTn assays to 
evaluate patients considered to be at risk, achieve greater diagnostic 
sensitivity when compared with traditionally adopted assays when patients 
present at the clinical setting for the first time (Reichlin et al., 2009). However, 
previous studies also highlight some limitations of using hs-cTn assays, such 
as inflated estimates of diagnostic sensitivity, because evidence suggests only 
90% of diagnostic sensitivity at presentation with the cut-off set at the 99th 
percentile. Therefore, the LoD cut-off strategy has been applied by some 
researchers to improve evaluations.  
Table 1-12. Potential Utility and Challenges of the High-Sensitivity Troponin 
Assay 
Potential Utility 
 
Potential Challenges 
More rapid diagnosis in ACS Not specific to etiology 
Population screening False positive interpretation 
Prognostic information in stable patients Biological variability 
Drug development and cardiotoxicity Lack of assay standardisation 
Adapted from (Sherwood and Kristin Newby, 2014) 
1.14. Point-of-care testing 
Several approaches in sensor technologies and biomarkers have been 
developed recently. These allowed clinical diagnostic testing to be moved 
closer to the patient and to be tested outside the traditional lab environment 
(central laboratory) in the hospital. However, this has led to the development 
of devices called Point-of-Care Testing (POCT) (Quinn et al., 2016).  POCT is 
defined as diagnostic testing at, or near, the area of patient care. It is also 
known as bedside testing or near-patient testing (Luppa et al., 2011). If 
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implemented appropriately, POCT can reduce the turnaround time (TAT) to 
therapeutic intervention, which is has had an impact on improved patient 
outcomes, see Table 1.13 for several advantages of POCT. Before 
implementing POCT in the hospital, careful selection of the device should 
consider the local and international performance recommendations. Also, 
clinical needs assessment should be undertaken. (Clinical needs assessment 
defines unmet needs within healthcare). This approach, reached by gathering 
the information regarding the scope of POCT, also determines the potential 
impact of the current gap between traditional laboratory testing and clinician 
decision-making. To identify the clinical needs, several processes are used to 
analyse the available information regarding the clinical needs and to evaluate 
the analytical targets in addition to improving the assay performance and 
utility. This assessment could be approached by clinical research as this could 
determine the gaps and find answers on how to fill them (Weigl et al., 2012). 
On the other hand, there is a range of barriers that might prevent successful 
implementation of POC testing that has been addressed in a recent literature 
review. See Table 1.14. for numbers of barriers to implementation of POC 
testing in hospitals 
In the UK, the Oxford Diagnostic Horizon Scanning Programme was 
established in 2008 to present efficient information, which is needed for 
identifying and summarising the evidence for arising diagnostic technologies 
relevant to clinical settings. The available POCTs on the market are identified 
through systematic literature searches. The programme aims to interact with 
clinicians and the diagnostic industry to summarise the analytical, diagnostic 
accuracy from the manufacturer or previous researchers of the biomarkers 
tested by POCT.  The finding then prioritised using a set of criteria. However, 
these criteria were divided into high priority or intermediate priority, see 
Table1.15 for the recommended criteria for the prioritisation of POCT. 
The detection of cardiac troponin is the most sensitive and specific biomarker 
of myocardial injury that is available to the physician in clinical settings and 
EDs (Wang et al., 2017).  The early identification or ruling out of the presence 
of ACS relies on a combination of signs and symptoms, cardiac biomarker 
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levels and findings in the ECG, according to the European Society of 
Cardiology (ESC) guidelines (Ibanez et al., 2017). 
Up-to-date, limited-need assessment studies on troponin testing by POCTs 
have identified diagnostic assessment gaps in hospital and emergency 
settings.  In the area of developing a new algorithm in EDs to rule out AMI 
patients, or using a new platform assay for analytes in order to transfer a test 
from the laboratory setting to POC, it is essential to evaluate the diagnostic 
accuracy of the device, evaluate the agreement between POCT and central 
laboratory methods, and evaluate the POCT not only on comparative 
analytical significance, but also on its sensitivity and specificity in clinical 
practice. See Appendix 1.1 
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Table 1-13. Benefits of Point-of-Care Testing 
The key benefits of point-of-care testing include: 
• Positive patient identification 
• Immediate diagnostic test results (reduced test and therapeutic turnaround time); 
• Reduction and/or elimination of specimen/sample transport; 
• Elimination of blood collection tubes and centrifugation with fresh whole blood 
specimen; 
• Reduced blood specimen volume; 
• Room temperature storage of test devices (few require refrigeration); 
• Data management and connectivity.  
• Connected POCT system benefits include: 
• Reduction in transcription errors; 
• Immediate data analysis—utilisation, QC, compliance, data mining; 
• Development of disease-specific algorithms—for example, tight glycaemic control. 
• New and novel approaches to patient care—for example, patient-centric care. 
Table 1-14. Barriers to Implementation of Point-of-Care testing in hospitals 
Barrier categories Key issues 
Economic issues  Cost per test of POC device is higher than central laboratory test 
Cost-effectiveness is difficult to compare between several sites 
Initial cost of implementation is high  
No specified budget for allocation 
Reimbursement structure within the hospital 
Quality assurance and 
regulatory issues  
Operation issues related to untrained or not competent staff 
Accreditation challenging to maintain regulatory compliance for a POC 
system 
Complex regulatory requirement associated with the accreditation 
Lack of investment in the research area of product qualification such as 
diagnostic studies and difficulty of the registration process of the product in 
the country   
Device performance and data 
management issues  
Lack of analytical performance studies in comparison to centralised 
laboratory testing 
Connectivity and data 
management issues  
Lack of acceptable connectivity capabilities 
Problems related to IT connectivity within the hospital  
Management structure and 
clinical governance  
Lack of interdepartmental management structure with clear clinical 
governance for POCT  
Adapted with changes from (Quinn et al., 2016) 
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Table 1-15. Recommended criteria for the prioritisation of POCT 
High priority Intermediate priority Yes or No 
answer 
Does the test have impact on morbidity 
and/or mortality of the disease? 
Available information on the prevalence of the 
disease  
 
Reduces the number of people falsely 
diagnosed in target condition? Low false- 
negative result?  
Is there a variation in treatment or patient 
outcomes resulting from POCT? 
 
 
Better diagnostic precision resulting in 
improvement in the delivery of diagnosis 
The current diagnostic pathway for the 
disease could be improved by obtaining 
information in also less risky or in a way more 
acceptable to patients. 
 
Does the POCT improve the ability to rule 
out the disease?  
Availability of safety profile of the POCT  
Is there available evidence of diagnostic 
accuracy in the setting needed to 
implement this POCT?  
The impact of the POCT to rule in the disease   
Is the POCT would improve diagnostic 
efficiency or is it cost-effective? 
It would be feasible to change current practice 
to incorporate this POCT 
 
Table data adapted with change from (Plüddemann et al., 2010) 
 
1.15. Accelerated chest pain protocols 
Recent ESC guidelines were published in 2015, which supported the use of a 
new algorithm combining performing serial measurements of hs-cTn (at 
admission and repeated at 3 h) in addition to the clinical information available 
from chest pain patients in order to evaluate and risk stratifying patients 
according to their risk of AMI. In order to shorten the length of stay in the ED, 
the guidelines also suggested an algorithm that is proven for some, but not all, 
hs-cTn assays (including the hs-cTnT from Roche Diagnostics), and provides 
immediate or very early exclusion of AMI (Roffi et al., 2015). This algorithm is 
based on either a “single sample strategy” (a single measurement at 
admission or at time 0) or two measurements of Hs-cTn performed at 
admission at time 0 and 1 h later. The threshold value for the “single sample 
strategy” is the limit of detection of the assay (LoD). Only 10% to 20% of 
patients who present to EDs with a suspected cardiac related chest pain are 
diagnosed with AMI (Six et al., 2008). A high-sensitivity assay for cardiac 
troponin T (hs-cTnT) enables a more reliable detection of very low 
47 
concentrations of troponin. However, a single hs-cTnT measurement below 
the LoD or the limit of blank (LoB) may rule out AMI (Body et al., 2012). Such 
tools have previously required patients to remain in hospital for long periods 
while undergoing further investigation as the turnaround time of the assay is 
about one hour. Moreover, because high-sensitivity assays are highly 
sensitive to detect troponin in blood, the increasing sensitivity of cTn assays 
lowers the number of potentially missed ACS diagnoses. This presents a 
diagnostic challenge because the gains in diagnostic sensitivity have 
inevitably come with a decrease in specificity and this results in ruling in more 
patients to the ED. On the other hand, the turnaround time of lab tests is about 
one hour. However, this requires the patient to be admitted to hospital and not 
being sent home, which leads to overcrowding in the ED. Finally, high-
sensitivity assays are not specific for the etiology of cardiac cell death, and this 
results in increased responsibility for the clinician to interpret each test in a 
clinical context (Sherwood and Kristin Newby, 2014). 
It is essential to establish the diagnosis of ACS rapidly in an ED to apply a 
suitable treatment for chest pain patients. An early rule-out of AMI prevents 
admission of patients without ACS and facilitates early discharge of patients. 
Moreover, a delay in rule-in of AMI may increase the risk of complications and 
mortality. In contrast, a delay in the rule-out of AMI may increase the time 
needed for patient assessments, unnecessary investigations, increased 
patient anxiety, as well as overcrowding in the ED. However, POCT allows 
measurement of biomarkers at short turnaround times (Larsson et al., 2015). 
POCT for troponins should be implemented when a central laboratory has 
failed to provide test results within 60 min (Hawkins, 2007). Several members 
of healthcare teams, e.g. doctors, nurses, ambulance staff can run the POC 
device and read the result after adequate training. A recent rapid rule-out 
protocol (2 hours) using a POC biomarker test, TIMI risk score and ECG 
finding was shown to be safe in identifying a low-risk group (Than et al., 
2011a). 
Aim and objectives  
The aim of the current research is to evaluate several strategies that may 
enable clinicians to make accurate diagnoses based on information available 
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in the ED and a single blood test for cardiac markers at the POC. The study 
comprises the following objectives: 
In chapter 3  
The aim of this study was to evaluate the inter-observer reliability of a novel 
commercially available lateral flow immunoassay for h-FABP interpreted 
contemporaneously by staff in the ED. Both the predictive values and the 
kappa coefficient are supposed to depend on the prevalence and this should 
be noticed when results of different studies are compared. 
In chapter 4 
The aim of the current study was to evaluate the diagnostic accuracy of POC 
h-FABP lateral flow immunoassay (True Rapid, FABPulous BV) device for 
diagnosing or excluding AMI using a single test at the time of patient 
presentation to the ED and three hours later. 
In chapter 5 
The primary aim of this study was to determine the diagnostic accuracy of the 
Abbot i-Stat handheld POC assay. The study was also aimed to determine 
whether serial troponin testing using the Abbott i-Stat POC troponin device 
can accurately ‘rule in’ and/or ‘rule out’ the diagnosis of (AMI) within 3 hours 
of arrival in the ED, using either the conventional 99th percentile cut-off or a 
novel ‘rule out’ cut-off set at either (a) the limit of detection of the assay, or (b) 
the lower limit of the reportable range of the assay. 
The objectives of this study were to address the following research questions: 
In patients with suspected ACS, can serial troponin testing within 3 hours of 
arrival in the ED using the Abbott i-Stat point of care device enable accurate 
identification of: 
a. Patients at sufficiently low risk of prevalent AMI, to enable safe 
avoidance of hospital admission. 
b. Patients at sufficiently high risk of prevalent AMI so that that the 
diagnosis of an ACS should be considered ‘ruled in’ 
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In chapter 6  
The aim of this study was to prospectively validate T-MACS with a 
contemporary POC cTn assay (i-Stat, Abbott Point of Care, New Jersey) in 
order to investigate the clinical diagnostic accuracy of i-Stat device to rule out 
AMI in EDs. 
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Chapter 2 : Materials and Methods 
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2.1. Methods  
2.1.1. Detailed plan of investigation 
2.1.1.1. Sitting  
A multicentre, prospective diagnostic cohort study was undertaken in the 
Emergency Departments at 14 sites across the United Kingdom. During the 
study time frame of February 2015 to March 2017 there were 1,613 patients 
enrolled. Sites were invited to take part through being sent standardised, 
structured feasibility questionnaires (see Appendix 2.1). The information from 
the questionnaires was evaluated to ensure that the site had the capabilities 
and the resources to run the study. Interested sites were then selected. This 
would have the advantages of facilitating recruitment of greater numbers of 
patients and improving the probability that our results could be generalised to 
other patient populations. The details of each recruiting centre are shown in 
Appendix 2.2. 
 
2.1.1.2. Current ED management process for patients with 
suspected cardiac chest pain 
Patients who presented to emergency departments (EDs) at eligible sites with 
complaints of chest pain with symptoms suggestive of acute coronary 
syndrome were recruited prospectively into the study. At the time of the study, 
patients who came to the ED and reported chest pain were triaged by an 
emergency department nurse using the validated Manchester Triage System, 
see Figure 2.1. Comprehensive clinical, electrocardiographic and biochemical 
data were  collected at the time of presentation using a custom-designed case 
report form (Appendix 2.3) for each patient who was eligible to participate in 
the study. In this observational study, patients were treated according to 
current departmental guidance for the management of cardiac chest pain, 
which is consistent with the guidance issued by the National Institute of Health 
and Care Excellence and the European Society of Cardiology (Alpert et al., 
2000; NICE, 2010). 
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Figure 2-1. Chest pain pathway Initial assessment and treatment of suspected 
ACS in MRI hospital 
Triage algorithm for patients with suspected ACS in MRI hospital 
2.1.1.3. Selection of participant and recruitment process 
2.1.1.3.1. Inclusion and exclusion criteria 
Patients who presented to emergency departments at eligible sites with 
complaints of chest pain and symptoms suggestive of acute coronary 
syndrome requiring a hospital admission for further investigation were 
recruited prospectively. Patients were required to enrol within 12 hours of the 
onset of symptoms. All patients in the study were assessed and treated at the 
direction of the emergency physician.  
Inclusion criteria: Adults patients (>18 years) who presented to the ED with 
pain, discomfort or pressure in the chest, epigastrium, neck, jaw, or upper 
limbs without an apparent non-cardiac source (compatible with the American 
Heart Association case definitions (26), which the treating physician believed 
warranted investigation for possible ACS; peak symptoms occurred <12 hours 
prior to presentation at the ED. 
Exclusion criteria: Patients with unequivocal evidence of ST elevation 
myocardial infarction who were being immediately transferred for primary 
53 
percutaneous coronary intervention (PCI); Patients with another medical 
condition that would necessitate hospital admission; Patients who lacked the 
capacity to provide written informed consent. 
2.1.2. Patient consent  
Screening and consent patients were identified at the time of arrival by clinical 
staff and Clinical research nurses. Eligible participants were approached by 
investigators and given verbal and written information about the study. All 
patients underwent routine venepuncture for clinical purposes at the time of 
presentation to the ED. In order that clinical procedures including intravenous 
cannulation and routine blood tests were not delayed and because it was not 
feasible to obtain informed consent within minutes of arrival in the ED, 
research nurses drew initial blood samples prior to obtaining written informed 
consent.  This allowed potential participants more time before providing full 
written informed consent (see Appendix 2.4 for the patient consent form). 
2.1.3. Data collection  
Each patient was assigned a study number at the time of presentation and 
each site engaged in the study had a unique number. At the time of inclusion, 
comprehensive clinical, electrocardiographic and biochemical data were 
collected and recorded in the custom designed Chest Pain Pathway designed 
for the patient’s clinical record and the clinical report form (CRF) for the 
purposes of this study. The treating physician in the ED in accordance with the 
contemporary international standard filled this form for specific needed data 
which included details of the patient’s complaint; previous clinical history; 
medication history; social history- including alcohol intake and tobacco use. 
Also, the family history of ischaemic heart disease found on physical 
examination; clinician’s impression (including the clinician’s judgement about 
whether or not AMI was present); 12-lead ECG findings (including the 
presence or absence of dynamic ECG changes such as T wave inversion or 
ST segment depression abnormal T inversion; dynamic change and left 
bundle branch block (LBBB) ; medication received pre-hospital and during the 
active study phase; disposition; findings of relevant laboratory tests and 
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medical history. The current location of patients who remained in hospital was 
recorded and any treatment given to the patient during their waiting in ED was 
recorded.  All patients underwent a standard clinical assessment and received 
standard treatment within the ED as detailed above. Demographic details 
including the time of presentation to the ED, name, sex, age, date of birth, 
ethnic origin, address and telephone number, were also recorded.  
2.1.4. Procedures for blood sampling and data recording 
The troponin test by (i-Stat, Abbott Point of Care) and H-FABP by the 
FABPulous point of care device were undertaken immediately following 
venepuncture by the author at the MRI site or by a clinical research nurses in 
the other sites. All patients who had consented to providing blood for research 
purposes also had additional samples drawn at the same time they arrived at 
the ED for routine laboratory troponin investigations. Additional samples were 
stored in the SST II Advance, lithium heparin and EDTA vials and labelled with 
a unique study number. After processing, any samples that had been tested 
in ‘real time’ using point of care devices, the additional samples were 
centrifuged within 30 minutes of venepuncture at 2,500g for 10 minutes. 
Plasma and serum were separated and aliquots of 500 to 2,000μL were stored 
in vials labelled with the patient’s unique study number. Sample characteristics 
(haemolysis, lipaemia, icterus) were recorded in the case report form. The 
serum and plasma were frozen at or -20°C or below within 4 hours of 
collection. Within 28 days, all samples were stored at -70°C or below for future 
analysis. The study protocol stated that each patient should have blood sent 
for reference standard laboratory-based troponin testing in accordance with 
contemporary national and international guidance. The sample-processing 
flowchart is illustrated in Figure 2.2. The overall schedule for blood sampling 
during this study is outlined in Table 2.1. The times of each blood draw, the 
result and the Sample characteristics (haemolysis, lipaemia, and icterus) were 
recorded on the case report form. (see Appendix 2.3). Disposition of patients 
(the patient’s destination) after leaving the ED the time from arrival at the ED 
to troponin results was determined by review of hospital records this (included 
the upload time for the troponin results from the central laboratory). 
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Table 2-1. Sample collection schedule 
Time point Vials for collection (volume 
of whole blood) 
Number of 
aliquots (volume) 
to be stored in the 
Biobank facility 
Schedule for ‘real time’ 
analysis 
Admission (T0) 
Samples 
collected as soon 
as possible after 
presentation and 
no more than 45 
minutes after 
clinical blood 
samples 
Lithium heparin x 1 (4ml) 
SST II Advance (BD 
Vacutainer) or similar 
(approximately 4.5ml) x 2 
(total approximately 13ml; 
approximately 4.5ml taken 
as part of routine clinical 
care) 
Serum: 2 (500µL) 
Lithium heparin 
plasma: 2 (500µL) 
 
Total 4 
Lithium heparin:  
Troponin I (point -of -care, in 
the ED) 
Serum: High sensitivity 
troponin T (Roche 
Diagnostics Elecsys 2012) 
Whole blood (not to be 
stored): 
H-FABP (FABP-ulous) 
3-hour (T3) 
Collected 3 
hours (+/- 30 
minutes) after T0 
sample 
Lithium heparin x 1 (4ml) 
SST II Advance (BD 
Vacutainer)or similar x 2 
(total approximately 8.5ml) 
Serum:2 (500µL) 
Lithium heparin 
plasma: 2 
(500µL)Total 4 
Lithium heparin:  
Troponin I (point of care, in 
the ED) 
Whole blood (not to be 
stored): H-FABP 
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Figure 2-2. The sample-processing flowchart in the BEST study 
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2.1.5. Blood sample labelling and storage  
After processing any samples that were tested in ‘real time’ using the  i-Stat 
POC device and the FABPulous, the additional samples were centrifuged at 
2,500g for 10 minutes. Plasma and serum was separated in aliquots of 500 to 
2,000µL. Eight aliquots made up of 4 aliquots of  serum and 4 aliquots of  
plasma (as described in Table 2.1) were stored initially at −20°C for less than 
4 hours then the samples were transferred to −80°C and kept frozen for future 
analysis if needed. 
2.1.6. Data recording 
Each patient was assigned a special study number at the time of presentation. 
Each site participating in the study also had a unique number; special labels 
were designed for each patient in the study. Each site followed the same 
instructions and labelling system. Photocopies of the ED record, the cardiac 
chest pain pathway form (CRF), the initial and subsequent ECGs recorded in 
the ED and the consent form were all placed in a secure file for each patient. 
Follow-up data were also initially recorded manually using the custom 
designed forms for data collection. Completed follow-up forms were added to 
the patient’s file. All patients records and CRF forms from each site were 
scanned and sent by email to the main site (MRI). All these records were 
reviewed and checked for any missing information and saved for the data 
analysis. 
2.1.7. Ethical approval and Considerations 
The National Research Ethics Service has ethically approved this study 
(Reference 14/NW/1344). Central Manchester University Hospitals NHS 
Foundation Trust and the and prince Sultan military medical city sponsored 
the study. This study was undertaken in compliance with the Declaration of 
Helsinki and local governance requirements. As per this study was conducted 
in the trust; a research passport has been obtained for the Author. Also, as 
this study was undertaken in the National Institute for Health Research (NIHR) 
funded time for the Chief Investigator and (NIHR) Portfolio adoption has been 
obtained (Reference UK CRN 18000). Patient information with a full 
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explanation of the study was given to all participating patients who potentially 
fulfilled the inclusion/exclusion criteria. All participants signed a study consent 
form before inclusion. 
2.1.8. Follow up after 30 days 
Patients were followed up 30 days after recruitment by the research nurses 
and patient were contacted by telephone, email, and letter or in person. All 
follow-up data and medical data were collected and recorded using custom 
designed forms (Appendix 2.3). These data covered all the medical records of 
the patient during these 30 days. If direct contact with a participant was not 
possible after 30 days, follow up information was obtained from their primary 
care practitioner. For all the living patients computerised hospital medical 
records were checked for details of patient admissions, outpatient 
appointment and relevant investigations.  If the patients attended, any other 
hospital during the follow-up time the entire medical records from that hospital 
were also checked. All electronic medical records were checked and 
documented by the author/ research nurses. All patients were asked if they 
had any health problems or any adverse event, any serious adverse events 
over the last 30 days or whether they had experienced any cardiac event or 
acute myocardial infarction. Patients were also asked if they had undergone 
cardiac stress testing, coronary angiography or (thallium scan). All relevant 
information was recorded including details of blood transfusion or if they had 
undergone any dialysis for renal failure. Additionally, any haemorrhagic or 
bleeding complications were recorded. The date of patient discharge from 
hospital and total number of nights spent in an emergency department 
observation ward were also recorded. See Appendix 2.5. for patient follow-up 
form.  
2.1.9. Tracking of missing data  
For any missing results or data, the site was contacted via email and phone 
asking for the missing data. For any missing troponin result, frozen samples 
were  checked and re-tested for the missing results by the author. 
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2.1.10. Outcome measures 
2.1.10.1. Evaluation of interobserver reliability of h-FABP  
In order to establish inter-observer reliability study in the clinical practice, we 
evaluated the inter-observer reliability of a novel, commercially available 
lateral flow immunoassay for h-FABP the FABPulous h-FABP True Rapid Test 
(FABPulous BV, Maastricht, Netherlands), which was interpreted 
contemporaneously by staff in the ED. To evaluate interobserver reliability, two 
independent investigators were asked to interpret the H-FABP result, blinded 
to each other’s interpretation, for a subgroup of approximately 40 patients from 
the inclusion cohort in the study. A kappa score (κ) was calculated using SPSS 
version 19.0 or later (SPSS Inc, Chicago, Illinois). The sample size used in this 
primary analysis was calculated by consulting guidelines regarding sample 
size for reliability studies (Walter et al., 1998) To demonstrate a κ of 0.8 with 
the minimal acceptable κ set at 0.6 and, setting the alpha (α) at 0.05 and beta 
(β) at 0.2, 39 patients were required to be assessed by two independent 
observers.  
2.1.10.2. Acute myocardial infarction 
Acute myocardial infarction (AMI) is defined according to the Third Universal 
Definition of Acute Myocardial Infarction as one that occurs within 30 days. 
Outcomes were adjudicated by two independent investigators (emergency 
physicians and consultants) in the EDs with reference to relevant clinical 
information but blinded to the results of the research investigators.  The 
primary outcome was a diagnosis of AMI according to the Third Universal 
Definition of AMI. By asset of the inclusion criteria, all patients who 
experienced symptoms and signs consistent with myocardial ischaemia and 
developed a rise and/or fall of troponin to above the 99th percentile.  
2.1.10.2.1. Primary analysis 
For the primary analysis, the diagnostic accuracy of troponin I by (i-Stat, Abbott 
Point of Care) was evaluated at presentation, presentation plus 1 hour, 
presentation plus 2 hours, and presentation plus 3 hours. Sensitivity, 
specificity, positive and negative predictive values, and the area under the 
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receiver operating characteristic (ROC) curve were calculated. Statistical 
analysis was completed in SPSS version 19.0 or later (SPSS Inc, Chicago, 
Illinois) or MedCalc version 12.0 or later (Mariakerke, Belgium). 
2.1.10.2.2. Secondary analysis  
Validation of the Troponin only Manchester Acute Coronary Syndromes 
decision was made using a single POC troponin test in the ED. 
2.1.11. Sample size/Power Calculations 
The primary driver of sample size in a study of this nature is the number of 
patients with the primary outcome, which makes a conservative estimate of its 
prevalence desirable. Based on subtle differences in the inclusion criteria 
compared to similar studies run by previous study (Body, Burrows et al. 2015) 
The specificity of a troponin-based algorithm would be expected to be 
approximately 90% (Body et al., 2011b) and the prevalence of the primary 
outcome in this cohort will be approximately 10% (Body et al., 2010). 
Assuming that in the current study we identify an algorithm with 100% 
sensitivity and negative predictive value, the lower bound of the 95% 
confidence interval would be >90% for sensitivity and >99% for negative 
predictive value with a sample size of 605 participants. Accounting for potential 
loss to follow up and missing data (approximately 5%). The current study plan 
to include a total of approximately 650 participants. 
2.1.12. Statistical techniques 
• For the primary analysis, the diagnostic accuracy of point of care 
Troponin I testing was evaluated at presentation, presentation plus 1 hour, 
presentation plus 2 hours, and presentation plus 3 hours. The sensitivity, 
specificity, positive and negative predictive values, positive and negative 
likelihood ratios and, the area under the receiver operating characteristic 
(ROC) curve were analysed. All statistical analyses were performed using 
either SPSS version 22.0 (IBM Software, USA) or the MedCalconline 
calculator version.  
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• For the secondary analyses : T-MACS was computed using the original 
reported formula: 
1/(1+exp-(-4.77+1.71E+0.85A+0.61R+1.42V+2.06S+1.21B+0.089T), where 
E is evidence of acute ECG ischaemia, A is worsening angina, R is pain 
radiation to the right arm or shoulder, V is pain associated with vomiting, S is 
sweating observed, B is systolic blood pressure <100mmHg and T is cardiac 
troponin concentration (ng/L) on arrival in the ED. For dichotomous variables, 
a value of ‘1’ is entered for ‘yes’ and ‘0’ for ‘no’. However, POC cTn 
concentrations below the LoD (10ng/L) were entered as 9ng/L. We calculated 
sensitivity, specificity, positive and negative predictive values. (Details of the 
calculations will be described later in chapter 5). 
2.2. Materials  
2.2.1. Equipment and consumables 
Table 2-2. Equipment and consumables 
Item Company/ code 
BD Vacutainer Flashback blood collection needles BD/ 368836 
Microcentrifuge tubes, screw-cap with O-ring seal Bunzl Healthcare/1153822 
Pipette non-sterile Bunzl Healthcare /13499108 
Heparin used in BD Vacutainer Bunzl Healthcare /vs367885 
Serum separator tubes (BD SSTTM II Advance) Bunzl Healthcare / VS367956 
Centrifuge  
Cryo box with lid cardboard Bunzl Healthcare /11872473 
i-STAT handheld POC Abbott Laboratories 
i-STAT Troponin cartridge Abbott Laboratories 
H-FABP True Rapid Test® (FABPulous BV,Maastricht, Netherlands) 
2.2.2: i-STAT - Instrument Description and System Overview 
2.2.2.1 Principle  
The i-STAT cardiac Troponin I (cTnI) (i-Stat, Abbott Point of Care, 99th 
percentile 80 ng/L, LoD 10 ng/L), is a portable, hand-held POCT device 
capable of being used with a range of cartridges to measure a variety of 
biochemical parameters. This device is designed to be used at the patient’s 
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bedside area and aimed to be used in critical care for the quantitative 
measurement of cardiac troponin I (cTnI) in whole blood. i-STAT test 
cartridges deliver lab-quality results at the patient site e.g. ED. The i-STAT 
(cTnI) test cartridge uses a two-site enzyme-linked immunosorbant assay 
(ELISA) method. Immunoassay is one of the most common protein assays 
which are becoming the gold-standard technique in clinical diagnostics for 
determining cardiac and other clinically relevant biomarkers. ELISA has been, 
since its discovery in the 1960s, a valuable tool in both clinical diagnostics and 
an  important research area (Yolken, 1982). This assay has been adapted for 
point of care microfluidic based diagnostic assays to detect the protein 
markers in the blood by using of the binding interactions between antigens and 
antibodies. The first immunoassay for cTnI detecting was invented in 1987 by 
a radiation technique in an antibody−antigen−antibody sandwich format 
(Cummins et al., 1987). The i-STAT cTnI test cartridge uses a two-site (ELISA) 
method (Abbott, 2015-2016). Antibodies specific for human cardiac troponin I 
(cTnI) are located on an electrochemical sensor made from a silicon chip. On 
the sensor silicon chip, there is also an antibody/alkaline phosphatase enzyme 
conjugate, which is responsible for a separate portion of the cTnI molecule. 
The whole blood or plasma sample is injected into the sensors enabling the 
enzyme conjugate to dissolve into the sample. However, the cTnI in the patient 
sample becomes labelled with alkaline phosphatase and is captured onto the 
surface of the electrochemical sensor during the incubation period, which is 
about seven minutes. The sample, as well as excess enzyme conjugate, is 
washed off the sensors. Inside the wash, fluid is a substrate for the alkaline 
phosphatase enzyme. The enzyme bound to the antibody/antigen/antibody 
sandwich separates the substrate releasing an electrochemically detectable 
product. The electrochemical sensor measures this enzyme that is 
proportional to the concentration of cTnI within the sample (Abbott, 2015-
2016).  
For the test analysis, approximately 16 µL of whole blood was first introduced 
into the cartridge in the sample area. Second, the cartridge was closed and 
inserted into the i-STAT device. Finally, the result was viewed on the device 
screen within 10 minutes then the result was ready to be recorded in the case 
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report form. The procedure is described in Figure 2.3 with information from 
(Abbott, 2015-2016) 
 
Figure 2-3. Four steps for the i-STAT troponin test. In the first picture, blood is 
placed in the i-STAT cartridge 
Second picture, cartridge is inserted to i-STAT 1 Analyser. Third picture: after 
10 minute result is showed in the analyser screen. Fourth picture: the i-STAT 
Analyser in the downloader/recharger (taken from Abbott, 2015-2016). 
2.2.2.2 Cartridges 
A whole blood sample of approximately 16µL is placed into the i-STAT 
cartridge sample area and then inserted to the device for analysis. The device 
automatically operates and controls the functions needed for the analysis, 
starting with the fluid movement within the i-STAT cartridge, calibration and 
then continuous quality monitoring. Troponin I cTnI cartridges were used once, 
and then discard. Cartridges are stored at room temperature 18 to 30°C or 64 
to 86°F for 14 days 
2.2.2.3 Analytical characteristics  
Table 2.3 and 2.4 illustrating analytical characteristics of (i-Stat, Abbott Point 
of Care) and important analytical definitions in the use of troponin assays 
(Abbott, 2015-2016; Abbot, 2013). 
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Table 2-3. Clinical characteristics of (i-Stat, Abbott Point of Care) 
Reportable range Reference range 
(99th Percentile 
value) 
Analytical 
sensitivity   
Functional sensitivities 
(Limit of quantitation) 
 
From 0.00 to 50.00 ng/mL 
(µg/L). Samples above the 
reportable range showed in 
the device screen > 50.00 
ng/mL.  
0.08 ng/mL  0.02 ng/mL. The 20% and 10% functional 
sensitivities for the cTnI 
method are 0.07 ng/mL and 
0.10 ng/mL, respectively 
Note: Data for Table 2. Clinical characteristics of (i-Stat, Abbott Point of Care) from Abbott i-
Stat troponin package insert information sheets (Abbot, 2013)  
Table 2-4. Important analytical definitions in the use of troponin assays 
Term Definition 
Analytical sensitivity is the lowest cTnI level that can be distinguished from zero. The analytical 
sensitivity is defined as the concentration at two standard deviations from 
a sample at 0.00 ng/mL (Abbott, 2015-2016) 
The limit of blank (LoB)  defined as the highest apparent concentration of a measure and expected 
when replicates of a blank sample containing no analyte are tested 
The limit of detection 
(LoD)  
is the lowest concentration of the measure and that can be detected at a 
specified level of confidence 
The limit of quantitation 
(LoQ)  
Functional sensitivity  
is defined, as the lowest concentration of measure and that can be 
determined with an acceptable level of precision.  Which is defined as the 
cTnI level at which the test method displays a particular percent 
coefficient of variation (%CV) 
99th Percentile value Cut-off concentration used to discriminate myocardial necrosis. In 
laboratory medicine, the 99th percentile is typically determined from a 
normal, healthy population. This is usually the “positive/negative” cut-off 
used in clinical practice 
Coefficient of variation 
(CV) 
A measure of how consistently an assay is able to produce the same 
result on the same sample. A CV of 10% is the level of precision 
suggested for troponin assays 
Note: Table terminology  and definitions  adapted with changes from (Armbruster and Pry, 
2008) 
2.2.3 The FABPulous B.V. (Maastricht, Netherlands) point of care device 
for Heart Fatty Acid Binding Protein detection  
The concept of this point of care (POC) test is using a combination of rapid 
whole blood filtration and subsequent lateral flow immunoassay in order to 
65 
deliver an accurate result within 5 minutes. The device is disposable, simple 
to use and needs no equipment. However, by design, (POC) devices are 
referred to as near-patient, to rapidly deliver bedside test results in order to 
support better patient management. This allows the FABPulous for H-FABP 
test to be completed by non-biomedical staff such as nurses and doctors. Also 
the short turnaround time of the test makes it useful for assessment of the 
patient`s blood in a busy environment such as an ED which needs to deliver a 
quick result at the patient site. 
2.2.3.1 Principle 
This is a qualitative, lateral flow immunoassay (LIA) combined with an 
integrated, one-step plasma filtration device. Inside the cartridge, a strip is 
present which contains an antibody that specifically binds the H-FABP that is 
present in the patient’s whole blood sample. The device consists of two parts: 
first, a blood collector to absorb the blood and a second small part that is 
docked onto the blood collector. This design allows a pressure-controlled 
filtration to produce diluted blood plasma (Figure 2.4). The cartridge contains 
a filter stack in addition to the (LIA) strip. The blood collector is placed in a 
paded area in the cartridge, after which the buffer contained within the blood 
collector is pressed in a controlled manner through the advanced filter stack 
to produce a diluted blood plasma, which then is guided to a lateral flow strip. 
The (LIA) takes place in the second part of the device. The stripe contains a 
control line (C) that detects free conjugated mouse H-FABP antibodies that 
shows the effective passage of buffer through the device. The test line (T) 
detects any H-FABP from a patient sample that is sandwiched by the colloidal 
gold-labelled mouse anti-H-FABP conjugate. see Figure 2.4. 
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Figure 2-4. Plasma Separation Device. 
Picture taken from (Fabpulous, 2016) 
2.2.3.2 Sample type 
Whole blood only. 
2.2.3.3 Interpretation of test results  
H-FABP is present in concentrations above 4ng/mL. The appearance of a line 
at the position marked with a “C” is the control line, indicating that the test has 
performed correctly. However, the test result is only valid when this control line 
is visible. A positive result is the appearance of a coloured line on the stripe if 
the concentration of H-FABP is elevated. This method takes just five minutes 
see Figure 2.5 for the interpretation and Figure 2.6 for a positive result in the 
FABPulous device (Fabpulous, 2016). 
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Figure 2-5.Result interpretation in The FABPulous device 
Picture 1, valid test with the appearance of the positive result in both control 
and H-FABP tests are visible. Picture 2: valid test showing negative result for 
h-FABP with no visible line and control is visible. In picture 3: invalid test 
showing positive result with visible line in test line but no visible line in the 
control line. Picture 4: showed invalid H-FABP test with no visible line for both 
control and H-FABP test. In this cases test 3 and 4 tests should be repeated. 
Picture modified with permeation from (Fabpulous, 2016). 
 
Figure 2-6. Positive result in the FABPulous device. 
H-FABP test positive result with a visible line for both control and H-FABP test area. Picture 
taken from (Fabpulous, 2016) 
2.2.3.4 Analytical characteristics 
The diagnostic sensitivity of the test is 93.6% and the specificity 67.4% from 
three hours to eight hours after onset of symptoms. The cut-off is 4ng/ml at 
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which 95% of H-FABP concentration is detected note: information taken from 
insert sheet of The FABPulous device (Fabpulous, 2016).   
2.2.4 High sensitivity troponin assay and contemporary troponin 
assays 
The reference standard for AMI was serial central laboratory cTn testing over 
at least 3 hours (for high sensitivity assays) or at least 6 hours (contemporary 
assays). At the time of writing this thesis and pending further evidence and 
international guidance, a significant rise and/or fall of troponin was considered 
to be >9.2ng/L for high sensitivity troponin T (Mueller et al., 2012) and at least 
20% for all other assays. 
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Chapter 3 : The inter-observer reliability of a novel qualitative point of 
care assay for heart-type fatty acid binding protein 
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Abstract 
Background: Heart-type fatty acid–binding protein (h-FABP) may help to 
improve the early diagnosis of acute coronary syndromes in patients 
presenting to the Emergency Department (ED) with chest pain. A novel 
qualitative point of care h-FABP lateral flow immunoassay (True Rapid, 
FABPulous BV) could provide results to clinicians within just 5 minutes. Given 
the qualitative nature of this test and prior to evaluation in a large diagnostic 
study, we aimed to determine inter-observer reliability when interpreted 
contemporaneously by staff in the ED.  
Methods:  In a nested prospective cohort study including adult patients with 
suspected cardiac chest pain, venous blood samples were tested for h-FABP 
(FABPulous BV) on arrival and 3 hours later. Each test result was 
independently interpreted by two different investigators after 5 minutes. The 
investigators were blinded to each other’s interpretation and recorded their 
findings on separate case report forms. We determined interobserver reliability 
by calculating the Cohen’s kappa score and 95% confidence intervals. 
Results: A total of 43 test results (from 31 patients) were each interpreted by 
two independent investigators. Absolute agreement between investigators 
was 93.0%, with a Cohen’s kappa score of 0.81 (95% CI 0.6 – 1.0), indicating 
near perfect agreement. In total, there were three (7.0%) disagreements. In 
each case one investigator reported a ‘weak positive’ result while the other 
interpreted the result as ‘negative’. 
Conclusions: These findings demonstrate the interobserver reliability of a 
qualitative point- of-care h-FABP assay. Further work must evaluate 
diagnostic accuracy and determine the clinical implications of the small rate of 
disagreement. 
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3.1. Introduction 
In patients presenting with acute chest pain, early and accurate diagnosis of 
acute myocardial infarction (AMI) permits interventions to reduce the mortality 
rate (Milosevic et al., 2016). It is important to identify patients who are not 
suffering from AMI, who can be sent home safely. Heart-type fatty acid binding 
protein (h-FABP) has been suggested as a cardiac marker to reliably detect 
myocardial ischemia in the absence of necrosis for initial identification and for 
differentiating patients with chest pain of symptoms other than coronary 
ischemia. It could also provide clinical utility complementary to that of cardiac 
troponins (cTn) the gold standard in acute myocardial infarction (Collinson et 
al., 2017). While levels of cardiac troponin may take several hours to rise after 
the onset of AMI, (h-FABP) is  released faster after myocardial injury because 
of its lower molecular weight and cytoplasmic location see Figure 3.1 (Banu et 
al., 2014). When the heart muscle (myocardium) is damaged, h-FABP is 
immediately release into the bloodstream prompting rapid elevation in the 
concentration of h-FABP (Willemsen et al., 2015a). Its plasma concentration 
increases  at least 30 min following the onset of AMI and return to the normal 
range within 12–24 hour in patients without renal impairment diagnosis (Glatz 
and Renneberg, 2014). There has been much interest in h-FABP as a 
biochemical marker. Several studies have shown to improve the patient’s 
diagnosis as an early diagnostic marker in ACS (Collinson et al., 2017; Carroll 
et al., 2013). Among patients presenting at the (ED) with suspected ACS, h-
FABP has been shown to be a strong independent predictor of major adverse 
cardiac events (MACE) within 30 days even after accounting for high 
sensitivity cardiac troponin, electrocardiographic (ECG) changes and clinical 
findings. As such, h-FABP was incorporated in the Manchester Acute 
Coronary Syndromes (MACS) decision rule ( Body et al., 2014).  This rule 
effectively risk stratifies patients following a single blood test for high-sensitivity 
cardiac troponin and h-FABP, taken at the time of arrival in the ED. It can be 
used to identify subjects who could have ACS immediately ‘ruled out’ (thus 
avoiding unnecessary hospital admission) and others in whom the diagnosis 
could be immediately ‘ruled in’. The MACS rule has now been validated with 
an automated laboratory-based h-FABP assay (Body et al., 2014c). However, 
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the requirement to run the h-FABP assay may present a barrier to clinical 
implementation, as this assay is not routinely used for other indications. 
Several point-of-care tests (POCT) designed to detect h-FABP in whole blood 
samples are available and could reduce the time taken for the result to be 
available  compared to laboratory blood tests, thus allowing better treatment 
and outcome (Mad et al., 2007b). The availability of a point of care (POC) 
assay may therefore support the diagnosis of chest pain patient in ED and this 
could minimise the barrier of the h-FABP test to be implemented in clinical 
decision rule. 
 
Figure 3-1. Release of h-FABP and cardiac troponins from the injured heart 
into plasma after acute myocardial infarction (AMI) 
Clinical biomarker measurements are usually subject to various types of error. 
This error due to imperfect lab conditions (e.g., operator error, contamination 
or variable storage conditions) this lead to having a measured valued 
differently from the correct value. However, assessing the quality of a 
biomarker is important, and this process consists of determining if the 
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biomarker has sufficient reliability and acceptable validity (Bartlett and Frost, 
2008). Reliability refers to “the degree to which the results obtained by a 
measurement procedure can be replicated” (Faerstein, 2016). The reliability in 
statistics is most often described in terms of interrater and intrarater reliability 
Interobserver agreement refers to the agreement between the determinations 
made by two different observers  (Looney, 2002). However, In order for any 
biomarker test to be used properly, it is essential that several parameters be 
established regarding the test before applying the test in clinical practice. Also, 
sufficient monitoring requires ensuring that the device meets the quality 
demands of psychometric properties such as feasibility in clinical practice, 
validity, reproducibility, sensitivity, specificity, predictive values, and finally the 
likelihood ratios. The most basic parameters that are essential to be 
established regarding any clinical biomarker are that it demonstrates a 
sufficient degree of reliability and validity between users (Kha and Chien, 
2001). Interestingly, if these two important parameters are not met, then the 
test’s value in assisting clinicians to decide on the patient diagnosis from the 
patient management plan or monitor a patient’s improvement is questionable 
(Bruno, 2011). Since the essential purpose of the diagnostic test is to support 
the decision making in determining whether a patient has or does not have a 
certain condition (Deeks and Altman, 2004). Reliable evidence from clinical 
trials is needed for making appropriate decision-making. However, in the 
context of clinical trials, the quality of a diagnostic study is evaluating the 
accuracy of the diagnostic test. In ED, It is essential to choose TAT goals that 
lead to improved patient care and clinician efficiency in addition to improved 
satisfaction for both patients and clinicians. POCT has an overall advantage 
in ensuring timeliness of test results. However; the accuracy and reliability of 
the results are often in question and must be addressed as well as meets the 
analytical goals.  POCT devices must be sufficiently accurate and precise to 
achieve the clinical purposes for which they are designed. Assessing the 
reliability of the device is essential since the performance of a diagnostic test 
is reliant on the ability of the observer to reliably and predictably evaluating the 
presence or absence of a positive result. 
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There is various commercially available qualitative and quantitative POC h-
FABP assays in the market see Figure 3.2. Quantitative assays report results 
as continuous variables and thus provide clinicians with a ‘number’. The 
disadvantages of quantitative assays include the financial cost of analysers 
and the requirement for regular quality control and calibration, which is often 
delegated to already over-stretch clinical staff. Qualitative assays, which 
provide a simple dichotomous result (positive or negative) have the advantage 
of removing the need for a separate analyser, thus reducing financial cost and 
saving staff time, although these potential benefits may depend on institution-
specific factors. Qualitative assays do, however, require interpretation, which 
has an element of subjectivity. In this study, The FABPulous h-FABP results 
of a lateral flow immunoassay were performed by determining the existence 
or absence of a test line next to a control line. Because lateral flow 
immunoassays necessitate interpretation, which has an element of 
subjectivity, an important first step in their evaluation is to establish inter-
observer reliability in clinical practice. The performance of a diagnostic test is 
dependent on the accuracy and the ability of the observers to reliably and 
predictably assess the presence or absence of a positive result. The reliability 
of the test must in some cases be measured by a determination of 
reproducibility. The reproducibility is measured by comparing results of 
repeated examinations of the same patient. A Kappa coefficient test is used to 
measure the reproducibility, which adjusts the observed agreement for an 
expected chance agreement. 
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Figure 3-2. A variety of POCT for heart fatty acid binding protein testing 
This picture illustrates different types of POC for h-FABP testing, (1) is the qualitative the 
FABPulous h FABP testing, (2) qualitative cardio-check POC for h-FABP. (3) Colloidal Gold-
labelled Quantitative Immunoassay Analyser for h-FABP testing 
3.1.1. Aim and objectives 
The aim of this study is to evaluate the inter-observer reliability of a novel 
commercially available lateral flow immunoassay for h-FABP interpreted 
contemporaneously by staff in the ED. Both the predictive values and the 
kappa coefficient are supposed to depend on the prevalence and this should 
be noticed when results of different studies are compared. 
3.2. Method 
3.2.1. Data collection and processing 
In a prospective cohort study nested within the larger Bedside Evaluation of 
Sensitive Troponin (BEST) study, the main thesis included consenting patients 
who presented to the ED with suspected cardiac chest-pain within 12 h of 
symptom onset. Participants were selected for inclusion in this sub-study by 
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accessibility sampling, dictated by the availability of two trained independent 
observers. Venous blood was drawn on arrival and 3 h later (without additive). 
Fresh whole blood samples were then immediately tested for h-FABP using 
the FABPulous h-FABP True Rapid Test (FABPulous BV,Maastricht, 
Netherlands; calibrated to provide a positive result at 4 ng/ml) according to 
manufacturer's instructions. This is a lateral flow immunoassay (LIA) combined 
with an integrated, one-step plasma filtration device that delivers whole blood 
into a correctly and consistently diluted plasma (Glatz and Renneberg, 2014). 
After 5 min, two independent observers including clinical research nurses, 
emergency physicians and my self-interpreted each test. It should be pointed 
out that the staff who interpreted tests in this study had the same background 
as the routine clinical staff who would be expected to interpret the h-FABP 
point of care test results in routine clinical practice. Moreover, each 
investigator had received a two-hour training session on how to perform and 
interpret the test results.  
The observers were both blinded to each other's interpretation and recorded 
their interpretation on separate case report forms. The investigators 
interpreted the result from the same test immediately. Interpretation was timed 
using a stop clock to ensure protocol adherence and a maximum delay of 2 
min was permitted between the two interpretations. The investigators 
interpreted the result from the same test without delay. Interpretation was 
timed using a stop clock to ensure protocol adherence and a maximum delay 
of 2 min was permitted between the two interpretations. 
3.2.3. Statistical methods 
The most basic approach to assess interrater agreement is to calculate the 
observed proportion of cases where the observers agreed. This approach 
alone is clearly insufficient, since it does not consider the fact that a certain 
amount of the agreement would be expected purely by chance. The kappa 
statistic is a useful method of assessing the extent of agreement beyond that 
expected by chance. This method is appropriate for assessment of 
interobserver reliability with regard to binary or ordinal scale data (Fleiss et al., 
2013). 
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The kappa coefficient was calculated after cross-tabulating the results from 
each interpreter in a 2x2 table using SPSS version 20.0 (SPSS Inc, Illinois).  
Kappa (κ) can be calculated by determining the proportion of agreement that 
could have been achieved beyond that expected by chance alone, as follows: 
(Viera and Garrett, 2005). 
𝑘𝑘 = (𝑃𝑃𝑃𝑃 − 𝑃𝑃𝑃𝑃)/(1− 𝑃𝑃𝑃𝑃)𝐾𝐾𝐾𝐾𝐾𝐾𝐾𝐾𝐾𝐾 
Where PO is the proportion observed and PE is the proportion expected by 
chance alone. Kappa is scored from 1 to 1. A κ score of 0 indicates that there 
is no agreement beyond that expected by chance, whereas a score of 1 
indicates perfect agreement. The (κ) score was further categorised according 
to Landis and Koch (Landis and Koch, 1977)   which is shown in Table 3A.1 
To demonstrate a κ of 0.8 with the minimal acceptable κ set at 0.6 and, setting 
the alpha at 0.05 and beta at 0.2, would require 39 patients to be assessed by 
two independent observers. 
3.2.4 Sample size calculation 
Sample size was calculated according to guidelines for reliability studies 
(Walter et al., 1998). However, in order to demonstrate a κ of 0.8 with the 
minimal acceptable κ (lower boundary of the 95% confidence interval) set at 
0.6 and, setting the alpha at 0.05 and beta at 0.2, we would require 39 patients 
to be assessed by two independent observers. 
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Table 3-1. The interpretation of Cohen's kappa classification 
The interpretation of Cohen's kappa classification by Landis and Koch is often used to judge 
the strength of agreement for κ (Landis and Koch, 1977) 
Value of kappa Level of agreement 
<0  
0.0–0.2  
0.2–0.4  
0.4–0.6  
0.6–0.8  
0.8–1.0  
Poor agreement 
Slight agreement 
Fair agreement 
Moderate agreement 
Substantial agreement 
 Almost perfect agreement 
 
3.3. Results 
3.3.1. Baseline characteristics 
The study was conducted from 2nd April to 8th May 2016. A total of 43 test 
results were interpreted by each of two independent investigators for this study 
(26 drawn on arrival and 17 at 3 h). The tests were drawn from a total of 31 
patients (12 of whom had tests from both arrival and 3 h later interpreted by 
two investigators). The mean patient age was 60.6 ± 12.49 years with 15 
males (48.4%) and 16 females (51.6%). Fourteen patients (45.2%) had 
hypertension, six patients (19.44%) were had hyperlipidaemia, and two 
patients had diabetes mellitus one patients  (3.2%) had type 2 and one patient 
(3.2%) had type 1 diabetes. Five patients (16.1%) were current smokers, one 
patient (3.2%) had renal impairment, 10 patients (32.3%) had a history of 
myocardial infarction and 8 patients (25.8%) had a history of prior angina and 
7 patients (22.6%) went to percutaneous coronary intervention (PCI). 
Admission ECGs were normal in 27 patients (87.1%), four patients (12.9 %) 
had acute ischaemia, eight patients (25.8%) had significant ST-segment 
depression and tow patients (6.5%) had ST-segment elevation. (Table 3A.2). 
3.3.2. Result interpretation  
A total of ten observers interpreted h-FABP results, including four doctors 
(emergency physicians), five nurses and one medical technologist. A total of 
21 (24.4%) test results were positive for h-FABP. Absolute agreement 
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between investigators was 93.0%, with a κ score of 0.81 (95% CI 0.6 to 1.0) 
associated with a p value <0.05 indicating near perfect agreement between 
investigators. In total, there were three (7.0%) disagreements in test result 
interpretation. Each of these disagreements appears to have arisen because 
one observer noted that a result was ‘weakly positive’ while the other rated the 
result as ‘negative’. In one patient, the discrepancy was noted in the admission 
blood sample although both observers recorded the result as ‘positive’ when 
the 3-hour sample was tested. The other two patients had concordant results 
for the admission blood samples (both positive in one patient; both negative in 
the other) but discrepancies were noted at 3 h. As the  tests were run on whole 
blood, we could not directly evaluate the impact of haemolysis in this study. 
No tests in this study were reported as uninterpretable. 
Table 3-2. Baseline characteristics of patients recruited to the interobserver 
reliability study 
  
Study participants (n= 31)  
Age, mean (standard deviation) 60 ± 12 
Male sex, n (%) 15 (48.4) 
Female sex, n (%) 16 (51.6) 
Hypertension, n (%) 14 (45.2) 
Hyperlipidaemia, n (%) 6 (19.4) 
Diabetes mellitus, n (%) 1 (3.2) 
Sweating , n (%) 16 (51.6) 
Current smoker, n (%) 5 (16.1) 
Previous ischaemic heart disease, n (%) 3 (9.7) 
Renal impairment, n (%) 1 (3.2) 
Clinicians interpreting test results 
Background of clinician interpreting test result, n 
(%) 
Emergency physician  47 (54.7) 
 Nurse (clinical research nurse) 18 (20.9) 
Medical technologist 21 (24.4) 
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3.4. Discussion  
In this study, we have demonstrated that the results of a novel lateral flow 
immunoassay for h-FABP can be interpreted in clinical settings by staff with 
various backgrounds with a high degree of interobserver reliability. A (κ) score 
of 0.81 demonstrates near perfect agreement and the lower boundary of the 
95% confidence interval is >0.6 indicating at least substantial agreement. 
These findings support the use of this test in clinical practice. In this current 
study we noted that three were discrepancies from our 43 observations, 
indicating discrepant results in 7% of cases. If results were to be wrongly 
interpreted as ‘negative’, this could lead to a missed diagnosis of ACS. 
However, the test has been calibrated to provide positive results at 4 ng/ml, 
which is lower than the reported 99th percentile (5.6 ng/ml) of quantitative 
measurements (Glatz and Mohren, 2013). This has the effect of introducing a 
‘safety margin’ to avoid genuine false negative results. Nowadays, POC tests 
have the potential to improve health care services and patient outcomes in an 
emergency sitting, especially in triage process. The impact, however, should 
be robustly evaluated in diagnostic studies prior to implementation.  Although 
h-FABP is not currently widely used, it may help to facilitate early ‘rule in’ and 
‘rule out’ of acute coronary syndromes in the ED, which would help to reduce 
unnecessary hospital admissions and identify the highest risk patients at the 
earliest possible opportunity. H-FABP is incorporated in the MACS decision 
rule, which has been shown to identify over one quarter of patients as eligible 
for immediate discharge from the ED with no missed AMIs and a low incidence 
of major adverse cardiac events within 30 days (Body et al., 2014). Although 
the MACS rule has been validated using an automated immunoassay for h-
FABP, which can be run using commercial laboratory analysers, the 
requirement to run an assay for an additional biomarker may present a barrier 
to clinical implementation. A POCT may facilitate clinical implementation. A 
number of prior studies have evaluated the diagnostic accuracy of h-FABP in 
chest pain patients suspected of ACS in an emergency department setting 
(Willemsen et al., 2015b; Slot et al., 2013; Agnello et al., 2017). The lateral 
flow immunoassay described in this study is a simple and inexpensive 
technology. It requires only a drop of blood and produces results with a 
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turnaround time of just 5 min. This novel assay may therefore enable the 
MACS rule to be used in other settings such as the pre-hospital environment 
or in the community.  
3.5. Limitations of the study 
This study does have some limitations. While our approach was pragmatic, 
the observers in this study had different levels of clinical experience. Each 
investigator received a standard 2 h training session prior to the study starting 
but was previously unexperienced to the use of this assay. It is possible that 
interobserver reliability will improve over time as staff members become more 
experienced in its use. This study cannot evaluate this approach. This study 
did not did not aim to evaluate diagnostic accuracy, which must also be 
established before the assay can be used in clinical settings. Prior to investing 
in such work, it was important to evaluate interobserver reliability. And as this 
study identified suboptimal reliability, the next chapter will evaluate the 
diagnostic accuracy of this assay in a  clinical setting. 
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4.1 Introduction  
Human Heart Fatty Acid Binding Protein (h-FABP) is a low molecular weight 
protein (15 kDa) present in cardiac myocytes. It is a transport protein which 
takes a role in the intracellular uptake and transport of long-chain fatty acids. 
It is composed of 132 amino acids, and it is one of the most abundant proteins 
in the myocardial tissue that forms 5-15% of the cytoplasmic proteins in the 
human heart. Because of the small size and the cytoplasmic   (Willemsen et 
al., 2015a). h-FABP concentrations reach the peak at approximately six to 
eight hours after symptom onset and back to normal level within twenty-four 
to thirty hours making it more efficient biomarker for myocardial injury 
comparing to other cardiac marker (Al-Hadi and Fox, 2009). See Figure 4.1 h-
FABP protein can be identified in the blood as early as one to three hours after 
onset of chest pain, the peak values reached at six to eight hours and plasma 
levels back to normal within twenty four to thirty hours  (Gururajan et al., 2010). 
Thus, h-FABP appears to be a very stable protein for early detection of 
myocardial necrosis as studies have shown that serum and plasma samples 
can be subjected to up to 8 freeze/thaw cycles without the loss of 
immunoreactivity make it useful for  in vitro clinical diagnostic purposes 
(Wodzig et al., 1997). Prof Glatz (Maastricht University, The Netherlands) was 
the first to report the  diagnostic potential of h-FABP in 1988 (Glatz et al., 
1988).  Numerous studies have evaluated the added value of h-FABP along 
with troponin in the ED setting for the early diagnosis of AMI (McCann et al., 
2008; Banu et al., 2014; McMahon et al., 2012b). These studies showed higher 
diagnostic performance of heart fatty acid binding protein when combining with 
initial cardiac troponin for acute myocardial infarction. In McCann study the 
sensitivity of h-FABP at initial time was higher than Troponin 76% (69–82), 
75% (69–81) and specificity was 61% (55–68) 94% (90–96) respectively. h-
FABP test were measured using ELISA test kit in this study. Bannu et al and 
his group were measured h-FABP in POC qualitative device, the researchers 
found that when combining h-FABP and troponin at initial time the diagnostic 
sensitivity for AMI was higher than the sensitivity of troponin by its own for the 
diagnosis of AMI. The sensitivity was 52.78 (35.49-69-59) for the troponin and 
h-FABP and 50 (32.9-67.1) for troponin only. McMahon group were measured 
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h-FABP and cTnI, creatine kinase-MB, and myoglobin for the early detection 
of AMI among patients who present to the ED. The researchers found that 
when combining cTnI measurement with h-FABP test the sensitivity for AMI 
diagnosis was increased (71.4% at 3 to 6 hours and 88.2% at 3 to 6 hours)  
comparing to  h-FABP test only were the sensitivity at 0 to 3 hours was (64.3%) 
and 3 to 6 hours was (85.3%) after chest pain onset. a number of studies have 
investigated the utility of h-FABP for assisting in the diagnosis of AMI and for 
prognostic stratification(Jones et al., 2017).  A meta-analysis of  twenty-two 
studies including 6602 patient with suspected AMI demonstrate that pooled 
sensitivity, specificity and AUC of h-FABP were 0.75 (0.68–0.81), 0.81 (0.75–
0.86) and 0.85 (0.82–0.88) respectively within six hours. On the other hand, a 
similar sensitivity (0.76, 0.69–0.82), specificity (0.80, 0.71–0.87) and AUC 
(0.85, 0.82–0.88) of h-FABP were observed in 4185 (63%) patients at patient 
presentation and three hours past presentation (Xu et al., 2017).  Improving 
diagnostic protocol to ‘rule out’ ACSs and triage decisions at the time of patient 
presentation to the emergency department (ED) is essential as the impact of 
implemented an accurate diagnostic protocol could reduce unnecessary 
hospital admissions and improve patient outcome. While the imperfect 
sensitivity and (NPV) of existing diagnostic protocol at the time of patient 
arrival in ED leads to unnecessary hospital admissions, suboptimal specificity 
and (PPV) also present challenges. Among patients presenting to the (ED) 
with suspected ACS, h-FABP has been shown to be an effective independent 
predictor of major adverse cardiac events (MACE) within 30 days even after 
accounting for high sensitivity cardiac troponin, electrocardiographic (ECG) 
changes and clinical information. H-FABP was incorporated in the Manchester 
Acute Coronary Syndromes (MACS) decision rule (Body et al., 2014).  This 
rule effectively risk stratifies patients using a single blood test, taken at the 
time of arrival in the ED, to identify subjects who could have ACS immediately 
‘ruled out’ (thus avoiding unnecessary hospital admission) and others in whom 
the diagnosis could be immediately ‘ruled in’. The MACS rule has now been 
recently validated with an automated laboratory-based h-FABP assay (Body 
et al., 2014c).  However, the requirement to run the h-FABP assay may 
present a barrier to clinical implementation, as this assay is not routinely used 
for other indications. As an alternative, h-FABP measured by POC may 
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possibly be a helpful diagnostic tool. Concerning AMI diagnosis, time is crucial, 
rapid triaging of chest pain patients presenting to ED is needed to identify 
positive cases for immediate application of appropriate treatment. The 
availability of an appropriate test that allows the rapid assessment of H-FABP 
in ED is beneficial to aid in the diagnosis of AMI. Several point of care testing 
methods both rapid qualitative or quantitative to determine h-FABP are 
available in the market (Rhee et al., 2008; Mad et al., 2007a).  
Up-To-Date, the performance of h-FABP for acute MI diagnosis has been 
focused on its comparison with troponin or ECG ischemia see Table 3B.2 for 
the recent clinical studies that have directly compared h-FABP and troponin 
applying quantitative or qualitative test in emergency sitting.  Finally, this 
chapter is to evaluate the diagnostic accuracy of qualitative (True Rapid, 
FABPulous BV) POC test  in the diagnosis of AMI by its own and in combining 
with troponin or ECG ischemia. The potential of such a quick device was 
valuable in several ways, it is a portable qualitative test this was allowing for 
testing h-FABP at the emergency department next to the patient, and this 
leading to decreasing the time of patient waiting in ED as this deceive 
measuring H-FAPB in 5 minutes. However, this avoids emergency to be 
overcrowded and avoided unnecessary referrals minimised patients anxiety in 
addition to extra costs (Yarmohammadian et al., 2017). 
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Figure 4-1. h-FABP: Release Kinetic. 
h-FABP concentrations reach the peak at approximately six to eight hours after 
symptom onset and back to normal level within twenty-four to thirty hours. h-
FABP has similar release kinetics to Myoglobin but  15 to 20 times more 
cardiac specific, making it more efficient biomarker for myocardial injury. 
Moreover, the normal serum or plasma value of h-FABP is much lower than 
with Myoglobin, which reduces the possibility of false-positive results. Picture 
adapted from (RANDOX, 2015).  
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4.2. Aim and Objective  
The aim of the current study is to evaluate the diagnostic accuracy of point of 
care h-FABP lateral flow immunoassay (True Rapid, FABPulous BV) device 
for diagnosing or excluding AMI using a single test at the time of patient 
presentation to the ED and three hours later. 
4.3. Methodology 
4.3.1. Data collection and processing 
This chapter reports the preliminary analysis of prospectively observational 
diagnostic cohort adults who were presented to ED at 14 different hospitals. 
For this analysis recruitment commenced in February 2015, patients recruited 
into the study if they met the inclusion criteria of : adults patients (>18 years) 
who present to the ED with pain, discomfort or pressure in the chest, 
epigastrium, neck, jaw, or upper limb. Also, patients without an apparent non-
cardiac source were this is compatible with the American Heart Association 
case definitions (Anderson et al., 2007)). Moreover, a patients with peak 
symptoms occurred <12 hours prior to presentation at the ED.  Patients were 
excluded if they had unequivocal evidence of ST elevation myocardial 
infarction who are being immediately transferred for primary percutaneous 
coronary intervention; Patients with another medical condition that would 
necessitate hospital admission; Patients who lack the capacity to provide 
written informed consent. Ethical approval and written informed consent were 
obtained from all subjects. 
  
88 
4.3.2. Measurements 
Comprehensive clinical data including were recorded in the case report form 
at the time of inclusion by the treating physician and study nurse in accordance 
with contemporary international standards. However, these data including 
details of: the presenting complaint, previous medical history, medication 
history and social history (including alcohol intake and tobacco use). In 
addition to the  family history of ischaemic heart disease, findings on physical 
examination, clinician’s impression this was including the clinician’s judgement 
about whether or not AMI is present and also 12-lead ECG findings (including 
the presence or absence of dynamic ECG changes such as T wave inversion 
or ST segment depression), medications received  were recorded either was 
it pre-hospital or during the active study phase,  disposition; findings of relevant 
laboratory tests and medical imaging were also recorded.  The initial venous 
blood samples to measure h-FABP were drawn on arrival of patients and three 
hours later. Fresh whole blood samples were then immediately tested for h-
FABP using the FABPulous h-FABP True Rapid Test (FABPulousBV, 
Maastricht, Netherlands; calibrated to provide a positive result at 4 ng/ml) 
according to manufacturer's instructions. The h-FABP was evaluated by the 
researcher, and time of drawing the initial blood sample and all the laboratory 
measurements were documented.  See Figure 4.2. For the appearance look 
of the positive result for the qualitative FABPulous h-FABP sample. 
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Figure 4-2. The qualitative FABPulous h-FABP 
The top figure is illustrate the positive test in the POC device, both lines (Control and sample) 
are performs in red colour results was available within 5 minutes.  
4.4. Follow up 
Patients were followed up throughout their inpatient course and thereafter until 
30 days. Data regarding length of stay; cardiac investigations and procedures; 
details of any haemorrhagic complications. 
4.5. Outcome 
In this study, two independent investigators (emergency physician and 
consultant in emergency medicine) defined a composite of acute myocardial 
infarction (AMI). Both were blinded for the outcome according to the Third 
Universal Definition of AM (Thygesen et al., 2012b). The reference standard 
for AMI was based on clinical information and the requirement of patients 
having a rise and/or fall of serial central laboratory cTn testing over at least 3 
hours (for high sensitivity assays) or at least 6 hours (contemporary assays) 
with at least one troponin level above the 99th percentile within 30 days. 
4.6. Statistics 
The primary analysis included all participants with complete blood drawn on 
arrival and 3 hours later. The goal of the primary analysis is to determine the 
performance characteristics of the FABPulous h-FABP True Raid Test. The 
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aim of a diagnostic test is to validate the presence or absence of a disease.  
In this study, The clinical performance of h-FABP as a diagnostic test is 
completely based on its ability to accurately classify chest pain patients to 
subgroups ( patients with AMI and patients without AMI). In this study the area 
under the receiver operating characteristic curve (AUC), sensitivity, specificity, 
(PPV) and (NPV) together with 95% confidence intervals were calculated  
(using SPSS V.20.0, SPSS, Chicago, Illinois; and/ or MedCalc V.12.4.0.0, 
Mariakerke, Belgium). However, the basic approach in the calculation of above 
measures is to presented the result in a 2x2 table with groups of subjects 
divided according to a gold standard (Sauerbrei and Blettner, 2009) as 
described earlier in chapter two.  
4.7. Result 
4.7.1. Diagnostic performance of (FABPulous-FABP) as the only 
biomarker to rule in and rule out AMI on patient arrival and three hours 
later 
A total of 691 patients were included in this “rule in” and “rule out” study. The 
h-FABP test results at arrival time to ED were found to be positive for 106 
patients (15%) and negative for 585 patients (85%). 44 patients (6%) were 
incorrectly classified as not having AMIs (false negative result). those are the 
patients who has negative results and having AMI (misclassified patients as 
false negative). Results are summarised in Table 4.1. The sensitivity and NPV 
to rule out AMI were 48.24% (95%CI: 37.26% to 59.34%) and 92.48 % 
(95%CI: 90.91% to 93.80%) respectively. While Specificity and PPV were 
89.27 % (95%CI: 86.53%to 91.62%) and 38.68% (95%CI: 31.45% to 46.44%) 
respectively Table 4.2. This strategy would allow 85 % of patients to be 
discharged (rule out percentage). In contrast at three hours post arrival, 663 
patients were included in the study for h-FABP analysis. The results of h-FABP 
test revealed positive for 89 patients (13%) and negative for 574 patients 
(86%). 32 patients (4.8%) were incorrected classification with missing AMIs 
(false negative result). see 4.3 and 4.4. Tables 
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Table 4-1. Two x two table and calculation of negative and positive predictive 
value as well as sensitivity and specificity for the FABPulous h-FABP True 
Raid Test only decision aid at patient presentation.(n= 691) 
TP: True positive, FP: False positive, FN: False negative, TN: True negative. 
Table 4-2. Significance of diagnostic Rule-out strategy of FABPulous h-FABP 
at patient presentation on patient arrival 
Diagnostic accuracy 
of the rule out 
strategy at patient 
presentation on 
patient arrival 
Value,% 95% Cl Percentage ‘ruled out’ 
AMI 
Sensitivity 48.24% 37.26% to 59.34% 585/691=84 % 
Specificity 89.27 % 86.53%to 91.62% 
PPV 38.68% 31.45% to 46.44% 
NPV 92.48 % 90.91% to 93.80% 
PPV: Positive predictive value, NPV: Negative predictive value, Percentage ‘ruled out’ AMI : 
FN+TN/ (TP+TN+FP+FN).   
Performance of h-FABP AMI No AMI Total 
h-FABP at initial Time 
(Time 0 on patient 
presentation to ED) 
Test Positive TP 41 FP 65 (TP + FP) 106 
Test Negative FN 44 TN 541 (FN + TN) 585 
Total (TP+FN) 
85 
( FP + TN) 606 (TP+TN+FP+FN) 691 
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Table 4-3. Two x two table and calculation of negative and positive predictive 
value as well as sensitivity and specificity for the FABPulous h-FABP True 
Raid Test only decision aid  with at three hours post arrival (n= 663) 
Performance of h-FABP AMI No AMI Total 
h-FABP at 3 hours 
post arrival 
Test 
Positive  
TP 48 FP 41 TP + FP 89 
Test 
Negative 
FN 32 TN 542 (FN+TN) 574 
Total (TP+FN) 80 (FP+TN) 583 (TP+TN+FP+FN) 663 
h-FABP at 3 hours post arrival: sample taken 3 hours post arrival, TP: True positive, FP: False 
positive, FN: False negative, TN: True negative. 
Table 4-4. Significance of diagnostic Rule-out strategy of FABPulous h-FABP 
at Three hours post presentation post arrival 
Diagnostic accuracy 
of the rule out 
strategy at three 
hours post arrival 
Value% 95% Cl Percentage ‘ruled out’ 
AMI 
Sensitivity 60.00% 48.44% to 70.80% 574/663=86.5% 
Specificity 92.97% 90.58% to 94.91% 
PPV 53.93% 45.33% to 62.31% 
NPV 94.43% 92.83% to 95.68% 
PPV: Positive predictive value, NPV: Negative predictive value, Percentage ‘ruled out’ AMI:  
FN+TN/ (TP+TN+FP+FN) 
4.7.2. Diagnostic performance of FABPulous h-FABP True Raid Test 
and troponin to rule in and rule out) AMI on patient arrival 
A total of 742 patients were included in this “rule in” and “rule out” AMI strategy. 
H-FABP and i-STAT troponin test cut off at the analytical sensitivity of the cTnI 
method (>0.02 ng/mL) which is the lowest cTnI level that can be distinguished 
from zero were found to be positive for 141 patients (19%) and negative for 
601 patients (80%). 101 patients (36%) those are the patients who has 
negative results and having AMI (misclassified patients as false negative). 
Results are summarised in Table-3a. The sensitivity and NPV to rule out AMI 
were 39.16% (95%CI: 31.69% - 47.02%) and 83.19 % (95%CI: 81.36%-
84.89%) respectively. While Specificity and PPV were 86.81 % (95%CI: 
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83.77%-89.46%) and 46.10% (95%CI: 39.20%- 53.15%) respectively (Table 
4.5 and 4.6. However, this strategy would allow 80 % of patients to be 
discharged. 
Table 4-5. Two x two table and calculation of negative and positive predictive 
value as well as sensitivity and specificity for rule-out and rule- in myocardial 
infarction on arrival and three hours later of patient arrival for h-FABP 
combined with i-STAT >02ng/m 
Performance of h-FABP AMI No AMI Total 
Maximum h-FABP+i-
STAT> 02ng/mL 
Test Positive TP 65 FP 76 TP+FP 141 
Test Negative FN 101 TN 500 (FN+TN) 601 
Total (TP+FN)166 (FP+TN) 576 (TP+TN+FP+FN) 
742 
Maximum h-FABP: Maximum h-FABP on arrival and 3 hours later is the highest FABPulous 
h-FABP recorded on arrival and three hours later, TP: True positive, FP: False positive, FN: 
False negative, TN: True negative 
Table 4-6. Significance of diagnostic Rule-out strategy of FABPulous h-FABP 
and i-STAT result on arrival and three hours later. 
Diagnostic accuracy of 
the rule out strategy 
Value% 95% Cl Percentage ‘ruled 
out’ 
Sensitivity 39.16% 31.69%-47.02% 601/742= 80% 
Specificity 86.81 % 83.77%-89.46% 
PPV 46.10% 39.20%-53.15% 
NPV 83.19 % 81.36%-84.89% 
PPV: Positive predictive value, NPV: Negative predictive value, Percentage ‘ruled out’ AMI:  
FN+TN/ (TP+TN+FP+FN) 
4.7.3. Diagnostic performance of FABPulous h-FABP True Raid Test 
combine with ECG interpretation and i-STAT troponin result to ‘rules in’ 
and ‘rules out’ AMI strategy 
A total of 702 patients were included in this “rule in” and “rule out” AMI strategy. 
h-FABP, ECG ischemia and i-STAT troponin tests resulted positive in 84 
patients (11%) and negative in 292 patients (41%). 2 patients (0.2%) were 
missing AMIs (false negative result). The results are summarised in Tables 4.7 
and 7.8. The sensitivity and specificity to rule out AMI were 97.67% (95%CI: 
91.85% -99.72%) and 47.40 % (95%CI: 43.40% -51.43%) respectively. 
Positive predictive value and negative predictive value were 20.59% 
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(95%CI:19.28%-21.96%) and 99.32% (95%CI: 97.37% -99.83%) respectively. 
This strategy would allow 41% of patients to be discharged.  
Table 4-7. Two x two table and calculation of negative and positive predictive 
value as well as sensitivity and specificity for the rule-out and rule- in 
myocardial infraction on arrival and three hours later of patient presentation 
Rule out strategy AMI No AMI Total 
Maximum h-FABP on arrival 
and 3 hours later+ECG 
interpretation + maximum i-
STAT <0.01 µg/L 
Strategy 
Test 
Positive 
TP 84 FP 324 (TP+FP) 408 
Test 
Negative 
FN 2 TN 292 (FN+TN) 294 
Total (TP + FN) 86 (FP+TN) 616 (TP+TN+FP+FN) 702 
Maximum h-FABP on arrival and 3 hours later: The highest FABPulous h-FABP recorded on 
arrival and three hours later, Maximum i-STAT result: The highest i-STAT troponin recorded, 
ECG interpretation: ECG shows acute ischaemia. 
Table 4-8. Significance of diagnostic Rule-out strategy of FABPulous h-FABP 
and ECG interpatient and i-STAT result on arrival and three hours later 
Diagnostic accuracy 
of the rule out 
strategy 
Value% 95% Cl Percentage ‘ruled 
out’ 
Sensitivity 97.67% (91.85%-99.72%) 294/702=41% 
Specificity 47.40% (43.40%-51.43%) 
PPV 20.59% (19.28%-21.96%) 
NPV 99.32% (97.37%-99.83%) 
PPV: Positive predictive value, NPV: Negative predictive value, Percentage ‘ruled out’ AMI: 
FN+TN/ (TP+TN+FP+FN) 
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4.4. Discussion 
h-FABP is a critical diagnostic biomarker in assessing patients for ACS 
(Mueller, 2014). In the current study, we have investigated whether it is 
possible to safely rule out AMI using FABPulous h-FABP True Raid Test as 
the only biomarker strategy measured at the time of patient arrival in ED with 
possible cardiac chest pain as well as in combination with ECG and i-STAT 
troponin results. The availability of an appropriate test that allows the rapid 
assessment of elevated marker concentrations in plasma is essential to 
support the diagnosis of MI Measurement. The diagnostic sensitivity of h-
FABP to rule out AMI by its own was higher three hours post arrival of patients 
comparing to the initial time sensitivity. However, the obtained results revealed 
lack of sensitivity of single h-FABPulous h-FABP test for diagnosis of AMI on 
patient arrival and three hours later with 48.24% and 60% sensitivity). These 
results are in line with previous finding from a diagnostic study, where the 
researchers used a) similar POCT at patient arrival and three hours later for 
chest pain patients attending ED with 3 hours of chest pain onset. The 
sensitivity of h-FABP test alone at patient arrival and 6 hours after admission 
was was 54%, 71% and 67% respectively (Verbrugge et al., 2015). One of the 
previous study on use of FABPulous device in diagnosing AMI on ED 
population reported sensitivity values of 57% at 3 hours, which increased to 
75% overall (Buntinx, 2013 ). h-FABP could be used in combination with or as 
an alternative of troponin in the current clinical pathway to aid early diagnosis 
of AMI. Our findings suggest that adding the h-FABP as a part of multi-marker 
strategy including i-STAT and ECG interpretation can be used for early 
exclusion of AMI where the sensitivity of this strategy was increased to 97.67% 
with only two patients missing AMIs. This strategy would allow 41% of patients 
with suspected cardiac chest pain to be immediately rule out and can be 
discharged from the hospital. 
Increasing number of studies have shown that h-FABP is a sensitive marker 
for the diagnosis of myocardial infarction. Several researchers have evaluated 
the diagnostic accuracy of h-FABP over myoglobin and troponin and found 
that at the first hour of myocardial injury, h-FABP has sensitivity equal to that 
of CK-MB and superior to that of myoglobin. (Gami et al., 2015; Pyati et al., 
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2016; Body et al., 2011a). It has been reported that h-FABP has superior 
sensitivity to contemporary cardiac troponin assays when measured at 
presentation in early presenters (<4h from symptom onset). A study by 
McMahons et al (2012) evaluate troponin, CK-MB, Myoglobin and h-FABP at 
different windows time of chest pain onset, and found that the optimum 
combination for the diagnosis of AMI across the different  time points was 
troponin and h-FABP together. However, the researcher strategy offered a 
negative predictive value (NPV) of 98% for the exclusion of AMI at just 3-6 
hours after chest pain onset. (McCann et al., 2008; McMahon et al., 2012a). 
Access to immediate cardiac biomarkers could facilitate early diagnosis of 
ACS. However, When it comes to AMI diagnosis, time is crucial, hence with 
rapid reduction in processing time of patient triage and shorter time to 
treatment are strongly linked to better survival (Hand, 1994). Much of the 
available literature and research evaluate the diagnostic accuracy of h-FABP 
on laboratory test. Point-of-care blood tests reduce the time taken for the result 
to be available for emergency physicians compared to laboratory blood tests, 
allowing definitive treatment to be started faster (Amundson and Apple, 2015). 
When measuring h-FABP obtaining a false negative result could cause a 
treating physician to miss the diagnosis of ACS, leading to a potentially 
dangerous outcome. False positive results, on the other hand, could lead to 
unnecessary patient distress and excessive interventions with their associated 
risks and costs(Lum et al., 2006).The sensitivity of anther POC device for h-
FABP test was reported in several studies. However, the sensitivity ranged 
widely from 8.7% to 98%, with a median value of 71% (Figiel et al., 2008; 
Cavus et al., 2006; Valle et al., 2008). New systematic reviews and meta-
analyses studies on the combination of h-FABP and high sensitivity troponin 
showed sensitivity, specificity and AUC of h-FABP  to be 0.75 (0.68-0.81), 0.81 
(0.75-0.86) and 0.85 (0.82-0.88) within six hours. Conversely, similar 
sensitivity (0.76, 0.69-0.82), specificity (0.80, 0.71-0.87) and AUC (0.85, 0.82-
0.88) of h-FABP were observed in 4185 (63%) patients in 0h/3h algorithm. The 
additional use of h-FABP improved the sensitivity of hs-Tn alone but  no 
increase in AUC with declined specificity (all p<0.001) (Xu et al., 2017). Some 
of the studies have reported improved detection and exclusion of AMI with 
early h-FABP test when compared with testing of cardiac troponin alone 
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(Ecollan et al., 2007; Body et al., 2011a; Keller et al., 2011b). Recently, a 
systematic review on four clinical studies (Mion et al., 2007; McCann et al., 
2008; Haltern et al., 2010; Body et al., 2011a) has shown  that the addition of 
h-FABP test to troponin increased sensitivity from (42–75 %) to (76–97 %) but 
decreased specificity from (95–100 % to 65–93 %). One of the previous work 
previous work using a cut-off of 4ng/ml, on the same device used in this study, 
revealed that POC offers sensitivity of 92% after 3 hours of symptom onset 
and NPV of 99% when used in conjunction with ECG. The sensitivity was 
higher for AMI diagnosis when results were combined with ECG) (Glatz and 
Renneberg, 2014). 
Diagnostic strategies is needed to overcome the current sensitivity deficit. In 
general, FABPulous h-FABP True Raid Test did not provide high sensitivity 
when it is used by its own. Previously, a computer model the Manchester 
Acute Coronary Syndrome (MACS) algorithm used a laboratory-based h-
FABP assay test, which can be run with commercially available analysers in 
hospital laboratories (Body et al., 2014b). This strategy required a new assay 
to be set up and operated by the laboratory staff, which is a barrier to clinical 
implementation. However, the present study offers further insight into potential 
use of FABPulous h-FABP True Raid Test (FABP-ulous, Netherlands), which 
gives the necessary clinical evidence to support the adoption as a way for 
emergency medical workers to rule out heart attacks before they are required 
to admit patients to hospital. The test provides dichotomous (positive/negative) 
results within 5 minutes and can be used at the patient site in ED.  
Strengths and limitation 
The current study applied the FABP True Rapid Test which is a whole blood 
medical device that is designed to provide a reliable measurement of the 
Heart-type Fatty Acid Binding Protein (h-FABP). To our knowledge this is the 
first study that evaluated this device in multicentre study with inclusion of a 
wider range of population group. In addition, the device used in the current 
study was meeting the demand of a lower cut-off value; the cut off value of this 
device was 4 ng/ml which was found to be the lower in the market to date.  
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5.1. Background 
Achieving a rapid and accurate diagnosis of acute myocardial infarction (AMI) 
is essential, since early intervention save lives. The diagnosis of AMI is based 
on several criteria, including observation of circulating cardiac troponin I or T 
(cTnI or cTnT) above the upper reference limit (URL) (Jaffe and Apple, 2012a). 
Immediate rule-out of AMI in patients presenting with symptoms of cardiac 
ischaemia facilitates early discharge of this group of patients helps to reduce 
overcrowding of emergency departments (ED) (Taylor et al., 2002). Current 
guidelines support the use of sensitive cTn assays in decision making of AMI 
diagnosis at admission and three hours post admission of patients (Roffi et al., 
2015). In most of the recently published data several rule out protocols were 
based on the use of high-sensitive (hs) cTnT or cTnI assays (Shah et al., 2015; 
Bandstein et al., 2014; Tobias Reichlin et al., 2015; Body et al., 2015b). The 
time needed for results to become available for emergency physicians from 
the hospital central laboratory usually delays the disposition decision for an 
additional one or two hours (Bingisser et al., 2012). The routine scenario in 
clinical practice is such that, when patients arrive at the ED with a complaint 
of chest pain, they are immediately subjected to a first blood test at time zero. 
Alternatively, this could be delayed to half an hour and second test could be 
taken three hours later, so that there is a time of three and half hours after 
patient arrival. The blood samples are then sent to the central laboratory for 
tests, which will take another hour or more. Now with a four hours processing 
target it is impossible to get reports of two tests with a turnaround time of one 
hour. The only way to get the results of a three hour sample for diagnosing the 
patient within the four -hour target is to analyse the troponin sample by point 
of care testing keeping in view very short turnaround time (TAT). A large and 
growing body of literature has investigated the performance and analytical 
accuracy of several laboratory troponin assays. However, an assay with high 
diagnostic sensitivity is inevitably associated with detecting troponin and the 
diagnosis of ACS (Bhoi et al., 2014). Point-of-care (POC) assays have the 
potential to improve the diagnosis of chest pain patients in ED, by delivering 
quick test results of cTn. The biggest advantage of point of care tests when 
compared with central laboratory is shorter turnaround time that saves time in 
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the range of 47 to 59 minutes (Venge et al., 2010; McCord et al., 2001). 
However, this advantage is at the cost of lower diagnostic accuracy and lower 
negative predictive value. At this time, the majority of the available (POC) 
assays cannot be considered sensitive or high sensitivity assays (Apple, 
2009). Currently, cTnI tests by POC display a lower diagnostic accuracy than 
central laboratory cTnI/T assays (Apple et al., 2012b). The consensus 
statement on the universal definition of myocardial infarction recommends that 
an increase in plasma troponin concentration above the 99th percentile of a 
normal reference population is used to confirm the diagnosis (Jaffe and Apple, 
2012b). Despite this recommendation, lowering the diagnostic threshold for 
troponin remains a challenge whether the benefits of improved sensitivity will 
overcome the problems that might arise from reduced specificity (Kavsak and 
Jaffe, 2009). Accelerated diagnostic protocols that apply a high-sensitivity 
troponin level below the level of detection (LoD) have been explored and give 
a promising tool for discharge at the time of patient arrival to the ED. Numerous 
observational studies have evaluated the (LoD) (lowest analyte concentration 
at which detection is feasible) of hs-cTn assays alone at presentation to ED 
(Body et al., 2015c; Carlton et al., 2016). In the literature, both the limit of blank 
(LoB) and limit of detection (LoD) have been used as thresholds to define 
detectability. In a recent meta-analysis of more than 9000 chest pain patients 
in ED from 11 comprehensive studies, the researchers have estimated the 
diagnostic accuracy of a single hs-cTnT concentration below the (LoD) in 
addition to a non-ischemic electrocardiogram (ECG). The researchers found 
out that 30.6% were classified as low risk and  pooled sensitivity for 30-days 
major adverse cardiac events (MACEs) was 98.0% (95% CI 94.7% to 99.3%). 
They concluded that the LoD cut-off concentration of the hs-cTnT assay, when 
combined with a non-ischaemic ECG, is actually safe for rule out AMI in 
patients presenting to EDs with possible emergency acute coronary syndrome 
(Pickering et al., 2017).  
 (POC) (cTn) assays are not 'high sensitivity' but some can detect cTn 
concentrations below the conventional 99th percentile cut-off. There is limited 
evidence for the diagnostic accuracy and clinical sensitivity of detecting AMI 
at patient’s presentation to ED. The Abbott i-Stat handheld POC assay 
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provides a cTnI result within 10 min. However, there is some evidence for the 
i-STAT at 3 hours but it is not good enough to rule out the patients based on 
that strategy. The existing evidence for the diagnostic accuracy of POC cTn 
testing is well known to be limited. There is currently no evidence that explores 
the cut-off set at the lower limit of detection of POC testing  in ruling out chest 
pain patients in EDs. 
5.2. Aim and objectives 
The primary aim of this present study was to determine the diagnostic 
accuracy of the Abbot i-Stat handheld POC assay. The study was also aimed 
to determine whether serial troponin testing using the Abbott i-Stat POC 
troponin device can accurately ‘rule in’ and/or ‘rule out’ the diagnosis of (AMI) 
within 3 hours of arrival in the ED, using either the conventional 99th percentile 
cut-off or a novel ‘rule out’ cut-off set at either (a) the limit of detection of the 
assay, or (b) the lower limit of the reportable range of the assay. 
The objectives of this study were to address the following research questions: 
In patients with suspected acute coronary syndromes can serial troponin 
testing within 3 hours of arrival in the ED using the Abbott i-Stat point of care 
device enable accurate identification of: 
a. Patients at sufficiently low risk of prevalent AMI, to enable safe 
avoidance of hospital admission. 
 
b. Patients at sufficiently high risk of prevalent AMI so that that the 
diagnosis of an ACS should be considered ‘ruled in’. 
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5.3. Materials and methods 
5.3.1. Data collection and processing 
In this study, we prospectively enrolled an adult population presenting to the 
ED at eighteen hospitals with suspected ACS. All patients who were included 
in the study were entered into this diagnostic analysis. Patients with 
unequivocal evidence of ST elevation myocardial infarction requiring 
immediate primary percutaneous coronary intervention (PCI) were excluded 
from the study. The full inclusion and exclusion criteria have been described 
in detail in section 2.1.3.  Comprehensive clinical, electrocardiographic and 
biochemical data were collected at the time of presentation using a CRF form 
(Appendix 2.3). The initial ECG findings and systolic blood pressure was 
recorded at the time of arrival in the ED. 
5.3.2. Interventions 
Subjects who consented and met the inclusion criteria of the study underwent 
venipuncture within 1 hour of arrival in the ED (or within 45 minutes of the 
collection of the first blood sample for clinical purposes). Venous whole blood 
was collected in lithium heparin and EDTA blood tubes at the following 
intervals: upon enrolment at presentation and three hours later. cTnI 
concentrations were analysed using the (Abbott Point of Care, New Jersey, 
99th percentile 0.08 ng/mL (µg/L), LoD 0.02 ng/mL, 0.10 ng/mL, and functional 
sensitivity at 10% CV). 
POC testing was undertaken immediately following venipuncture by a clinical 
research nurse or the author. Tests were undertaken in accordance with 
manufacturer’s instructions. After the analysis, the time and result were 
recorded in the participant’s case report form. As part of the patient’s routine 
clinical care, all patients were subjected to reference standard laboratory-
based troponin testing in accordance with the latest national and international 
guidance. Additional samples were stored in SST II Advance, lithium heparin 
and EDTA vials and labelled with a unique study number. After processing any 
samples that were tested in real time using point of care devices, the additional 
samples was centrifuged within 30 minutes of venepuncture at 2,500G for 10 
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minutes. Plasma and serum were separated and aliquots of 500 to 2,000μL 
and then stored in vials labelled with the patient’s unique study number. 
Sample characteristics (haemolysis, lipaemia, icterus) were also recorded in 
the case report form. The serum and plasma were then frozen at or -20℃ or 
below within 4 hours of sample collection. The sample collection schedule has 
been described earlier in (Chapter 2) and the overall schedule for blood 
sampling during this study is outlined in section 2.1.4.  
The reference standard for AMI was serial central laboratory cTn testing over 
at least 3 hours (for high sensitivity assays) or at least 6 hours contemporary 
assays), the time window of blood sampling was set according to the local 
hospital standard procedures of each sites. A blood sample was collected and 
sent to the laboratory for cTn testing. The diagnostic evaluation and patient 
management continued as per the standards of the treating hospital system 
without intervention per study protocol. Cardiac events and any procedures 
were recorded during the index hospitalization. A 30-day telephonic follow up 
and by medical record review was carried out. All diagnoses of AMI were 
performed according to the third universal definition of AMI guidelines  (Jaffe, 
2013). 
5.3.3. Outcome measuring and defining outcomes 
The primary outcome of this study was rapid diagnosis AMI. Outcomes were 
adjudicated by two independent investigators with reference to relevant clinical 
information but blinded to the results of research investigations. Discrepancies 
were resolved by consultation with a third independent investigator. AMI was 
defined according to the Third Universal Definition of AMI (Jaffe, 2013) 
however, by the inclusion criteria, all patients has symptoms and signs 
consistent with myocardial ischaemia. Therefore, patients who were deemed 
to have met this outcome if they developed a rise and/or fall of troponin to 
above the 99th percentile. At the time of writing this thesis and pending further 
evidence and international guidance, a significant rise and/or fall of troponin 
was considered to be >9.2ng/L for high sensitivity troponin T (Mueller et al., 
2012) and at least 20% for all other assays.  
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5.3.4 Statistical methods  
In this study we assessed the overall diagnostic accuracy of (i-Stat, Abbott 
Point of Care) and hs-cTnT by ROC curve analysis with SPSS version 20.0. 
Diagnostic sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV), and likelihood ratios were calculated at the standard 
(99th percentile cut-offs 80ng/L) and at the LoD of the assay (LoD 0.02 ng/mL) 
and at the functional sensitivity (10ng/L) of the assay (0.01 ng/mL (µg/L). All 
statistical analyses were performed using either SPSS version 22.0 (IBM 
Software, USA) or MedCalc online calculator version Construct 2x2 table at 
0.02 µg/mL and 0.08 µg/mL for AMI diagnosis (crosstab by SPSS) (2x2 table).  
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5.4  Result 
5.4.1. Study population 
During the study time frame of February 2015 to March 2017 there were 1,613 
patients enrolled. Of this cohort, some patients were excluded for missing i-
Stat on arrival, and the patients who did not have an ECG recorded were also 
excluded. This left 733 patients in the final group for analysis consisting of 457 
men (62.3%) and 276 women (37.7%). The mean age was 58 years (standard 
deviation 16). Acute myocardial infarction (AMI) was diagnosed in 90 (12.3%) 
patients. 
5.4.2 Receiver operating characteristic (ROC) curve for the i-STAT 
troponin assay at presentation, for diagnosis of AMI in the total study 
population. 
As an illustration, the corresponding empirical ROC curve was drawn in Figure 
(4.1 a,b) by a nonparametric method using SPSS software which shows the 
ROC curves for diagnosis of AMI with each time point presented in the total 
study population. At patient presentation, the ROC AUCs was 0.870, and 
standard error was 0.025 while at three hours later (maximum relative change) 
of patient presentation the AUCs was 0.910, and standard error was .021.  
There was significant improvement in the AUCs for the maximum change of 
troponin. The calculation of sensitivity and specificity of various cut-off values 
of i-STAT troponin for diagnosis of AMI at the initial time and three hours later 
of patient presentation are shown in Tables 5.1 and 5.2. Via from the ROC 
curve, the optimum cut-off value for the diagnosis of AMI (Figures 5.1 and 5.2) 
appeared to be at 0.005 µg/L, which corresponded to a sensitivity of 87% and 
a specificity of 69.7%. Conversely, at the LoD 0.02 µg/L the sensitivity was 
62.8%, and the specificity was 94% to rule out AMI, which is a higher 
diagnostic accuracy than the 99th percentile cut off 0.08 µg/L that 
corresponded to a sensitivity of 45% and specificity of 98%. Although the i-
Stat has higher specificity, it would not be the better choice of the two cut-offs 
for ruling in.  
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Figure 5-1. Receiver operating characteristic (ROC) curve for the i-STAT 
troponin assay at presentation, for diagnosis of AMI in the total study 
population 
 
Figure 5-2. Receiver operating characteristic (ROC) curve analysis for the i-
STAT troponin assay measured at three hours after presentation in the total 
study population, for a diagnosis of AMI 
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Table 5-1. Optimal cut off-values of i-STAT at each cut-off value at initial time 
for AMI with 95% CI 
Optimal cut-off-
value (ng/mL) 
Sensitivity% Specificity% 95% AUC 
Lower Limit-Upper 
Limit 
0.005 µg/L 87% 69.7% 0.870 
0.821-0.919 0.02 µg/L 62.8% 94% 
0.08 µg/L 45% 98% 
Area under the Curve (AUC): The c-statistic or AUC, is derived from receiver-
operating characteristic curves (ROC) and is used to determine the 
discriminatory ability of a diagnostic test. The AUC equals 0.5 when the 
diagnostic test corresponds to random chance (null hypothesis), and 1.0 
shows perfect diagnostic accuracy. Note: definition reproduced from Hajian 
Tilaki with permission. 
 
Table 5-2. Optimal cut off-values of i-STAT at each cut-off value at three hours 
later 
Optimal cut-off-value (µg/L) Sensitivity% Specificity% AUC (95% CI) 
(Lower Bound-Upper Bound) 
0.005 µg/L 94% 54% 0.910 
(0.869-0.952) 0.02 µg/L 80% 84% 
0.08 µg/L 65% 99% 
Abbreviations: AUC, area under the curve.  
5.4.3  Performance of the i-STAT POC assay at the limit of detection .02 
ng/mL (µg/L) (LoD, 20ng/L) 
A total of 693 patients were included in this analysis, of which 86 (12.4%) 
patients had AMI. The proportion of patients had AMI are summarised in Table 
5.3. (2x2 Table) However, with this rule out strategy at LoD (0.02 µg/L) the 
diagnostic sensitivity to rule out AMI was 62.79% (95% CI 51.70% - 72.98%) 
and a negative predictive value of 94.69 % (95% CI 93.13% -95.92%). This 
cut-off would miss the diagnosis of 32 (4.6%) patients. On the other hand, the 
diagnostic specificity was 94.07 % (95% CI 91.88% -95.81%) and positive 
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predictive value of was 60.00% (95% CI 51.23%-68.17%). The diagnostic 
sensitivity at lower limit of detection cut-off value (0.02 ng/ml) to rule out AMI 
three hours after patient arrival to ED was 83.72% (95% CI 74.20%-90.80%) 
and a negative predictive value of 97.37 % (95% CI 95.81% to 98.36%). On 
the other hand, the diagnostic specificity was 84.92 % (95% CI 81.83% to 
87.67%) and the positive predictive value was 43.90% (38.81%-49.12%). The 
results are summarised in Table 5.4, 5.5 and 5.6. 
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Table 5-3. Two x two table and calculation of negative and positive predictive 
value as well as sensitivity and specificity for the rule-out and rule- in 
myocardial infarction on arrival using the 0.02 ng/ml cut-off 
i-STAT T0 at 0.02  ng/mL : i-STAT troponin result at initial time , TP: True positive, FP: False 
positive, FN: False negative, TN: True negative. 
Table 5-4. Rule-out strategy, POC cTn<0.02 ng/ml on arrival 
Diagnostic test 
performance 
measure 
 
Value,% 95% Confidence Interval 
Lower Limit-Upper Limit 
Percentage ‘ruled 
out’ 
(Total FN+TN)/100 
Sensitivity 
 
62.79% 
 
51.70% - 72.98  
603/693 ×100 
87% Specificity 
 
94.07 % 
 
88% -95.81 
PPV 
 
60.00% 
 
51.23-68.17 
NPV 
 
94.69 % 
 
93.13 - 95.92 
PPV: Positive predictive value, NPV: Negative predictive value, Percentage ‘ruled out’ AMI : 
FN+TN/ (TP+TN+FP+FN) X100 
Table 5-5. Two x two table and calculation of negative and positive predictive 
value as well as sensitivity and specificity for the rule-out and rule- in 
myocardial infarction at three hours later of patient presentation using the 0.02 
ng/mL cut-off 
 AMI No AMI Total 
Max i-STAT 0.02 ng/mL  >.02 ng/mL  TP 72 FP 92 164 
 FN 14 TN 518 532 
Total 86 610 696 
Max i-STAT 0.02 ng/mL (µg/L): The highest i-STAT troponin recorded on arrival & 3 hours TP: 
True positive, FP: False positive, FN: False negative, TN: True negative  
 
 
 AMI No AMI Total 
Performance of the i-STAT POC assay at 
the lower limit of detection 0.02  ng/ml 
>0.02  
ng/ml 
TP54 FP 36 90 
 FN 32 TN 571 603 
Total 86 607 693 
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Table 5-6. Rule-out strategy, POC cTn<0.02 ng/mL on arrival & 3 hours post 
arrival 
Diagnostic test 
performance 
measure 
Value,% 95% Confidence Interval, 
Lower Limit-Upper Limit 
Percentage 
‘ruled out’ 
 
Sensitivity 
 
83.72% 
 
74.2-90.80 
 
 
532/696×100 
76.4% Specificity 
 
84.92 % 
 
81.83 87.6 
PPV  
 
43.90% 
 
38.8 -49.12 
NPV 
 
97.37% 
 
95.8 -98.36 
PPV: Positive predictive value, NPV: Negative predictive value, Percentage ‘ruled out’ AMI : 
FN+TN/ (TP+TN+FP+FN) X100 
5.4.4  Performance of the i-STAT POC assay at the conventional 99th 
percentile cut-off 0.08 ng/mL 
With this rule out strategy at the 99th percentile cut-off value (0.08 ng/ml) at 
initial i-STAT on arrival,42 patients had AMI (5 patients had false positive 
result) see Table 5.7. The diagnostic sensitivity to rule out AMI was 43.02% 
(95% CI 32.39% 54.15%) and a negative predictive value of 92.47% (95% CI 
91.09% to 93.66%). Using this diagnostic cut-off would miss 49 (7.6%) 
patients. Conversely, the diagnostic specificity was 99.18 % (95% CI 98.09%-
99.73%) and positive predictive value of 88.10% (95% CI 74.94%-94.82%). 
The results are summarised in Tables 5.8, 5.9 and 5.10 
Table 5-7. Two x two table and calculation of negative and positive predictive 
value as well as sensitivity and specificity for the rule-out and rule- in 
myocardial infarction at arrival of patient presentation using the 0.08 ng/ml the 
conventional 99th percentile cut off 
 AMI  No AMI Total 
Troponin i-STAT at<0.08 ng/ml 
on arrival 
 
 
<0.08 ng/ml 
 
TP 37 FP 5 42 
 FN 49 TN 602 651 
Total 86 607 693 
TP: True positive, FP: False positive, FN: False negative, TN: True negative, <0.08 ng/ml:the 
conventional 99th percentile cut-off.   
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Table 5-8. Rule-out strategy, POC cTn 0.08, ng/ml the conventional 99th 
percentile cut-off on arrival 
Diagnostic test 
performance 
measure 
Value,% 95% Confidence Interval 
Lower Limit-Upper Limit 
Percentage ‘ruled out’ 
Sensitivity 43.02% 32.39%- 54.15% 651/693×100=94% 
Specificity 99.18 % 98.09% to 99.73% 
PPV 88.10% 74.94% to 94.82% 
NPV 92.47 % 91.09% to 93.66% 
PPV: Positive predictive value, NPV: Negative predictive value, Percentage ‘ruled out’ AMI: 
FN+TN/ (TP+TN+FP+FN) X100 
Table 5-9. Two x two table and calculation of negative and positive predictive 
value as well as sensitivity and specificity for the rule-out and rule- in 
myocardial infarction on arrival & 3 hours later of patient presentation using 
the 0.08µg/L cut-off 
 AMI No AMI Total 
Troponin i-STAT <.08 
ng/ml on arrival & 3 
hours 
<0.08 
ng/ml 
TP 56 FP 8 64 
0.00 FN 30 TN 602 632 
Total 86 610 696 
TP: True positive, FP: False positive, FN: False negative, TN: True negative, 08 ng/ml the 
conventional 99th percentile cut-off  
Table 5-10. Rule-out strategy, POC cTn 08 ng/ml on arrival & 3 hours post 
arrival 
Diagnostic test 
performance 
measure 
Value,% 95% Confidence 
Interval 
Lower Limit-Upper Limit 
Percentage ‘ruled 
out’ 
(Total FN+TN)/100 
Sensitivity 65.12% 54.08% to 75.08% 632/696× 100=90% 
Specificity 98.69 % 97.43% to 99.43% 
PPV 87.50% 77.56% to 93.41% 
NPV 95.25 % 93.76% to 96.40% 
PPV: Positive predictive value, NPV: Negative predictive value, Percentage ‘ruled out’ AMI: 
FN+TN/ (TP+TN+FP+FN) X100 
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5.4.5  Performance of i-STAT POC assay at the functional sensitivity 
(10ng/L) of the assay (0.01 ng/mL  
With this rule out strategy at the functional sensitivity of the assay at patient 
presentation the diagnostic sensitivity to rule out AMI using this cut-off was 
94.19% (95% CI 86.95% - 98.09%) and a negative predictive value of 98.48 
% (95% CI 96.51%- 99.35%). However, using this diagnostic cut-off would 
miss diagnosis of five (.8%) patients. Conversely, the diagnostic specificity 
was 53.28 % (95% CI 49.23% to 57.30%) and positive predictive value of 
98.48 %( 95% CI 96.51%-99.35%). The results are summarised in Tables 5.11 
and 5.12.  Summary of the diagnostic accuracy specification for i-STAT 
cardiac troponin assay for ruling out AMI at different cut offs are illustrated in 
Table 5.13 
Table 5-11. Two x two table and calculation of negative and positive predictive 
value as well as sensitivity and specificity for the rule-out and rule- in 
myocardial infarction on arrival and three hours later of patient presentation  
using the functional sensitivity 
 AMI No AMI Total 
i-STAT<0.01 ng/mL (µg/L).on 
arrival & 3 hours 
<0.01 ng/ml TP 81 FP 285 366 
 FN 5 TN 325 330 
Total 86 610 696 
TP: True positive, FP: False positive, FN: False negative, TN: True negative, <0.01 ng/ml: the 
functional sensitivities for the cTnI method 
 
Table 5-12. Rule-out strategy, POC cTnat the functional sensitivity of the 
assay <0.01 ng/ml on arrival & 3 hours post arrival 
Diagnostic test 
performance 
measure 
Value,% 95% Confidence Interval 
Lower Limit-Upper Limit 
Percentage 
‘ruled out’ 
Sensitivity 94.19% 86.95% to 98.09% 330/369 ×100 
89.5% 
 
Specificity 53.28 % 49.23% to 57.30% 
PPV 22.13% 20.46% to 23.90% 
NPV 98.48 % 96.51% to 99.35% 
PPV: Positive predictive value, NPV: Negative predictive value, Percentage ‘ruled out’ AMI: 
FN+TN/ (TP+TN+FP+FN) X100 
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Table 5-13. Summary of the diagnostic accuracy specification for i-STAT 
cardiac troponin assay for ruling out AMI at different cut offs 
Rule-out 
strategy, 
POC cTn 
Percentage 
‘ruled out’ 
Sensitivity% Specificity% PPV NPV 
<0.02 
ng/ml on 
arrival 
87% 62.79% 
51.70%-72.98 
94.07% 
88%-95.81 
60.00% 
51.23-68.17 
94.69% 
93.13-95.92 
<0.08 
ng/ml on 
arrival 
94% 43.02% 
32.39% 54.15 
99.18% 
98.09%-99.73 
88.10% 
74.94%-94.82 
92.47% 
91.09%-93.66 
<0.02 
ng/ml  on 
arrival & 3 
hours post 
arrival 
76.4% 83.72% 
74.2-90.80 
84.92% 
81.83% to 
87.67% 
43.90% 
38.8 -49.12 
97.37% 
95.8-98.36 
<0.08 
ng/ml on 
arrival & 3 
hours 
90% 65.12% 
54.08%-
75.08% 
98.69% 
97.43%-
99.43% 
87.50% 
77.56%-
93.41% 
95.25% 
93.76%-
96.40% 
<0.01 
ng/ml on 
arrival & 3 
hours 
47% 94.19% 
86.95%-
98.09% 
53.28 % 
49.23%-
57.30% 
22.13% 
20.46%-
23.90% 
98.48 % 
96.51%- 
99.35% 
PPV: Positive predictive value, NPV: Negative predictive value, Rule-out strategy, POC cTn 
<0.02 ng/ml Lower limit of detection cut-off, 0.08 ng/ml the conventional 99th percentile cut-
off, POC cTn <0.01 ng/ml: the functional sensitivities for the cTnI method  
5.4.6  Diagnostic Accuracy of the Functional sensitivity of i-STAT POC 
on arrival and 3 hours post arrival with ischemic ECG 
In 702 patients with complete data of ECG and the maximum i-STAT troponin 
result of chest pain patients presented to ED, we have evaluated the 
diagnostic accuracy of i-STAT troponin results at the LoD .02 ng/ml at 
presentation and three hours post presentation to (EDs) in combination with 
the emergency physician’s assessment of ECG for ruling out AMI within 30 
days. We observed that Troponin concentrations were below the lower limit of 
detection (0.02 ng/ml) in 582 (75%) out of 786 patients.  However, this cut-off, 
together with an ECG of acute ischemia, would allow up to 45.7%  of patients 
among 702 patients to be discharged with a sensitivity of  94.19% (95% CI, 
86.95% -98.09%) and an NPV 98.43 % (95% CI 96.38% -99.32%) and 
specificity of  51.57 % (95%CI,47.51%-55.61%) and a PPV 21.60% (95% CI 
115 
20.00%-23.30%). None of the five (7%) patients with false-negative results 
died within 30 days of presentation. The results are summarised in Table 5.14 
and 5.15. 
Table 5-14. Two x two table and calculation of negative and positive predictive 
value as well as sensitivity and specificity for the rule-out and rule- in 
myocardial infarction on arrival and three hours later of patient presentation 
with the functional sensitivity 
 
Maximum i-STAT result: The highest i-STAT troponin recorded, ECG interpretation: ECG 
shows acute ischemia 
Table 5-15. Rule-out strategy, POC cTnat the functional sensitivity of the 
assay <0.1 ng/ml on arrival & 3 hours 
Diagnostic test 
performance 
measure 
Value% 95% Cl Percentage ‘ruled out’ 
(Total FN+TN)/100 
Sensitivity 94.19% 86.95% to 98.09% 326/702×100=46% 
Specificity 52.11 48.08% to 56.12% 
PPV 21.54%  19.94% to 23.24% 
NPV 98.47 % 96.47% to 99.34% 
 
5.4.7  Diagnosing AMI  
The primary outcome of the study was the diagnosis of AMI, however patients 
were considered to have AMI if troponin results were above the 99th percentile 
as per the Third Universal Definition and based on absolute delta by 
calculating the maximum difference between two troponin levels at time 0 and 
3 hours after patient arrival in ED (Jaffe, 2013). The reference standard for 
AMI was serial central laboratory cTn testing over for at least 3 hours (for high 
sensitivity assays) or at least 6 hours (contemporary assays) according to the 
protocol of the different sites.   
 AMI No AMI  Total 
Maximum i-STAT result 
and  
ECG interpretation 
Strategy  
Test +ve TP 81 FP 295 376 
Test -ve FN 5 TN 321 326 
 
Total 86 616 702 
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5.5  Discussion 
The reliable determination of troponin even at concentrations well below the 
previously defined 99th percentile values has become possible. 
Concentrations below the 99th percentile measured with several different 
assays have been shown to provide robust prognostic information. In this 
study we determine the diagnostic accuracy of a contemporary POC cTn 
assay used on arrival and 3 hours later in patients with  suspected ACS, at the 
conventional 99th percentile and novel LoD cut-offs(Parikh et al., 2008). In 
order to support emergency medicine physicians in the appropriate triage and 
management of chest pain patients there has been a prompt improvement in 
testing threshold sensitivity for POC cardiac troponin testing. Several attempts 
have been made to detect cardiac troponin alone or in addition to another 
cardiac marker panel with lower detection thresholds and more accurate 
detection resulting in a numerous and different POCT research studies 
(Peacock et al., 2016; Lee-Lewandrowski et al., 2011b). The main finding of 
this study is that the i-Stat, Abbott POC assay detected 12% of all patients with 
AMI in the ED by sitting the cut-off set at the LoD of  0.02 ng/ml. In this study 
we found that the LoD cut-off had significantly greater sensitivity than the 99th 
percentile (95%CI, 83.72% 74.2-90.80) but lower specificity (95%CI,43.90% 
38.8 -49.12%) than the 99th percentile cut-off. However, the use of an 
unconventional cut-off set at the LoD of a contemporary POC cTn assay 
substantially improves sensitivity.  
With the current study strategy serial sampling over 3 hours, the probability of 
a missed AMI diagnosis would have been 2.63% using the LoD cut-off and 4.7 
% with the 99th percentile cut-off. This could be used to ‘rule out’ AMI within 3 
hours in almost half of all patients if clinicians and patients are willing to accept 
a small risk of missed AMI. This findings makes an important support to the 
use of the LoD as a clinical cut-off in results obtained from  POC devices to 
support the clinical judgment as those assays are not highly sensitive as the 
laboratory assays.  
The findings of the current study also corroborate previous research that 
highlights the analytical sensitivity of the POC troponin I assay (i-STAT). The 
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study indicated that more AMI cases are detected by lowering the decision 
cut-off to half of the 99th percentile troponin concentration on the i-STAT using 
the 0.04 ng/ml cut-off. In this study Schneider et al evaluates the analytical 
sensitivity of POC troponin I assay (i-STAT) and more sensitive troponin 
assays (Beckman  CoulterAccuTnI and Abbott Architect cTnI). However,  the 
true positive rate in the study was improved to 81% and  the false negative 
rate decreased to 6.8% while the false positive rate increased to 7.3% 
(Schneider et al., 2013). Conversely, to current study were the false negative 
rate of the LoD .02 ng/ml was 4.6%.  Our finding is significantly higher clinical 
sensitivity. Despite the low clinical sensitivity if emergency physicians rely on 
i-STAT result only to rule out patients, combining this finding with clinical 
information would support the diagnostic accuracy of a clinical decision rule in 
an ED setting.  
This is the first study exploring the diagnostic accuracy of i-STAT POC (cTnI) 
testing for serial blood sample on arrival and 3 hours later in patients with 
suspected (ACS) at the conventional 99th percentile and novel LoD cut-offs. 
In this study, the diagnostic sensitivity of the i-STAT POC assay at the LoD at 
patient presentation was 62.79%. Recently, a study by Sardi,. et al, supports 
lowering the cut-off value of the i-STAT POC troponin values from the 0.08 as 
suggested by the manufacturer to 0.035 to be in line with the results of the 
gold standard troponin (Sardi et al., 2016). On the other hand, the results of 
the current study provides evidence supporting the good performance of i-
STAT POC testing for ruling out AMI when the 3 hour test is added after patient 
presentation to ED. With the additional test performed at 3 hours, later the 
diagnostic sensitivity was improved to 83.72% and 97.37% NPV. 5 % of 
patients will miss a diagnosis with this strategy. 
The finding of the current study is in line with one of the previous study by 
Krone et al., 2007 who suggested that in patients with a high clinical probability 
of ACS increase in troponin above the lower limit of detection (LoD) but below 
the ESC/ACC decision limit recommendation is also related with greater risk 
of complication) (Krone, 2007). 
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In the area of high sensitivity assay, several studies had been previously 
shown that lowering the diagnostic threshold of the assay was associated with 
a change in clinical practice, with more referrals to cardiac specialists, more 
coronary angiography, and wider use of evidenced based treatments (Body et 
al., 2016b; Bandstein et al., 2014). To date, many studies compare 
conventional central laboratory assays to POC troponin, but insufficient data 
is available on the comparison of diagnostic accuracy of POC testing  with 
hsTn troponin assay. The diagnostic performance of hsTnT and troponin POC  
at the 99th percentile and conventional rule in cut offs has been evaluated in 
a study by Slagman and his group,  clinical routine troponin samples from 3432 
patients presenting to the ED was tested in both assays. 3.6% of patients had 
a diagnosis of NSTEMI for the hsTnT assay, 28.4% of all values were at or 
below the (LOD) as compared to 75.7% of the POC-TnT-values. The 
diagnostic performance was similar for both assays, the sensitivity at the 99th 
percentile cut off for hsTnT and POC was 92% and 85% respectively, the NPV 
at the 99th percentile was similar for both assay 99% (Slagman et al., 2017). 
This finding is in agreement with results of the previou year by James et al.  In 
this study the researcher compared the performance of a POCT cTnI assay in 
contrast to a central lab cTnT assay. The odds ratio for 30-day death or MI 
was 1.64 (95% CI: 1.31-2.06) for the POCT assay and 4.29 (CI: 3.02-6.09) for 
the central lab assay (James et al., 2004). Other result are similar to this finding 
in a  study by TerAvest et al,the researchers compared the analytical and 
diagnostic performance of the AQT-90 POC TnT assay with central laboratory 
hsTnT in 261 samples from patients presenting to ED of whom 13% had a final 
diagnosis of NSTEMI. The authors report a much lower sensitivity of the POC 
TnT (68% vs 85.48) but a very similar sensitivity for hsTnT (91% vs. 92.74%), 
and also a lower NPV of the POC TnT (95% vs. 99.37%)(TerAvest et al., 
2016). A study by (Venge et al., 2010) showed that the POC cTnI assays are 
less sensitive for outcome prediction of patients with myocardial injury. The 
researcher evaluated two different POC assays with a central laboratory 
assay. The i-Stat (Abbott Diagnostics) and Stratus CS (Siemens Healthcare 
Diagnostics) as POC assays Access AccuTnI (Beckman Coulter, Fullerton, 
CA) and Architect cTnI (Abbott Diagnostics) as laboratory assays. However, 
they found that by implementing the 99th percentiles upper reference limit, the 
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Access AccuTnI identified 88% and Architect cTnI identified 81% of all patients 
who died of cardiovascular disease as compared with 50% and 54% for i-Stat 
and Stratus CS, respectively. The high negative predictive values for the 
laboratory assays were 97% as compared with 89% to 93% for the POC 
assays. Negative likelihood ratios were 0.25 (CI 0.15-0.041) and 0.59 to 0.68 
(CI 0.47-0.79), respectively. Another study by (Palamalai et al., 2013)  
evaluated four point of care cardiac troponin I assays to rule in and rule out 
AMI they found out that the analytical variability that exists between POC cTnI 
assays determines substantial diagnostic differences for ruling in and ruling 
out AMI in patients presenting with symptoms suggestive of ACS. 
This finding is particularly important to assist the triage system and patient 
management in the ED environment (Storrow et al., 2008). With the optimal 
goal for patient satisfaction outcome and improving the health system overall 
(Thygesen et al., 2010).   In the current study we evaluated the diagnostic 
sensitivity therefore we could improve the true positive detection rate of such 
assay with an acceptable number of false positive results in a real life 
population made in EDs. In the current study i-Stat showed comparable 
performance to the central laboratory high sensitivity assay. This study 
demonstrates the potential of quantitative of i-Stat, Abbott POC cTn assay 
measurement in the ED for diagnostic performance of AMI. 
When high sensitivity troponin assays were developed in the market this has 
been raised the emphasis on earlier diagnosis and faster discharge from EDs 
and the gap between point of care troponin and laboratory might extend.  On 
the other hand, a study reported that POC troponin assays identify the majority 
of patients with ACS (Rathore et al., 2008). Results that indicate a need for 
rapid clinicians intervention should be delivered to requesting clinical as a 
matter of urgency. Reporting troponin result is until now facing challenges in 
interpretation of results in the ED. For this reason, it is very important for 
clinicians to understand certain basic characteristics of assays, and also work 
should be done to improve the reference intervals and establishment of 
decision thresholds in order to critically interpret the troponin assay. This is 
essential for the successful implementation of the assay for the use in clinical 
practice.  
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Delivering troponin results over an appropriate timescale may provide 
therapeutic and psychological benefits to patients and to the health system 
overall from the starting of patient safety to the cost effective for patient care.  
There is a significant differences in analytical characteristics of troponin assay. 
Each assay requires an individual assessment protocol to be set between the 
emergency physician and laboratory specialist. In the meantime, there are a 
concerns around the lack of analytical sensitivity of POC assays compared to 
laboratory assay were POC assay have higher level of imprecision and this 
resulted in lower clinical sensitivity for AMI diagnosis in ED. 
This study demonstrates the importance of presenting both sensitivity and 
NPV to evaluate the diagnostic accuracy of early strategies to exclude AMI.  
In this study, the Low concentrations at LoD for i-STAT cardiac troponin I 
determined on presentation and three hours later to the emergency 
department (ED) showed to have an excellent negative predictive value (NPV) 
96.36% for the identification of acute myocardial infarction when combined 
with ECG. A study similar to our finding has been evaluated the clinical 
performances of another POC device (MinicarecTnI). The researchers found 
that, with the addition of the three hours sample the NPV was increased to 
99% three hours later instead of 95% for the initial sample only (Venge et al., 
2017).  
The selection of an appropriate diagnostic threshold requires careful 
consideration of concentrations seen in the normal and disease free 
population and those seen in diseased populations. There is always a 
continuous balance between the sensitivity and specificity of any marker. If the 
cut-off concentration used is low, the sensitivity is improved at the expense of 
specificity unless the marker is 100% cardiac specific, and only present in 
diseased populations.(Henderson and Bhayana, 1995). 
However, this allows the use of low cut off concentration that improves the 
utility of troponin for risk stratification in our main project (BEST Study). In 
addition, the main advantage of using the i-STAT POC is the ability to meet 
the turnaround time of a cTn result within 60 min from the time of phlebotomy 
to the result availability to emergency physician. Recent evidence supports the 
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use of hs-cTn assays in rule out of MI within 1 hour after admission. Using the 
laboratory assays often delayed the turnaround time recommended for 
troponin testing. Since the clinicians depend on fast TAT in order to achieve 
early diagnosis and treatment of chest pain patients and more importantly to 
achieve early discharged form ED. Implementation of sufficiently sensitive 
POC cTnI assay could support earlier discharge by providing a rapid cTnI 
measurement (Bingisser et al., 2012). A recent meta-analysis by S. Goodacre 
et al reported that the sensitivity of troponin at patient presentation is about 
70-80 % and this is depending on the assay used (Goodacre et al., 2013). The 
clinical performance of i-STAT POC has been reported in diagnostic 
evaluation study of four POC cardiac troponin I assays. In this study, 
researchers compared the diagnostic sensitivity of different POC to a central 
laboratory cTnI assay for detecting myocardial injury and diagnosing AMI. With 
Abbott, i-STAT troponin assay plasma was obtained at presentation, 3 hours 
and 6 hours for 169 patients presenting with symptoms suggestive of (ACS). 
They find out that there was a significant (p <.005) improvement at 3 h and 6 
h post presentation for all POC and the sensitivity was varied between the 
assays.  Clinical sensitivity for i-stat at time zero was 32% (13, 57), 68% (43, 
87), and 68% (43, 87) at presentation, time three and time 6 hours 
respectively.  All PPVs in the study for all POC tests were ≤50% at all time-
points (Palamalai et al., 2013). 
Previous work has evaluated the diagnostic performance of VITROS(R) 
Troponin I-ES assay (Ortho-clinical Diagnostics, Rochester, NY) and reported 
that in  patient admission and 6-hours  TnI levels with this device had AMI 
sensitivities of 69% (95% CI 55%-81%) and 94% (95% CI 84%-99%), 
respectively. The specificities were 78% (95% CI 73%-82%) and 81% (95% 
CI 77%-85%) and MI was clinically diagnosed in 52 (13.6%) of patients during 
initial hospitalisation (Apple et al., 2009). Similar findings of our result have 
recently been described by Diercks et al (2012) as they reported that 9.6% 
patients from total of 858 patients were diagnosed with AMI. The sensitivity, 
specificity, positive likelihood ratio, and negative likelihood ratio over 3 hours 
were 84.1%, 93.4%, 12.8, and 0.17, respectively when using the Cardio 3 TnI 
POC device in ED. There was no significant improvement in diagnostic 
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accuracy associated with adding 6-hour serial testing to the 3-hour sample 
and there was no change in diagnostic accuracy between 0 time and 3 hours 
of testing however (Diercks et al., 2012). Existing data suggest that POC 
cardiac markers can accelerate decision-making in the ED. Goodacre et al 
2011 evaluate the clinical effectiveness of POC cardiac marker panel in 
patients presenting to the (ED) with suspected AMI the study conclude, that 
the time to ACS diagnosis is faster when POC testing is performed and the 
diagnostic at 4 hours was: Odds ratio: 3.81 (3.01 to 4.82, p < 0.001)(Goodacre 
et al., 2011). The first-draw sample for cardiac marker testing is very important. 
Previous study evaluated POC with old generation troponin assay and 
reported that only 63% of patients with an MI showed a positive cardiac marker 
on the first draw specimen using a multi marker platform  with an older, 
qualitative, POCT cardiac marker technology with a specificity of 81 % (Kratz 
et al., 2002). A similar finding for our study has recently been reported the 
diagnostic sensitivity of i-STAT POC when first draw of troponin sample at time 
0 of patient presented to ED is used. The sensitivity of AMI using i-STAT was 
63% and NPV was 95% and 10.8% of AMI identified in the study (Lee-
Lewandrowski et al., 2011a). Another study evaluate the diagnostic of POC 
(Spectral Cardiac STATus) at time 0,4h and 8 hours  comparing POC testing 
to the central Stratus laboratory assay the sensitivity at time 4 was  88.0% 
(82.4 to 92.1) and NPV was 97.0% (90.8 to 99.2) (Hillis et al., 1999). 
In conclusion, the use of an unconventional cut-off set at the LoD of a 
contemporary POC cTn assay substantially improves sensitivity. However, 
this could be used to ‘rule out’ AMI within 3 hours in almost half of all patients 
if clinicians and patients are willing to accept a small risk of missed AMI. Next 
chapter will demonstrate the diagnostic accuracy of the T-MACS accelerated 
diagnostic protocol celebrated with Troponin tested by the  (i-STAT). 
5.6  Strength of the study  
The analytical sensitivity gap between central laboratory testing platforms and 
POCT assays for cardiac troponin is very important and has limited the 
adoption of POCT for several hospitals. The strength of our study is to improve 
the clinical sensitivity of the i-stat POC test with a novel LoD cut-off. The 
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current study is unique in several ways. (1) this is the first study to evaluate 
early rule out strategy for Acute Myocardial Infarction using an unconventional 
cut-off set at the LoD of a contemporary POC cTn assay (i-STAT) (the optimal 
‘delta’ troponin (serial measurement) for the assay and ECG interpretation., 
(2) this study has evaluated the diagnostic accuracy of the POC i-STAT 
troponin assay in combination with the emergency physician’s assessment of 
an ECG for ruling out AMI. To our knowledge, no previous study so far has 
evaluated this combination. (3) the findings of this study will increase the 
evidence-based literature for implementing the i-STAT cTnI POC sitting at the 
LoD cut-off system along ESC/ACC guidelines.  Finally,(4) this study was 
focussed on the clinical performance of the respective assay in terms of their 
ability to identify a level of cTnI that would support a diagnosis of MI (i.e. above 
the L cut-off). 
5.7  Limitation and strength of the study 
One of the limitation of this study is the lack of consideration for the coefficient 
of variation. It is agreed that a diagnostic tool should be able to establish a cut-
off score as long as the coefficient of variation (mean/standard deviation) at 
this point is less than 10%.(Roffi et al., 2016).  In the current study, a cut-off of 
0.02 ng/ml was studied, which does not satisfy these criteria. It has been 
reported that, for this assay, the total imprecision (CV) of 10% and 20% were 
seen at 0.09 and 0.07 respectively (Apple et al., 2004). 
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6.1. Background 
Acute chest pain is a very common presentation at emergency departments 
worldwide. Almost 700,000 patients present to the ED per year in England and 
Wales, which equates to approximately 25% of emergency medical 
admissions (Goodacre et al., 2005).However, reports suggest that as little as 
10% of patients are diagnosed with AMI (Than et al., 2014b) and 15% are 
diagnosed with ACS (Pollack et al., 2006).  From the clinical point of view, risk 
assessment, referral of patients with a suspected ACS is highly important for 
patient health and survival. The prompt evaluation of such patients is 
important, as prolonged assessment contributes to high workload, ED 
overcrowding, occupying bed spaces, which is placing an additional burden 
on health care systems resulting in adverse patient outcomes, and increased 
mortality (Bernstein et al., 2009). Distinguishing whether a patient presenting 
with chest pain has an acute coronary syndrome or a non-cardiac problem is 
difficult (Carlton et al., 2015a). However, Emergency physicians must rapidly 
identify and treat patients with chest pain whilst also avoiding unnecessary 
investigation and admission for the group of patients who can be safely 
discharged. It has been reported that 6% of patients discharged from a UK 
emergency department have subsequently been proven to have prognostically 
significant myocardial damage (Collinson et al., 2000). Another study found 
the rate of missed diagnosis in the ED to be 2% (Suter, 2007). Most 
importantly, the majority of hospital admissions for chest pain could be avoided 
with improved diagnostic technology such as POCT. Currently the lack of 
sensitivity and NPV of existing diagnostic technology at the time of patient 
arrival in hospital leads to unnecessary hospital admissions and contributes to 
overcrowding of ED. On the other hand, there is a challenge to maintain a 
reasonable specificity and PPV. However, there are excessive and developing 
strategies that would permit early exclusion of acute coronary syndromes 
(ACS) in ED. The availability of accelerated diagnostic protocol in ED could 
avoid unnecessary hospital admissions and facilitate patient triage. The risk 
assessment should be performed as soon as a clinical diagnosis of ACS is 
made according to The National Institute of Health and Clinical Excellence 
(NICE) guidelines; also, it must be based upon rapidly available clinical and 
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laboratory information (Cooper et al., 2010). Additionally, it is recommended 
that the accelerated diagnostic protocol selected is user-friendly, suitably 
validated, and conformable between observers and users. Numerous risk 
stratification scores are available and are based on clinical history, ECG 
findings and cardiac markers (Antman et al., 2000; Granger et al., 2003; Body 
et al., 2014; Six et al., 2012). One of the most commonly used is the (TIMI) 
risk score. This score was designed, established and validated in cohorts of 
patients with ACS (Antman et al., 1999). Previously, it has been reported that 
over half of elderly patients who do not have AMI have elevated troponin levels 
on arrival when high sensitivity troponin assay is applied (Reiter et al., 2011). 
Decision rules combining clinical features, ECG findings and novel biomarkers 
have been derived to improve risk stratification for patients with ACS have 
been developed recently. See section 1.5.  
The Manchester Acute Coronary Syndrome (MACS) rule (Body et al., 2014c) 
and Troponin- only MACS (T-MACS) rule (Body et al., 2016a) are clinical 
decision aids which prospectively validated rule out and risk stratification 
strategy for ACS based on a single blood test on arrival in patients presenting 
with suspected cardiac chest pain to the ED. The computer based MACS 
model involves a combination of high-sensitivity troponin T (hs-TnT), (h-
FABP), ECG findings and clinical data as described earlier). Both rules are 
designed to give the probability that a patient will undergo a major adverse 
event. See section 1.4.3.5.  
In recent years, the number and percentage of patients spending over four 
hours in A&E departments has increased.  It has been reported recently in the 
latest Accident and Emergency NHS Statistics that in 2016, more than 16.2% 
of patients were classified major and spent over 4 hours in A&E. This is highest 
percentage for over a decade as reported. In 2016 compared to 2015 the 
number of patient attendances increased by 5.2%, which is equivalent to an 
average of 3,200 more people attending A&E each day in England (Baker, 
2017). The number of attendances is raised each year and this will affect the 
health outcome if the patient is not treated as soon as possible. However, with 
the long turnaround time of central laboratory tests and the chance to rule in 
patients without AMI and having high troponin result tested by high sensitivity 
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assay, the implementation of POC troponin in combination with a clinical 
decision rule could help in  ‘rule in’ and ‘rule out’ ACS  in the ED setting. 
Nevertheless, the evaluation of serial troponin testing by POC incorporation 
with a clinical decision rule is not yet available. Recently, there has been much 
interest in POCT, as it has the benefit over central laboratory-based assays of 
reducing the time and delivering results faster to clinicians as mentioned 
earlier. Moreover, it is capable of reducing ED overcrowding, speeding up 
patient management process, reducing hospital admissions, assisting in 
appropriate treatment plan and finally supporting and extending laboratory 
testing within the hospital. Several type of POC devices are available in the 
market Figure 6.1. However, implementing POC device/test in a busy 
environment such as ED is challenging, as the analytical characteristics of 
these assays are significantly different from central laboratory assays. Hence, 
diagnostic studies and research clinical trials are needed to evaluate the 
effectiveness of such devices in patient’s outcome and risk stratification in 
emergency setting. 
In the United Kingdom, the National Health Service (NHS) has a government 
target of four hours within which minimum of 95% patients attending ED should 
be diagnosed, treated and then admitted or discharged. However, the target 
for 95% of all attendees to be discharged, admitted or transferred within 4 
hours has not been met in the monthly data since July 2015 as reported in 
latest statistics report from NHS (Vile et al., 2017). 
All patients with acute chest pain who are assessed as having medium or high 
risk of a (MI) should be given high sensitivity troponin blood tests, following the 
guidance from National Institute for Health and Care Excellence (NICE) 
advises. (NICE) recommends that two blood tests for high sensitivity cardiac 
troponin should be taken three hours apart. However, with the turnaround time 
of a central laboratory test, this would mean all patients are admitted to 
hospital. This concern raised the need to validate the T-MACS rule with 
contemporary cardiac troponin assays such as (i-STAT) where this assay do 
not meet criteria for being labelled as ‘high sensitivity’ assay. 
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6.2. Aim and objectives 
The aim of this study was to prospectively validate T-MACS with a 
contemporary POC cTn assay (i-Stat, Abbott Point of Care, New Jersey) in 
order to investigate the clinical diagnostic accuracy of the i-Stat device to rule 
out AMI in ED. 
 
Figure 6-1. A variety of POCT platforms 
(A) Cardiac Reader, Roche Diagnostics; (B) Stratus CS, Siemens Healthcare; (C) Triage, 
Alere; (D) Cobas h232, Roche Diagnostics; (E) iSTAT, Abbott Laboratories; (F) Meritas, Trinity 
Biotech; (G) LABGEOIB10, Samsung; (H) PATHFAST, Mitsubishi Chemical Europe and (I) 
AQT90, Radiometer. Picture adapted from (Gaze, 2016). 
6.3. Methods  
6.3.1. Participants 
During the study time frame of February 2015 to March 2017 there were 1,613 
patients enrolled. Of this cohort, some patients were excluded for missing i-
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Stat on arrival, and the patients who did not have an ECG recorded were also 
excluded. This left 634 patients in the final group for analysis consisting of 457 
men (62.3%) and 276 women (37.7%). The mean age was 58 years (standard 
deviation 16) In this study, we included patients who were presented to the ED 
with a primary complaint of chest pain and the emergency physicians 
suspected might be cardiac in nature and warranted further investigation for a 
possible ACS. Samples were analysed by POC (i-Stat assay (Abbott Point of 
Care, New Jersey) set in the ED of 14 hospitals around the UK. Inclusion and 
exclusion criteria were described in detail earlier section 2.1.1.3.1. All 
participants provided written informed consent. 
6.3.2. Laboratory analyses and data collection 
Blood samples drawn on arrival were analysed for cTnI using the POC i-Stat 
assay (Abbott Point of Care, New Jersey, 99th percentile 0.08 ng/mL (µg/L), 
LoD 0.02 ng/mL, 0.10 ng/mL, and functional sensitivity at 10% CV). All patient 
have undergone serial central laboratory cTn testing over at least 3 hours (if a 
high sensitivity assay was in use) or at least 6 hours (for contemporary assays) 
for reference standard following the recommended guidelines. The initial ECG 
findings and systolic blood pressure were recorded at the time of patient arrival 
in the ED. ECG in the study were interpreted by the treating clinicians.  
6.3.3. Application of the T-MACS decision aid with a POC cTn test 
The T-MACS decision aid uses a formula to calculate the probability (p) that a 
patient has ACS (defined as a diagnosis of AMI relating to the patient’s initial 
presentation or the occurrence of a MACE within 30 days). In this study, the 
original T-MACS formula was applied using the POC i-Stat assay (reported in 
ng/L). The T-MACS rule estimates the probability (p) of acute coronary 
syndromes as follows:  
1/(1+exp-(-4.77+1.71E+0.85A+0.61R+1.42V+2.06S+1.21B+0.089T), where 
E is evidence of acute ECG ischaemia, A is worsening angina, R is pain 
radiation to the right arm or shoulder, V is pain associated with vomiting, S is 
sweating observed, B is systolic blood pressure <100mmHg and T is cardiac 
troponin concentration (ng/L) on arrival in the ED.  
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Consistent with the previous approach, patients with cTnI concentrations 
below the reportable range of the assay (10 ng/L) were entered as 9ng/L. The 
calculation in real clinical practice would be computer-based. The predictors 
in the T-MACS measurement scale are shown in (Table 6.1). For dichotomous 
variables, a value of ‘1’ is entered for ‘yes’ and ‘0’ for ‘no’. The estimated 
probability of each group is described in (Table 6.2) 
Table 6-1. Predictors in the Manchester Acute Coronary Syndromes (MACS) model 
Variable Measurement scale 
Variable Measurement Scale 
Acute ECG ischaemia (treating clinician’s interpretation) Dichotomous 
Worsening (or crescendo) angina Dichotomous 
Pain radiating to the right arm or shoulder Dichotomous 
Vomiting in association with the presenting Dichotomous 
Sweating observed by the treating clinician Dichotomous 
Systolic Blood Pressure <100 mm Hg on arrival Dichotomous 
Admission cTn by i-STAT (ng/L) Continuous 
6.3.4. Statistical analysis  
The diagnostic accuracy of T-MACS was evaluated by calculating sensitivity, 
specificity, PPV and NPVs, positive and negative likelihood ratios. All statistical 
analyses were performed using either SPSS version 22.0 (IBM Software, 
USA) or MedCalc online calculator version. The model classified patients into 
four distinct risk groups based on their calculated risk probability according to 
the cut offs applied in the derivation of the original TMACS rule. The four risk 
groups with associated suggestion for patient disposition are presented in 
Table 6.2. (ROC) curves were constructed to assess the diagnostic accuracy 
and the corresponding sensitivity and specificity of the T-MACS score estimate 
the probability of risk group. 
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Table 6-2. T-MACS Groups risk probability 
Risk group defined by T-
MACS  
Probability threshold in the T-
MACS Rule 
Interpretation 
Very low risk <2% ACS ruled out consider discharge 
Low risk Between 2% and 4.9% Consider serial troponin in ED e.g. 3h 
troponin then consider discharge if 
normal 
Moderate risk Between 5% and 94.9% Serial troponin in general ward and 
consider stress testing and/or CT 
coronary angiography thereafter. 
High risk >95% ACS ruled in, refer to cardiology for 
treatment 
6.3.5. Follow-up 
All patients were underwent reference standard troponin testing in accordance 
with contemporary national and international guidance. Acceptable protocols 
for reference standard troponin testing include: 
• If a contemporary (not high sensitivity) troponin assay is used: 
Laboratory-based troponin testing on arrival and either 6 hours after 
arrival or 10 to 12 hours after the onset of peak symptoms (Thygesen 
et al., 2010). 
• If a high sensitivity troponin assay is used: Laboratory-based troponin 
testing on arrival and either 3 hours after arrival or 10 to 12 hours after 
the onset of peak symptoms (DG15, 2014; Apple et al., 2002). 
A high sensitivity troponin assay is defined as an assay that can detect 
troponin concentrations in at least 50% of apparently healthy individuals with 
a CV <10% at the 99th percentile cut-off (Apple et al., 2012a).  
All participants were followed up by telephone, email, letter, home visit or in 
clinic after 30 days. If the patients were un-contactable, the research nurses 
contacted the general practitioner for important information needed for results.  
6.3.5. Outcome  
The primary outcome of this study is rapid diagnosis of acute myocardial 
infarction. Outcomes was adjudicated by two independent investigators with 
reference to relevant clinical information but blinded to the results of research 
investigations. Discrepancies was resolved by consultation with a third 
independent investigator. AMI was defined according to the Third Universal 
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Definition of AMI (Jaffe, 2013) however, by the inclusion criteria, all patients 
has symptoms and signs consistent with myocardial ischaemia. Therefore, 
patients who deemed to have met this outcome if they develop a rise and/or 
fall of troponin to above the 99th percentile. At the time of writing this thesis 
and pending further evidence and international guidance, a significant rise 
and/or fall of troponin was considered to be >9.2ng/L for high sensitivity 
troponin T (Mueller et al., 2012) and at least 20% for all other assays.  
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6.4. Results 
634 patients were included in this study between February 2015 and March 
2017 all of whom completed follow-up. Table 6.3 illustrate baseline 
characteristics in patients among the study. In this study 76 patients 12% of 
patients had AMI, proportion of patients with AMI in each of the T-MACS risk 
groups are illustrated in Figure 6.2 and Table 6.4. In the current study, with a 
single i-STAT cardiac troponin I (cTnI) assay threshold of <0.10 ng/mL, The 
T-MACS rule successfully stratified patients according to their risk of AMI, T-
MACS would have ‘ruled out’ as per the Table 6.5 and Table 6.6 it is 41.8%% 
(n=265) with a sensitivity of 97.4% (90.8 - 99.7%) and NPV of 99.3%  (97.1 – 
99.8%). On the other hand, the T-MACS would have ‘ruled in’ as per the Table 
6.7 and Table 6.8 it is 7% (n=44) patients with a specificity of 93.56% (91.27% 
to 95.40%) and a PPV of 50.00% (42.08% to 57.92%). In total 42% of patients 
would have been classified as ‘very low risk’ by the T-MACS rule (with a 
recommendation that they could be immediately discharged) with two (2.3%) 
missed AMIs. Two AMIs were missed based on serial laboratory cTn 
concentrations. (CRF) form were checked and hostiles were contacted for 
follow up. One of these two patients had hs-cTnT concentrations of 6ng/L and 
16ng/L on arrival and at 3 hours respectively. The patient underwent coronary 
angiography, which showed diseased coronary artery bypass grafts that was 
not felt to require coronary intervention. The other patient had hs-cTnT 
concentrations of 15ng/L and 35ng/L, was given a clinical diagnosis of AMI 
and underwent percutaneous coronary intervention eight days after initial 
admission .T-MACS probability calculated for the risk groups has an AUC of 
0.883 (95% CI. 84 to .92) showing a very good discrimination for risk 
stratification patients in emergency department. See Figure 6.3 
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Table 6-3. Baseline characteristics of included patients 
Variable Total  
Age in years, mean (SD) 55 (15.5) 
Men (%) 62.3 
MAIN SITE OF PAIN 
Central chest   
 
64.5% 
Left anterior chest 25.8% 
Left lateral chest  6.6% 
Right anterior chest 3.5% 
Epigastrium  5.7% 
Back    4.9% 
Arms/shoulders  9% 
Jaw/neck/throat 7.8% 
PAIN RADIATION 
Left arm  
26.8% 
Left shoulder   12.5% 
Right arm   5.6% 
Right shoulder  4.3% 
Throat or jaw  11.8% 
Neck    9.9% 
Back  8.7% 
Left chest   5.6% 
Right chest 2.9% 
Legs    2% 
ASSOCIATED SYMPTOMS 
Nausea    
  
22.1% 
Vomiting 5.2% 
Dyspnoea   
  
24% 
Light-headedness 19.5% 
Vertigo   3% 
Sweating 30% 
PAST MEDICAL HISTORY 
Previous myocardial infarction (%) 
 
22.9% 
Previous angina (%) 26% 
Previous PCI/stent 18.9% 
Previous CABG 6% 
Hyperlipidaemia (%) 35% 
Hypertension (%) 45.3% 
Type 2 Diabetes mellitus (%)  16.4% 
RELEVANT SOCIAL HISTORY 
Current smoking 
 
20% 
Alcohol use 36% 
ECG interpretation: 
Acute ischaemia  
7% 
ST elevation (STEMI)   5% 
LBBB  5% 
ST depression    10.3% 
Abnormal T inversion  7.7% 
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Table 6-4. Proportion of patients with AMI in each of the T-MACS risk groups total 
number of patients including in the analysis 634 
Risk groups Number (%) with AMI Number (%) with no AMI Total number (%) in risk 
group 
High risk group TP 38(86.4%) FP 6 (13.6%) 44 (7%) 
Moderate risk 20 (13.5%) 128 (86.5%) 148 (23%) 
Low risk 16 (9%) 161 (90 %) 177 (28%) 
Very low risk group FN 2 (.8%) TN 263 (99%) 265 (42%) 
Total  76 (12%) 558 (88%) 634 
 
Number (%) with AMI 
 
Figure 6-2. Proportion of patients with AMI in each of the T-MACS risk groups 
Performance of the (Troponin-only Manchester Acute Coronary syndromes (T-
MACS) in the patient population (n= 634). The suggested disposition for each 
group is as follows: (Very low risk .8%) were patients who were discharged 
immediately. (Estimated probability of AMI is <2%), (low risk 9.0%) were the 
patients who were admitted to low dependency environment, such as 
emergency department observation unit. (Estimated probability of AMI is 
between 2% and 4.9%), (Moderate risk 13.5%) were admitted to the acute 
ward, such as medical admissions unit (estimated probability of AMI is 
between 5% and 94.9%), (High risk 86.4%) were admitted to coronary care 
unit or high dependency environment (estimated probability of AMI is ≥ 95%). 
AMI: acute myocardial infarction. 
0.8%
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Table 6-5. Prevalence of AMI stratified by T-MACS risk group 
T-MACS AMI No AMI Total 
Patients 
group  
All other risk groups TP 74 FP 295 369 
Very low risk group FN 2 TN 263 265 
Total 76 558 634 
Table 6-6. Test characteristics of T-MACS (very low risk vs all other risk groups) 
Diagnostic accuracy of 
the rule out strategy 
Value% 95% Cl Percentage ‘ruled out’ 
Sensitivity 97.4% 90.8 - 99.7% 265/634 ×100 
 
41.8% 
Specificity 47.1% 42.9 – 51.4% 
PPV 20.1% 18.7 – 21.5% 
NPV 99.3% 97.1 – 99.8% 
Table 6-7. Two x two table showing the prevalence of AMI stratified by T-MACS risk 
group (high risk vs all other risk groups) 
Sensitivity and specificity for the rule-out and rule- in myocardial infarction by T-MACS for high 
risk group only are also reported 
T-MACS AMI No AMI Total 
High risk group  TP 38 FP 38 44 
All other risk groups FN 6 TN 552 558 
Total 44 590 634 
AMI Formula: AMI was defined according to the Third Universal Definition of AMI 
TP: True positive, FP: False positive, FN: False negative, TN: True negative. 
Table 6-8. Significance of diagnostic Rule-out strategy of T-MACS for high-risk group 
only 
Diagnostic accuracy of the 
rule out strategy 
Value% 95% Cl Percentage ‘ruled in’ 
Sensitivity 86.36% 72.65% to 94.83% 44/634×100 
6.9% Specificity 93.56% 91.27% to 95.40% 
PPV 50.00% 42.08% to 57.92% 
NPV 97.77 % 95.42% to 98.93% 
 
6.11. ROC curve for T-MACS probability 
T-MACS probability calculated for the risk groups has an AUC of 0.883(95% 
CI. 84 to .92) showing a very good discriminator for risk stratification patients 
in emergency department see Figure 6.3. 
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Figure 
6-3. 
Receiver operating characteristic curves showing the overall accuracy of T-MACS  
Probability for risk stratification of chest pain patients in ED sitting which considered to ‘rule 
out’ strategy in the current study.  
6.5. Discussion  
The T-MACS rule has been validated based on previous findings that the 
original T-MACS rule can effectively ‘rule out’ and ‘rule in’ acute coronary 
syndromes (ACS) following a single blood test and the calculation score is able 
to stratify the risk of adverse events within 30 days in ED patients with 
suspected cardiac chest pain. POC troponin tests are less sensitive than hs-
Tn laboratory assays. However, integrating the POC result into clinical 
algorithm and delivering rapid result helps in facilitating early decision and 
delivering rapid results. In the present study, by setting the cut off levels of 
POC at 0.10 ng/mL and functional sensitivity at 10% CV, the T-MACS rule has 
successfully ‘ruled out’ > 41.8% of patients with suspected cardiac chest pain 
following a single blood test, with a sensitivity of 97.4% (90.8 - 99.7%) and 
NPV of 99.3%  (97.1 – 99.8%), in a very short turnaround time of 5-10 minutes. 
On the other hand T-MACS has risk stratified the patients who were at high 
risk to have AMI with a specificity of 93.56% (91.27% to 95.40%) and a PPV 
of 50.00% (42.08% to 57.92%). Setting a POC assay at low threshold levels 
could help in several ways, it helps in taking clinical decision in a shorter time, 
also helps in safe discharge of more patients and finally reduces length of stay 
(Ryan et al., 2009). While on the other hand, prolonged diagnosis leads to 
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overcrowding of emergency department, increased cost of health care and 
resources used (Pines et al., 2009; Thokala et al., 2012) To our knowledge, 
this was the first study to date that evaluated POC test in combination with the 
medical history of the patients, ECG interpretation and clinical information in 
order to exclude AMI in a busy environment setting. In this study population, 
more than 40% of patients were identified as very low risk group to rule out 
strategy. Despite the fact that the assay used in T-MACS is less sensitive than 
hs-Tn laboratory, a threshold of 10 ng/ml  for ‘ruling out’ ACS allowed 41.8% 
of patients to be discharged with only <2% of ACS cases were undetected. 
Several clinical decision rules have been derived based on flow of patients in 
emergency department; however, these strategies were aimed to reduce 
unnecessary hospital admissions for chest pain patients. Latest studies have 
confirmed that very low troponin concentrations at patient arrival can be used 
to risk stratify patients (Body et al., 2015c; Bandstein et al., 2014). Numerous 
studies of (ADP) using contemporary sensitive cTn assays suggest that early 
serial sampling time for a period of 60-120 min, in addition to use of either 
absolute or relative cTn concentration might facilitate safe early discharge of 
low-risk patients with chest pain. A large multicenter ASPECT study (Asia-
Pacific Evaluation) used POCT biomarkers (CKMB, Myoglobin) as well as 3rd 
generation troponin (Than et al., 2011a). This study has shown a diagnostic 
sensitivity of 82.9% (95% CI 79-86.2) and NPV of 96.1% (95% CI95-96.9) to 
rule out patients and specificity of 56% (95% CI 54.3-57.7) and PPV 20.1% 
(95%CI 18.2-22.0) to rule in patients. However, the study has shown lack of 
cost effectiveness using the multimarket POC panel). Few years later, the 
researchers enrolled the same patient population (of ASPECT) for another 
study trial (ADAPT), the Accelerated Diagnostic Protocol to Assess Patients 
with symptoms of chest pain. However, in this study, the researchers used 
troponin only as a single biomarker in the protocol and their strategy was 
successful to identify 20% of patients at low risk (392/1975). The ADP protocol 
had a sensitivity of 99.7% (95% CI 98.1-99.9%) and NPV of 99.7% (95% CI 
98.6-100%), specificity of 23.4% (95% CI 21.4-25.4%) and positive predictive 
value of 19% (95% CI 17.2-21%). However, in this study the researchers used 
TIMI score which has debateable application to acute ED population since it 
was originally developed for use in patients with unstable angina or non-ST-
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elevation myocardial infarction (Hess and Jaffe, 2012). POCT multi- marker 
strategy was evaluated in ED setting by some authors. However, to test the 
advantages of POC in emergency setting especially for turnaround time, other 
authors (McCord et al., 2001) have evaluated the effectiveness of an 
accelerated 90 min protocol for diagnosis of AMI in ED setting using serial 
multi-marker POCT (cTn, CK-MB and myoglobin). In this study all chest pain 
patients were rapidly diagnosed within 90 min and the admission rate to the 
coronary care unit was decreased by 40%). Another study by Goodacre et al 
demonstrated the serial evaluation of cardiac marker over 90 minutes in ED 
setting. The researchers found out that, the implementation of POC could lead 
to an increase in the proportion of patients who are successfully discharged 
from the ED by 63% and with high-risk patients, the percentage increases to 
83%. On the other hand, there were a total of 120 patients (11.6%) who were 
successfully diagnosed and treated within 4 hours of arrival to ED. This pilot 
work suggests that POC cardiac markers can facilitate discharge of low-risk 
patients from the ED without a significant affecting rate in patient attendance 
and without affecting the 4-hour waiting target setting by NHS (Goodacre et 
al., 2011).There is also an alternative way to rule out chest pain patients by 
evaluating the History, Electrocardiogram, Age, Risk Factors, and Troponin 
(HEART) score or triage rule-out using high-sensitivity Troponin protocol. It 
has been addressed that this score can be an alternative way to safely 
discharge chest pain patients presenting to ED (Leite et al., 2015; Backus et 
al., 2010; Six et al., 2013). However, the latest systematic review which 
evaluated the diagnostic accuracy of HEART for early rule out of acute 
coronary syndromes in ED has been reported to have lower sensitivity of 
96.7% (95% CI 94.0-98.2%) and specificity of 47% (95% CI 41.0-53.5%) when 
compared with current study (Van and Body, 2017). More importantly, that 
none of these protocols were derived in the area of point of care. Another 
systematic review on latest predictive tools for the assessment of patients with 
chest pain has been recently reported which included six different studies out 
of 19126 initially identified references in emergency setting. The main findings 
of the study were AMI and angina. One of the study used the probability of not 
having (CAD) by using certain predictors which were based on age, gender, 
clinical characteristics of chest pain, any past medical history of cardiovascular 
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disease and any abnormalities in ECG as an outcome (Ayerbe et al., 2016). A 
study by Sanches et al. presented a tool to triage patients in ED and identified 
patients at low risk who do not need admission in chest pain unit. Researchers 
in this observational study found out that patients who do not have any of these 
five variables could be safely ruled out that they didn’t have ACS. The 
variables included in this tool were- age of over 40 years diabetes, past history 
of ACS and crushing chest pain (Lopez et al., 2011). This tool was later 
validated in 4231 patients and again 100% patients (n=213) without any of the 
five variables were confirmed not to have CAD. However, the usage of this 
protocol is limited due to its low specificity.  
In recent years, there is growing interest supporting the single test LoD rule 
out strategy. However, despite the advantages and disadvantages of these 
strategies, T-MACS rule have has the advantage of facilitating rapid diagnosis 
for chest pain patients in ED and providing useful pre-test probability result to 
emergency physician. The rule produces nearly 97.37% diagnostic sensitivity 
for detection of acute myocardial infarction and 99.16 % NPV. Current study 
describe a clinical decision rule utilising low cardiac troponin concentrations 
with a cut-off setting at lowest reportable range to risk stratify patients. No 
previous research has evaluated such approaches within a protocol to rule in/ 
rule out chest pain patients. A previous study evaluated similar cut-off (0.010 
µg/L at 99th percentile were (0.02 ng/ml) for different POC assay. However 
the researchers found that this cut-off was helpful in stratify patients mainly for 
the AMI patients as compared to the central laboratory hs-cTnT assay (Dupuy 
et al., 2017).   
This study aims to address the effectiveness of T-MACS using the POC test. 
From analytical point of view, in the current study we applied the LoD of 
troponin test in the T-MACS rule. Since the coefficient of variation (CV) of less 
than 10% was considered most ideal.  The CV of 10% and 20% were seen at 
0.09 and 0.07 ng/ml, respectively as published in previous work by Apple et 
al. 2004. However, in their work, the i-STAT POC cTnI assay was quite close 
to meeting the European Society of Cardiology (ESC) and The American 
College of Cardiology (ACC) guidelines and criteria for 10% imprecision at the 
99th percentile. Previous protocols were limited by low specificity and Negative 
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predictive value. However, this study strongly recommend the Implementation 
of this decision rule in emergency setting as such a protocol  has the potential 
to improve the efficiency and safety of early rule-out/rule in patients with 
suspected acute coronary syndrome. Furthermore, a single test of Troponin 
by POC has the potential to improve patient outcome by delivering quick 
results that leads to faster therapeutic interventions, diagnosis with minimal 
inconvenience to patients and no requirement for serial blood sampling to risk 
stratified patients. Nevertheless, for those patients who were classified as ‘low 
risk’ and ‘moderate risk’, serial sampling for over 3 hrs is required for further 
investigation as these patients will remain in ‘observation zone’). In the current 
study, two patients were classified “very low risk” by T-MACS and had AMI. 
Lately, a clinical survey of the acceptable risk of MACE event in chest pain 
patients after patient discharge from ED had reported that <1% of acute MI 
was missed by emergency physicians in the ED with risk scores including two 
negative troponins (Than et al., 2013). For those patients who are in ‘very low 
risk’ group, a shared decision making might be helpful as this approach is 
based on several studies that suggested when low-risk patients are 
appropriately informed of their risk for ACS and are shared in decision-making 
procedure, approximately 20% lower rate of observation unit admission is 
promising (Hess et al., 2012b; Rising et al., 2017; Erik P. Hess et al., 2016). 
See table 6.9 for the comparison of the T-MACS with the current protocol. 
Table 6-9. Comparison of the T-MACS with the current protocol 
The test characteristics of the 3 ADPs with the best performance (with 95% CI) were as 
follows: 
Study Sensitivity NPV Specificity PPV 
(Christenson et al., 2006) 99.4% 
(98.1-99.9) 
93.8 % 
(78.0-98.9) 
4.7% 
(3.9-5.0) 
37.2% 
(36.7-37.4) 
(Hess et al., 2012a) 99.7% 
(98.3-100) 
98.9% 
(99.3-99.9) 
14.1% 
(13.3-14.3) 
39.7% 
(39.2-39.8) 
(Than et al., 2011a) 99.2 % 
(97.5-99.8) 
98.1 % 
(94.1-99.5) 
23.8 % 
(22.9-24.2) 
42.5 % 
(41.8-42.7) 
Present Study (Rule out 
strategy of T-MACS for low 
risk group) 
97.37% 
(90.82-99.68) 
99.25%  
(97.10-99.81) 
99.25% 
(97.30-
99.91) 
97.37% 
(90.29-99.33) 
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6.6. Conclusions 
Using information available at the time of patient arrival to ED and results from 
a single blood test by the i-STAT cardiac troponin I (cTnI) assay, the (Troponin-
only Manchester Acute Coronary syndromes (T-MACS), could enable nearly 
half of the chest pain patients to be immediately discharged. This rule also 
classified patients to high-risk patients, moderate risk patients, and low-risk 
patients in addition to very low-risk patients. Additionally this classification 
according to patient risk probability will support emergency physicians to 
discriminate patients according to their risk, which helps to speed up the 
process of patient triage and transfer patients to target specialist referral faster. 
Moreover, this rule might reduce the stressful environment of ED where 
patients arrive in pain, and panicky contributes to the complexity and 
uncertainty of the decision situation. With a single blood test at the time of 
arrival in the ED, T-MACS identifies >40% of patients as being at ‘very low 
risk’. These patients have <1% probability of ACS, which may be considered 
to ‘rule out’. Similarly, T-MACS can ‘rule in’ ACS in approximately 7% of 
patients with high PPV. Future work should focus on evaluation of the impact 
of T-MACS when used in practice, particularly when combined with serial 
troponin sampling over 1–3 hours and in conjunction with shared decision-
making. To my knowledge, this is the first successful validation of a single test 
‘rule out strategy’ using a POC cTn assay. Emergency department crowding 
due to prolonged stays and unnecessary hospital admissions results in bed 
shortages and this contribute to insufficient resource utilization. Thus, 
improving the ability to accurately rule out AMI could optimize emergency 
department triage of chest pain patients. However, the impact of T-MACS role 
in clinical practice will contribute on resource utilization and holds a great 
promise on health care system.  Finally, this strategy will have significant 
benefits on healthcare services in NHS by reducing hospital admission rate, 
improve patients length of stay and support the 4 hours NICE recommendation 
for patients treatment and management. Nevertheless, analysis of economic 
and cost effectiveness is needed to evaluate the strategy in real time.  
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6.7. Strength and limitation of the study 
This is the first multi-centre study evaluating troponin by POC assay in 
emergency department within a clinical decision role with assured protocol 
standardisation and uniformity procedure between the several sites. This gives 
strength to the current study by having the possibility of inclusion of a wider 
range of population group. However, this increases the generalizability of the 
study. Moreover, The advantages of this computer clinical decision role is that 
it combines clinical information, ECG findings and novel lower reportable 
range cut-off for cTn i-STAT and result aims to ‘rule in’ ACS as well as ‘rule 
out’ chest pain patients. This new evidence suggest that a model using POC 
as the only biomarker gives similar sensitivity and high specificity as a ‘rule 
out’ tool from previous finding T-MACS (Body et al., 2016a) . Moreover, the 
turnaround time of POC device in T-MACS might help to risk stratify the patient 
and rapidly identify very low-risk patients in order to reduce unnecessary 
hospital admissions. As this is a prospective study with a follow-up of patients 
for 30 days, it minimizes the risk of selection bias since the outcome of the 
patient is not known at the beginning. The TMACS role adds a new exposure 
for which the beneficial health effect of using POC cTn in emergency 
department can help to safely stratified chest pain patient with acceptable risk. 
Moreover, the study added numerous outcomes for the benefit of POC in ED 
setting. It is important to mention that the 4th universal definition has been 
published in August 2018, However, the reference standard of this study is the 
3rd Universal Definition as that was the definition in force at the time that this 
work has been taking. Conversely, this study has some limitations that require 
consideration. There are some quality issues associated with POC assay, as 
the assay employed in the current study is less analytically sensitive than the 
assays performed in the central laboratory were the precision of the current 
POC assay using concentration below the LoD did not meet the recommended 
guidelines by ESC/ACC. This raised the concerns of laboratory about the 
precision of the assay at the cut-off level used in the current study. However, 
this was not reflected in a high false negative rate in this study, suggesting that 
diagnostic accuracy, as a ‘rule out’ test was not compromised.  
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6.8. Future directions 
While the results of the current study are promising, the effectiveness of such 
diagnostic strategy requires testing in a future validation study. However, to 
assess this rule out strategy, a randomised control trial is required. Also, 
subsequent research should now evaluate the use of T-MACS in the pre-
hospital environment and paramedics as this assay allows for high level of 
clinical decision management of patient community by supporting the clinical 
judgments for not to transport the patients and identifying patients who benefit 
from hospital management. Finally, a future impact analysis would be needed 
to perform regarding the utility of the T-MACS rule in clinical practice. Our work 
however, emphasize the importance of developing newer generations of POC 
cTn assay with greater precision at low concentrations. 
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The basic details of each recruiting centre 
Site number Site name Annual number of 
ED attendances 
Type of centre 
1 Central Manchester 
University Hospitals 
NHS Foundation 
Trust 
985,29 Teaching hospital 
2 Basildon & Thurrock 
University Hospitals 
NHS Foundation 
Trust 
115089 District General 
Hospital 
3 Wirral University 
Teaching Hospital 
NHS Foundation 
Trust 
89652 Teaching hospital 
4 Imperial College 
Healthcare NHS Trust 
273,355 Teaching hospital 
5 St. George’s 
Healthcare NHS Trust 
154,418  
187 
6 Royal Bolton Hospital 
NHS Foundation 
Trust 
112994  
7 Taunton and 
Somerset NHS 
Foundation Trust 
585,70  
8 Royal Devon & 
Exeter NHS 
Foundation Trust 
105,999  
9 Harrogate and District 
NHS Foundation 
Trust 
483,18  
10 Northumbria 
Healthcare NHS 
Foundation Trust 
166,777  
11 Basingstoke and 
North Hampshire 
NHS Trust 
119190  
12 Nottingham University 
Hospital NHS 
Foundation Trust 
194371 Teaching hospital 
13 University Hospital 
Birmingham NHS 
Trust 
102,054 Teaching hospital 
14 Kings College 
Hospital NHS 
Foundation Trust 
231578 Teaching hospital 
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